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CHAPTER-1 
 
GENERAL INTRODUCTION TO CHROMATOGRAPHY, 
VARIOUS CHROMATOGRAPHIC TECHNIQUES AND ITS 
APPLICATION IN PHARMACEUTICAL AND CHEMICAL 
INDUSTRUES 
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1.0 DISCOVERY OF CHROMATOGRAPHY 
Chromatography is a physicochemical method for separation of complex mixtures was 
discovered at the very beginning of the twentieth century by Russian–Italian botanist M. 
S. Tswett. [1]. In his paper “On the new form of adsorption phenomena and its 
application in biochemical analysis” presented on March 21, 1903 at the regular meeting 
of the biology section of the Warsaw Society of Natural Sciences, Tswett gave a very 
detailed description of the newly discovered phenomena of adsorption-based separation 
of complex mixtures, which he later called “chromatography” as a transliteration from 
Greek “color writing” [2]. Serendipitously, the meaning of the Russian word “tswett” 
actually means color. Although in all his publications Tswett mentioned that the origin of 
the name for his new method was based on the colorful picture of his first separation of 
plant pigments (Figure 1), he involuntarily incorporated his own name in the name of the 
method he invented. The chromatographic method was not appreciated among the 
scientists at the time of the discovery, as well as after almost 10 years when L. S. Palmer 
[3] in the United States and C. Dhere in Europe independently published the description 
of a similar separation processes.  
Twenty-five years later in 1931, Lederer read the book of L. S. Palmer and later found an 
original publications of M. S. Tswett, and in 1931 he (together with Kuhn and 
Winterstein) published a paper [4] on purification of xantophylls on CaCO3 adsorption 
column following the procedure described by M. S. Tswett. In 1941 A. J. P. Martin and 
R. L. M. Synge at Cambridge University, in UK discovered partition chromatography [5] 
for which they were awarded the Noble Prize in 1952. In the same year, Martin and 
Synge published a seminal paper [6] which, together with the paper of A.T. James and A. 
J. P. Martin [7], laid a solid foundation for the fast growth of chromatographic techniques 
that soon followed. 
Prior to the 1970's, few reliable chromatographic methods were commercially available 
to the laboratory scientist. During 1970's, most chemical separations were carried out 
using a variety of techniques including open-column chromatography, paper 
chromatography, and thin-layer chromatography. However, these chromatographic 
techniques were inadequate for quantification of compounds and resolution between 
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similar compounds. During this time, pressure liquid chromatography began to be used to 
decrease flow through time, thus reducing purification times  
 
Figure 1:  Tswett's Experiment 
 
of compounds being isolated by column chromatography. However, flow rates were 
inconsistent, and the question of whether it was better to have constant flow rate or 
constant pressure was debated [8]. High pressure liquid chromatography was developed 
in the mid-1970's and quickly improved with the development of column packing 
materials and the additional convenience of online detectors. In the late 1970's, new 
methods including reverse phase liquid chromatography allowed for improved separation 
between very similar compounds. By the 1980's HPLC was commonly used for the 
separation of chemical compounds. New techniques improved separation, identification, 
purification and quantification far above the previous techniques. Computers and 
automation added to the convenience of HPLC. Improvements in type of columns and 
thus reproducibility were made as such terms as micro-column, affinity columns, and 
Fast HPLC began to immerge. 
 
By the 2000 very fast development was undertaken in the area of column material with 
small particle size technology and other specialized columns. The dimensions of the 
General Introduction typical HPLC column are 100-300 mm in length with an internal 
diameter between 3-5 mm. The usual diameter of micro-columns, or capillary columns, 
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ranges from 3 μm to 200 μm [9]. In this decade, sub 2 micron particle size technology 
(column material packed with silica particles of < 2μm size) with modified or improved 
HPLC instrumentation becomes popular with different instrument brand name like UPLC 
(Ultra Performance Liquid Chromatography) of Waters and RRLC (Rapid Resolution 
Liquid Chromatography) of Agilent. 
 
Today, chromatography is an extremely versatile technique; it can separate gases, and 
volatile substances by GC, in-volatile chemicals and materials of extremely high 
molecular weight (including biopolymers) by LC and if necessary very inexpensively by 
TLC. All three techniques, (GC), (LC) and TLC have common features that classify them 
as chromatography systems. Chromatography has been defined as follows,  
“Chromatography is a separation process that is achieved by distributing the components of 
a mixture between two phases, a stationary phase and a mobile phase. Those components 
held preferentially in the stationary phase are retained longer in the system than those that 
are distributed selectively in the mobile phase. As a consequence, solutes are eluted from the 
system as local concentrations in the mobile phase in the order of their increasing 
distribution coefficients with respect to the stationary phase; ipso facto a separation is 
achieved” [10]. 
 
 
2. VARIOUS TYPES OF CHROMATOGRAPHY  
 
Chromatography can be classified by various ways (I) On the basis of interaction of 
solute to the stationary phase [11], (II) On the basis of chromatographic bed shape [12, 
13], (III) Techniques by physical state of mobile phase 
2.1 ON THE BASIS OF INTERACTION OF SOLUTE TO STATIONARY 
 PHASE  
2.1.1 ADSORPTION CHROMATOGRAPHY  
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Adsorption chromatography is probably one of the oldest types of chromatography 
around. It utilizes a mobile liquid or gaseous phase that is adsorbed onto the surface of a 
stationary solid phase. The equilibration between the mobile and stationary phase 
accounts for the separation of different solutes.  
 
Figure 2: Schematic figure for adsorption phenomenon in chromatography 
 
2.1.2 PARTITION CHROMATOGRAPHY  
 
This form of chromatography is based on a thin film formed on the surface of a solid 
support by a liquid stationary phase. Solute equilibrates between the mobile phase and the 
stationary liquid 
 
Figure 3: Schematic figure for Partition phenomenon in chromatography 
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2.1.3 ION EXCHANGE CHROMATOGRAPHY  
 
In this type of chromatography, the use of a resin (the stationary solid phase) is used to 
covalently attach anions or cations onto it. Solute ions of the opposite charge in the 
mobile liquid phase are attracted to the resin by electrostatic forces. 
 
Figure 4: Schematic figure for Ion exchange phenomenon in chromatography 
 
2.1.4 MOLECULAR EXCLUSION CHROMATOGRAPHY  
 
Also known as gel permeation or gel filtration, this type of chromatography lacks an 
attractive interaction between the stationary phase and solute. The liquid or gaseous 
phase passes through a porous gel which separates the molecules according to its size. 
The pores are normally small and exclude the larger solute molecules, but allow smaller 
molecules to enter the gel, causing them to flow through a larger volume. This causes the 
larger molecules to pass through the column at a faster rate than the smaller ones. 
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Figure 4: Schematic figure for Molecular Exchange phenomenon in chromatography 
 
 
2.2 ON THE BASIS OF CHROMATOGRAPHIC BED SHAPE  
2.2.1 COLUMN CHROMATOGRAPHY  
 
Column chromatography is a separation technique in which the stationary bed is within a 
tube. The particles of the solid stationary phase or the support coated with a liquid 
stationary phase may fill the whole inside volume of the tube (packed column) or be 
concentrated on or along the inside tube wall leaving an open, unrestricted path for the 
mobile phase in the middle part of the tube (open tubular column). Differences in rates of 
movement through the medium are calculated to different retention times of the sample 
[14]. 
In 1978, W.C.Still introduced a modified version of column chromatography called flash 
column chromatography [15] [16]. The technique is very similar to the traditional column 
chromatography, except for that the solvent is driven through the column by applying 
positive pressure. This allowed most separations to be performed in less than 20 minutes, 
with improved separations compared to the old method. Modern flash chromatography 
systems are sold as pre-packed plastic cartridges, and the solvent is pumped through the 
cartridge. Systems may also be linked with detectors and fraction collectors providing 
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automation. The introduction of gradient pumps resulted in quicker separations and less 
solvent usage.  
In expanded bed adsorption, a fluidized bed is used, rather than a solid phase made by a 
packed bed. This allows omission of initial clearing steps such as centrifugation and 
filtration, for culture broths or slurries of broken cells. 
 
 
2.2.2 PLANAR CHROMATOGRAPHY  
 
Planar chromatography is a separation technique in which the stationary phase is present 
as or on a plane. The plane can be a paper, serving as such or impregnated by a substance 
as the stationary bed (paper chromatography) or a layer of solid particles spread on a 
support such as a glass plate (thin layer chromatography). Different compounds in the 
sample mixture travel different distances according to how strongly they interact with the 
stationary phase as compared to the mobile phase. The specific Retention factor (Rf) of 
each chemical can be used to aid in the identification of an unknown substance.  
2.2.3 PAPER CHROMATOGRAPHY  
 
Paper chromatography is a technique that involves placing a small dot or line of sample 
solution onto a strip of chromatography paper. The paper is placed in a jar containing a 
shallow layer of solvent and sealed. As the solvent rises through the paper, it meets the 
sample mixture which starts to travel up the paper with the solvent. This paper is made of 
cellulose, a polar substance, and the compounds within the mixture travel farther if they 
are non-polar. More polar substances bond with the cellulose paper more quickly, and 
therefore do not travel as far.  
2.2.4 THIN LAYER CHROMATOGRAPHY  
 
Thin layer chromatography (TLC) is a widely employed laboratory technique and is 
similar to paper chromatography. However, instead of using a stationary phase of paper, 
it involves a stationary phase of a thin layer of adsorbent like silica gel, alumina, or 
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cellulose on a flat, inert substrate. Compared to paper, it has the advantage of faster runs, 
better separations, and the choice between different adsorbents. For even better resolution 
and to allow for quantification, high-performance TLC can be used.  
2.2.5 DISPLACEMENT CHROMATOGRAPHY  
 
The basic principle of displacement chromatography is, “A molecule with a high affinity 
for the chromatography matrix (the displacer) will compete effectively for binding sites, 
and thus displace all molecules with lesser affinities”.[17]  
There are distinct differences between displacement and elution chromatography. In 
elution mode, substances typically emerge from a column in narrow, Gaussian peaks. 
Wide separation of peaks, preferably to baseline, is desired in order to achieve maximum 
purification. The speed at which any component of a mixture travels down the column in 
elution mode depends on many factors. But for two substances to travel at different 
speeds, and thereby be resolved, there must be substantial differences in some interaction 
between the biomolecules and the chromatography matrix. Operating parameters are 
adjusted to maximize the effect of this difference. In many cases, baseline separation of 
the peaks can be achieved only with gradient elution and low column loadings. Thus, two 
drawbacks to elution mode chromatography, especially at the preparative scale, are 
operational complexity, due to gradient solvent pumping, and low throughput, due to low 
column loadings.  
Displacement chromatography has advantages over elution chromatography in that 
components are resolved into consecutive zones of pure substances rather than “peaks”. 
Because the process takes advantage of the nonlinearity of the isotherms, a larger column 
feed can be separated on a given column with the purified components recovered at 
significantly higher concentrations.  
2.3 TECHNIQUES BY PHYSICAL STATE OF MOBILE PHASE  
2.3.1 GAS CHROMATOGRAPHY  
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Gas chromatography (GC), also sometimes known as Gas-Liquid chromatography, 
(GLC), is a separation technique in which the mobile phase is a gas. Gas chromatography 
is always carried out in a column, which is typically "packed" or "capillary".  
Gas chromatography (GC) is based on a partition equilibrium of analyte between a solid 
stationary phase (often a liquid silicone-based material) and a mobile gas (most often 
Helium).  
The stationary phase is adhered to the inside of a small-diameter glass tube (a capillary 
column) or a solid matrix inside a larger metal tube (a packed column). It is widely used 
in analytical chemistry; though the high temperatures used in GC make it unsuitable for 
high molecular weight biopolymers or proteins (heat will denature them), frequently 
encountered in biochemistry, it is well suited for use in the petrochemical, environmental 
monitoring, and industrial chemical fields. It is also used extensively in chemistry 
research.  
2.3.2 LIQUID CHROMATOGRAPHY  
 
Liquid chromatography (LC) is a separation technique in which the mobile phase is a 
liquid. Liquid chromatography can be carried out either in a column or a plane. Present 
day liquid chromatography that generally utilizes very small packing particles and a 
relatively high pressure is referred as high performance liquid chromatography (HPLC).  
In the HPLC technique, the sample is forced through a column that is packed with 
irregularly or spherically shaped particles or a porous monolithic layer (stationary phase) 
by a liquid (mobile phase) at high pressure. HPLC is historically divided into two 
different sub-classes based on the polarity of the mobile and stationary phases. Technique 
in which the stationary phase is more polar than the mobile phase (e.g. toluene as the 
mobile phase, silica as the stationary phase) is called normal phase liquid 
chromatography (NPLC) and the opposite (e.g. water-methanol mixture as the mobile 
phase and C18 = octadecylsilyl as the stationary phase) is called reversed phase liquid 
chromatography (RPLC). Ironically the "normal phase" has fewer applications and RPLC 
is therefore used considerably more.  
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Specific techniques which come under this broad heading are listed below. It should also 
be noted that the following techniques can also be considered fast protein liquid 
chromatography if no pressure is used to drive the mobile phase through the stationary 
phase.  
2.3.3 AFFINITY CHROMATOGRAPHY  
 
Affinity chromatography [18] is based on selective non-covalent interaction between an 
analyte and specific molecules. It is very specific, but not very robust. It is often used in 
biochemistry in the purification of proteins bound to tags. These fusion proteins are 
labeled with compounds such as His-tags, biotin or antigens, which bind to the stationary 
phase specifically. After purification, some of these tags are usually removed and the 
pure protein is obtained. Affinity chromatography often utilizes a biomolecule's affinity 
for a metal (Zn, Cu, Fe, etc.). Columns are often manually prepared. Traditional affinity 
columns are used as a preparative step to flush out unwanted biomolecules. However, 
HPLC techniques exist that do utilize affinity chromatography properties. Immobilized 
Metal Affinity Chromatography (IMAC) is useful to separate aforementioned molecules 
based on the relative affinity for the metal (I.e. Dionex IMAC). Often these columns can 
be loaded with different metals to create a column with a targeted affinity.  
2.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY  
 
Supercritical fluid chromatography is a separation technique in which the mobile phase is 
a fluid above and relatively close to its critical temperature and pressure. 
 
3. INTRODUCTION TO HIGH PERFORMANCE LC [19]  
 
The acronym HPLC, coined by the late Prof. Csaba Horvath for his 1970 Pittcon paper, 
originally indicated the fact that high pressure was used to generate the flow required for 
liquid chromatography in packed columns. In the beginning, pumps only had a pressure 
capability of 500 psi. This was called high pressure liquid chromatography, or HPLC.  
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The early 1970s saw a tremendous leap in technology. These new HPLC instruments 
could develop up to 6,000 psi of pressure, and incorporated improved injectors, detectors, 
and columns. HPLC really began to take hold in the mid-to late-1970s. With continued 
advances in performance during this time (smaller particles, even higher pressure), the 
acronym HPLC remained the same, but the name was changed to high performance 
liquid chromatography.  
 
 
Figure 2: High-Performance Liquid Chromatography [HPLC] System 
High performance liquid chromatography is now one of the most powerful tools in 
analytical chemistry. It has the ability to separate, identify, and quantitate the compounds 
that are present in any sample that can be dissolved in a liquid. Today, compounds in 
trace concentrations as low as parts per trillion (ppt) may easily be identified. HPLC can 
be, and has been, applied to just about any sample, such as pharmaceuticals, food, 
nutraceuticals, cosmetics, environmental matrices, forensic samples, and industrial 
chemicals. The components of a basic high-performance liquid chromatography (HPLC) 
system are shown in the simple diagram in Figure 5 (Schematic Diagram).  
A reservoir (Solvent Delivery) holds the solvent (called the mobile phase, because it 
moves). A high-pressure pump solvent manager is used to generate and meter a specified 
flow rate of mobile phase, typically milliliters per minute.  
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An injector (sample manager or auto sampler) is able to introduce (inject) the sample into 
the continuously flowing mobile phase stream that carries the sample into the HPLC 
column. The column contains the chromatographic packing material needed to effect the 
separation. This packing material is called the stationary phase because it is held in place 
by the column hardware. A detector is needed to see the separated compound bands as 
they elute from the HPLC column (most compounds have no color, so we cannot see 
them with our eyes).  
The mobile phase exits the detector and can be sent to waste, or collected, as desired. 
When the mobile phase contains a separated compound band, HPLC provides the ability 
to collect this fraction of the eluate containing that purified compound for further study. 
This is called preparative chromatography. The high-pressure tubing and fittings are used 
to interconnect the pump, injector, column, and detector components to form the conduit 
for the mobile phase, sample, and separated compound bands.  
The detector is wired to the computer data station, the HPLC system component that 
records the electrical signal needed to generate the chromatogram on its display and to 
identify and quantitate the concentration of the sample constituents. Since sample 
compound characteristics can be very different, several types of detectors have been 
developed. For example, if a compound can absorb ultraviolet light, a UV-absorbance 
detector is used. If the compound fluoresces, a fluorescence detector is used. If the 
compound does not have either of these characteristics, a more universal type of detector 
is used, such as an evaporative-light-scattering detector (ELSD). The most powerful 
approach is the use multiple detectors in series. For example, a UV and/or ELSD detector 
may be used in combination with a mass spectrometer (MS) to analyze the results of the 
chromatographic separation. This provides, from a single injection, more comprehensive 
information about an analyte. The practice of coupling a mass spectrometer to an HPLC 
system is called LC/MS. 
 
3.1 ISOCRATIC AND GRADIENT LC SYSTEM OPERATION 
Two basic elution modes are used in HPLC. The first is called isocratic elution. In this 
mode, the mobile phase, either a pure solvent or a mixture, remains the same throughout 
the run. A typical system is outlined in Figure 2. 
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Figure 2: Isocratic LC System 
The second type is called gradient elution, wherein, as its name implies, the mobile phase 
composition changes during the separation. This mode is useful for samples that contain 
compounds that span a wide range of chromatographic polarity. As the separation 
proceeds, the elution strength of the mobile phase is increased to elute the more strongly 
retained sample components. 
 
Figure -3: High-Pressure-Gradient System 
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In the simplest case, shown in Figure 3, there are two bottles of solvents and two pumps. 
The speed of each pump is managed by the gradient controller to deliver more or less of 
each solvent over the course of the separation. The two streams are combined in the 
mixer to create the actual mobile phase composition that is delivered to the column over 
time. At the beginning, the mobile phase contains a higher proportion of the weaker 
solvent [Solvent A]. Over time, the proportion of the stronger solvent [Solvent B] is 
increased, according to a predetermined timetable. Note that in Figure 3, the mixer is 
downstream of the pumps; thus the gradient is created under high pressure. Other HPLC 
systems are designed to mix multiple streams of solvents under low pressure, ahead of a 
single pump. A gradient proportioning valve selects from the four solvent bottles, 
changing the strength of the mobile phase over time [see Figure 4]. 
 
Figure -4: Low-Pressure-Gradient System 
 
 
Today's HPLC requires very special apparatus which includes the following. 
1. Extremely precise gradient mixers. 
2. HPLC high pressure pumps with very constant flow. 
3. Unique high accuracy, low dispersion, HPLC sample valves. 
4. Very high efficiency HPLC columns with inert packing materials. 
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5. High sensitivity low dispersion HPLC detectors. 
6. High speed data acquisition systems. 
7. Low dispersion connecting tubes for valve to column and column to detector. 
3.1.2 HPLC GRADIENT MIXTURES 
HPLC gradient mixers must provide a very precise control of solvent composition to 
maintain a reproducible gradient profile. This can be complicated in HPLC by the small 
elution volumes required by many systems. It is much more difficult to produce a 
constant gradient when mixing small volumes then when mixing large volumes. For low 
pressure systems this requires great precision in the operation of the miniature mixing 
General Introduction valves used and low dispersion flows throughout the mixer. For 
multi-pump high pressure systems it requires a very precise control of the flow rate while 
making very small changes of the flow rate. 
3.1.3 HPLC PUMPS 
Because of the small particles used in modern HPLC, modern LC pumps need to operate 
reliably and precisely at pressures of 10,000 psi or at least 6,000 psi. To operate at these 
pressures and remain sensibly inert to the wide variety of solvents used HPLC pumps 
usually have sapphire pistons, stainless steel cylinders and return valves fitted with 
sapphire balls and stainless steel seats. For analytical purposes HPLC pumps should have 
flow rates that range from 0 to 10 ml/min., but for preparative HPLC, flow rates in excess 
of 100 ml/min may be required. It is extremely difficult to provide a very constant flow 
rate at very low flow rates. If 1% is considered acceptable then for 1ml/min a flow 
variation of less than 10μl/min is required. This level of constancy is required because 
most HPLC detectors are flow sensitive and errors in quantization will result from change 
in flow rate. 
3.1.4 HPLC SAMPLE VALVES 
Since sample valves come between the pump and the column it follows that HPLC 
sample valves must also tolerate pressures up to 10,000 psi. For analytical HPLC, the 
sample volume should be selectable from sub micro liter to a few micro liters, whereas in 
preparative HPLC the sample volume may be even greater than 10 ml. To maintain 
system efficiency the sample valve must be designed to have very low dispersion 
characteristics, this is true not only for flow dispersion but also for the less obvious 
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problems of dispersion caused by sample adsorption/desorption on valve surfaces and 
diffusion of sample into and out of the mating surfaces between valve moving parts. It 
goes without saying that the valves must deliver a very constant sample size but this is 
usually attained by the use of a constant size sample loop. 
 
3.1.5 HPLC COLUMNS 
HPLC columns are packed with very fine particles (usually a few microns in diameter). 
The very fine particles are required to attain the low dispersion that give the high plate 
counts expected of modern HPLC. Plate counts in excess of 25,000 plates per column are 
possible with modern columns, however, these very high efficiencies are very rarely 
found with real samples because of the dispersion associated with injection valves, 
detectors, data acquisition systems and the dispersion due to the higher molecular weight 
of real samples as opposed to the common test samples. Packing these small particles into 
the column is a difficult technical problem but even with good packing a great amount of 
care must be given to the column end fittings and the inlet and outlet connection to keep 
dispersion to a minimum. The main consideration with HPLC is the much wider variety 
of solvents and packing materials that can be utilized because of the much lower 
quantities of both which are required. In particular very expensive optically pure 
compounds can be used to make Chiral HPLC stationary phases and may even be used as 
(disposable) HPLC solvents. 
 
3.1.6 HPLC DETECTORS [20-25] 
UV/Vis spectrophotometers, including diode array detectors, are the most commonly 
employed detectors. Fluorescence spectrophotometers, differential refractometers, 
electrochemical detectors, mass spectrometers, light scattering detectors, radioactivity 
detectors or other special detectors may also be used. Detector consists of a flow-through 
cell mounted at the end of the column. A beam of UV radiation passes through the flow 
cell and into the detector. As compounds elute from the column, they pass through the 
cell and absorb the radiation, resulting in measurable energy level changes. Fixed 
(mercury lamp), variable (deuterium or high-pressure xenon lamp), and multi-wavelength 
detectors are widely available. Modern variable wavelength detectors can be programmed 
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to change wavelength while an analysis is in progress. Multi-wavelength detectors 
measure absorbance at two or more wavelengths simultaneously. In diode array multi-
wavelength detectors, continuous radiation is passed through the sample cell, and then 
resolved into its constituent wavelengths, which are individually detected by the 
photodiode array. These detectors acquire absorbance data over the entire UV-visible 
range, thus providing the analyst with chromatograms at multiple, selectable 
wavelengths, spectra of the eluting peaks and also peak purity. 
Differential refractometers detectors measure the difference between the refractive index 
of the mobile phase alone and that of the mobile phase containing chromatographic 
compounds as it emerges from the column. Refractive index detectors are used to detect 
non-UV absorbing compounds. Fluorimetric detectors are sensitive to compounds that 
are inherently fluorescent or that can be converted to fluorescent derivatives either by 
chemical transformation of the compound or by coupling with fluorescent reagents at 
specific functional groups. Potentiometric, voltametric, or polarographic electrochemical 
detectors are useful for the quantitation of species that can be oxidized or reduced at a 
working electrode. These detectors are selective, sensitive, and reliable, but require 
conducting mobile phases free of dissolved oxygen and reducible metal ions. 
Electrochemical detectors with carbon-paste electrodes may be used advantageously to 
measure nanogram quantities of easily oxidized compounds, notably phenols and 
catechols. 
In order to give an accurate chromatographic profile the detector sampling (cell) volume 
must be a small fraction of the solute elution volume. If the detector volume were larger 
than the elution volume then you would have peaks that appeared with flat tops as the 
whole peak would be resident in the detector at the same time. This means that as column 
volumes decrease and system efficiencies increase the volume of the detector cell volume 
must also decrease. It is odds for the requirement for detector to maintain high sensitivity 
as this is usually dependant on having a larger cell volume. Again, this requires the very 
careful design of modern detectors. Many types of detectors can use with HPLC system 
like UV-Visible or PDA (Photo Diode Array), RI (Refractive Index), Fluorescence, ECD 
(Electro Chemical Detector), ELSD (Evaporative Light Scattering detector) and many 
others hyphenated techniques like MS, MS/MS and NMR as well as evaporative IR. 
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3.1.7 HPLC DATA ACQUISITION 
 
In HPLC data acquisition system the higher sampling rate needed for the rapidly eluting 
narrow peaks of the HPLC chromatogram. Although the theoretical number of samples 
needed for good quantization are actually quite small, for real systems a hundred samples 
or more per peak is recommended; thus, for a 4 sec wide peak, a rate of 25 samples per 
second may be required. The same data analysis and reporting software can be used as in 
ordinary LC. 
 
3.1.8 CONCLUSION 
HPLC is probably the most universal type of analytical procedure; its application areas 
include quality control, process control, forensic analysis, environmental monitoring and 
clinical testing. In addition HPLC also ranks as one of the most sensitive analytical 
procedures and is unique in that it easily copes with multi-component mixtures. It has 
achieved this position as a result of the constant evolution of the equipment used in LC to 
provide higher and higher efficiencies at faster and faster analysis times with a constant 
incorporation of new highly selective column packings. 
 
4. INTRODUCTION TO ULTRA PERFORMANCE LC [26]  
 
In 2004, further advances in instrumentation and column technology were made to 
achieve very significant increases in resolution, speed, and sensitivity in liquid 
chromatography. Columns with smaller particles (1.7 micron) and instrumentation with 
specialized capabilities designed to deliver mobile phase at 15,000 psi (1,000 bars) were 
needed to achieve a new level of performance. A new system had to be holistically 
created to perform ultra-performance liquid chromatography, now known as UPLC 
technology.  
Basic research is being conducted today by scientists working with columns containing 
even smaller 1-micron-diameter particles and instrumentation capable of performing at 
100,000 psi. This provides a glimpse of what we may expect in the future. UPLC refers 
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to Ultra Performance Liquid Chromatography. It improves in three areas: 
chromatographic resolution, speed and sensitivity analysis. It uses fine particles and saves 
time and reduces solvent consumption [27-31]. UPLC is comes from HPLC. HPLC has 
been the evolution of the packing materials used to effect the separation. An underlying 
principle of HPLC dictates that as column packing particle size decreases, efficiency and 
thus resolution also increases. As particle size decreases to less than 2.5μm, there is a 
significant gain in efficiency and it’s doesn’t diminish at increased linear velocities or 
flow rates according to the common Van Deemter equation [32]. By using smaller 
particles, speed and peak capacity (number of peaks resolved per unit time) can be 
extended to new limits which is known as Ultra Performance. 
 
The classic separation method is of HPLC (High Performance Liquid Chromatography) 
with many advantages like robustness, ease of use, good selectivity and adjustable 
sensitivity. Its main limitation is the lack of efficiency compared to gas chromatography 
or the capillary electrophoresis [33, 34] due to low diffusion coefficients in liquid phase, 
involving slow diffusion of analytes in the stationary phase. The Van Deemter equation 
shows that efficiency increases with the use of smaller size particles but this leads to a 
rapid increase in back pressure, while most of the HPLC system can operate only up to 
400 bar. That is why short columns filled with particles of about 2μm are used with these 
systems, to accelerate the analysis without loss of efficiency, while maintaining an 
acceptable loss of load.  
To improve the efficiency of HPLC separations, the following can be done,  
(1) Work at higher temperatures  
(2) Use of monolithic columns  
 
4.1. USE OF THE UPLC SYSTEM  
Elevated-temperature chromatography also allows for high flow rates by lowering the 
viscosity of the mobile phase, which significantly reduces the column backpressure [35, 
36]. Monolithic columns contain a polymerized porous support structure that provides 
lower flow resistances than conventional particle-packed columns [37-39].  
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4.1.1 PRINCIPLE  
 
The UPLC is based on the principal of use of stationary phase consisting of particles less 
than 2 μm (while HPLC columns are typically filled with particles of 3 to 5 μm). The 
underlying principles of this evolution are governed by the van Deemter equation, which 
is an empirical formula that describes the relationship between linear velocity (flow rate) 
and plate height (HETP or column efficiency). The Van Deemter curve, governed by an 
equation with three components shows that the usable flow range for a good efficiency 
with small diameter particles is much greater than for larger diameters [40-43] 
H=A+B/v+Cv 
Where A, B and C are constants and v is the linear velocity, the carrier gas flow rate. The 
A term is independent of velocity and represents "eddy" mixing. It is smallest when the 
packed column particles are small and uniform. The B term represents axial diffusion or 
the natural diffusion tendency of molecules. This effect is diminished at high flow rates 
and so this term is divided by v. The C term is due to kinetic resistance to equilibrium in 
the separation process.  
The kinetic resistance is the time lag involved in moving from the gas phase to the 
packing stationary phase and back again. The greater the flow of gas, the more a 
molecule on the packing tends to lag behind molecules in the mobile phase. Thus this 
term is proportional to v.  
Therefore it is possible to increase throughput, and thus the speed of analysis without 
affecting the chromatographic performance. The advent of UPLC has demanded the 
development of a new instrumental system for liquid chromatography, which can take 
advantage of the separation performance (by reducing dead volumes) and consistent with 
the pressures (about 8000 to 15,000 PSI, compared with 2500 to 5000 PSI in HPLC). 
Efficiency is proportional to column length and inversely proportional to the particle size 
[44]. Therefore, the column can be shortened by the same factor as the particle size 
without loss of resolution. The application of UPLC resulted in the detection of additional 
drug metabolites, superior separation and improved spectral quality [45, 46].  
4.1.2 SAMPLE INJECTION  
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In UPLC, sample introduction is critical. Conventional injection valves, either automated 
or manual, are not designed and hardened to work at extreme pressure. To protect the 
column from extreme pressure fluctuations, the injection process must be relatively 
pulse-free and the swept volume of the device also needs to be minimal to reduce 
potential band spreading. A fast injection cycle time is needed to fully capitalize on the 
speed afforded by UPLC, which in turn requires a high sample capacity. Low volume 
injections with minimal carryover are also required to increase sensitivity [47]. There are 
also direct injection approaches for biological samples [48, 49].  
4.1.3 UPLC COLUMNS  
 
Resolution is increased in a 1.7 μm particle packed column because efficiency is better. 
Separation of the components of a sample requires a bonded phase that provides both 
retention and selectivity. Four bonded phases are available for UPLC separations: 
ACQUITY UPLCTM BEH C18 and C8 (straight chain alkyl columns), ACQUITY 
UPLC BEH Shield RP18 (embedded polar group column) and ACQUITY UPLC BEH 
Phenyl (phenyl group tethered to the silyl functionality with a C6 alkyl) [50]. Column 
chemistry provides a different combination of hydrophobicity, silanol activity, hydrolytic 
stability and chemical interaction with analytes.  
ACQUITY UPLC BEH C18 and C8 columns are considered the universal columns of 
choice for most UPLC separations by providing the widest pH range. They incorporate 
trifunctional ligand bonding chemistries which produce superior low pH stability. This 
low pH stability is combined with the high pH stability of the 1.7 μm BEH particle to 
deliver the widest usable pH operating range. ACQUITY UPLC BEH Shield RP18 
columns are designed to provide selectivities that complement the ACQUITY UPLC 
BEH C18 and C8 phases.  
ACQUITY UPLC BEH Phenyl columns utilize a trifunctional C6 alkyl tether between 
the phenyl ring and the silyl functionality. This ligand, combined with the same 
proprietary endcapping processes as the ACQUITY UPLC BEH C18 and C8 columns, 
provides long column lifetimes and excellent peak shape. This unique combination of 
ligand and endcapping on the 1.7 μm BEH particle creates a new dimension in selectivity 
allowing a quick match to the existing HPLC column. An internal dimension (ID) of 2.1 
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mm column is used. For maximum resolution, choose a 100 mm length and for faster 
analysis, and higher sample throughput, choose 50 mm column. 
 
 
 
Figure 5: Different column chemistry available for UPLC 
Half-height peak widths of less than one second are obtained with 1.7μm particles, which 
gives significant challenges for the detector. In order to integrate an analyte peak 
accurately and reproducibly, the detector sampling rate must be high enough to capture 
enough data points across the peak. The detector cell must have minimal dispersion 
(volume) to preserve separation efficiency. Conceptually, the sensitivity increase for 
UPLC detection should be 2-3 times higher than HPLC separations, depending on the 
detection technique. MS detection is significantly enhanced by UPLC; increased peak 
concentrations with reduced chromatographic dispersion at lower flow rates promote 
increased source ionization efficiencies.  
The ACQUITY UPLC System consists of a binary solvent manager, sample manager 
including the column heater, detector, and optional sample organizer. The binary solvent 
manager uses two individual serial flow pumps to deliver a parallel binary gradient. 
There are built-in solvent select valves to choose from up to four solvents. There is a 
15,000-psi pressure limit (about 1000 bar) to take full advantage of the sub-2μm particles. 
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The sample manager also incorporates several technology advancements. Using pressure 
assisted sample introduction, low dispersion is maintained through the injection process, 
and a series of pressures transducers facilitate self-monitoring and diagnostics. It uses 
needle-in-needle sampling for improved ruggedness and a needle calibration sensor 
increases accuracy. Injection cycle time is 25 seconds without a wash and 60 sec with a 
dual wash used to further decrease carry over. A variety of microtiter plate formats (deep 
well, mid height, or vials) can also be accommodated in a thermostatically controlled 
environment. Using the optional sample organizer, the sample manager can inject from 
up to 22 micro titer plates. The sample manager also controls the column heater. Column 
temperatures up to 65°C can be attained. To minimize sample dispersion, a “pivot out” 
design allows the column outlet to be placed in closer proximity to the source inlet of an 
MS detector [51].  
For UPLC detection, the tunable UV/Visible detector is used which includes new 
electronics and firmware to support Ethernet communications at the high data rates. 
Conventional absorbance-based optical detectors are concentration sensitive detectors, 
and for UPLC use, the flow cell volume would have to be reduced in standard 
UV/Visible detectors to maintain concentration and signal. According to Beer’s Law, 
smaller volume conventional flow cells would also reduce the path length upon which the 
signal strength depends. A reduction in cross-section means the light path is reduced, and 
transmission drops with increasing noise. Therefore, if a conventional HPLC flow cell 
were used, UPLC sensitivity would be compromised. The ACQUITY Tunable 
UV/Visible detector cell consists of a light guided flow cell equivalent to an optical fiber. 
Light is efficiently transferred down the flow cell in an internal reflectance mode that still 
maintains a 10mm flow cell path length with a volume of only 500mL. Tubing and 
connections in the system are efficiently routed to maintain low dispersion and to take 
advantage of leak detectors that interact with the software to alert the user to potential 
problems [52].  
4.1.4 ADVANTAGES  
1. Decreases run time and increases sensitivity.  
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2. Provides the selectivity, sensitivity, and dynamic range of LC analysis.  
3. Maintaining resolution performance.  
4. Expands scope of Multiresidue Methods.  
5. UPLC’s fast resolving power quickly quantifies related and unrelated compounds  
6. Faster analysis through the use of a novel separation material of small particle 
size. 
7. Operation cost is reduced.  
8. Less solvent consumption.  
9. Reduces process cycle times, so that more product can be produced with existing 
resources.  
10. Increases sample throughput and enables manufacturers to produce more material 
that consistently meet or exceeds the product specifications, potentially 
eliminating variability, failed batches, or the need to re-work material [53, 54].  
11. Delivers real-time analysis in step with manufacturing processes.  
12. Assures end-product quality, including final release testing.  
 
 
4.1.5 DISADVANTAGES  
 
Due to increased pressure requires more maintenance and reduces the life of the columns 
of this type. So far performance similar or even higher has been demonstrated by using 
stationary phases of size around 2 μm without the adverse effects of high pressure. In 
addition, the phases of less than 2 μm are generally non-regenerable and thus have 
limited use [55, 56]. 
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5. APPLICATIONS OF CHROMATOGRAPHY 
 
In recent times chromatography is most widely used analytical tool for various 
applications. Hence it could not be possible for include all of it but some of very 
important and recently developed applications are discussed here,  
 
5.1.  AFFINITY CHROMATOGRAPHY: CLINICAL APPLICATIONS [57] 
Affinity chromatography is a type of liquid chromatography that makes use of biological-
like interactions for the separation and specific analysis of sample components. This 
work describes the basic principles of affinity chromatography and examines its use in 
the testing of clinical samples, with an emphasis on HPLC-based methods. Some 
traditional applications of this approach include the use of boronate, lectin, protein A or 
protein G, and immunoaffinity supports for the direct quantification of solutes. Newer 
techniques that use antibody-based columns for on- or off-line sample extraction are 
examined in detail, as are methods that use affinity chromatography in combination with 
other analytical methods, such as reversed-phase liquid chromatography, gas 
chromatography, and capillary electrophoresis. Indirect analyte detection methods are 
also described in which immunoaffinity chromatography is used to perform flow-based 
immunoassays. Other applications that are include affinity-based chiral separations and 
the use of affinity chromatography for the study of drug or hormone interactions with 
binding proteins. Some areas of possible future developments are then considered, such 
as tandem affinity methods and the use of synthetic dyes, immobilized metal ions, 
molecular imprints, or aptamers as affinity ligands for clinical analyte. 
5.2.  PROTEIN PURIFICATION : MEMBRANE CHROMATOGRAPHY [58] 
Adsorption chromatography is increasingly used for protein purification and medical 
applications. Synthetic membranes have advantages as support matrices in comparison to 
 
Chapter – 1                                                                                                                                                    General Introduction 
Department of Chemistry, Saurashtra University, Rajkot-360005.                                                              Page 26 
 
conventional bead supports because they are not compressible and they eliminate 
diffusion limitations. As a result, higher throughput and faster processing times are 
possible in membrane systems. In this paper, there are various applications of membrane 
chromatography by focusing on affinity, ion exchange, hydrophobic interaction, 
reversed-phase and multistage chromatography. The prospects of further development of 
membrane chromatography are massive. 
5.3. LC-MASS SPECTROMETRY IN ANALYTICAL TOXICOLOGY [59] 
Liquid chromatography-mass spectrometry (LC-MS), after long-term development that 
has introduced seven major interfacing techniques, is finally suitable for application in 
the field of analytical toxicology. Various compound classes can be analyzed, and 
sensitivities for more or less polar analytes that are as good as or better than those of gas 
chromatography-mass spectrometry can be obtained with modern interfaces. In addition, 
because ionization is often softer than classical electron impact, some LC-MS interfaces 
are able to handle fragile species that are otherwise not amenable to MS. [59] 
 
5.4. ENANTIOSELECTIVE CHROMATOGRAPHY AS A ALTERNATIVE 
 FOR THE PREPARATION OF DRUG ENANTIOMERS [60] 
The preparative separation of enantiomers by chromatography on Chiral stationary 
phases (CSPs) has been recognized as being a useful alternative to the more conventional 
approaches such as enantioselective synthesis and enzymatically catalyzed 
transformations. The possible contribution of enantioselective chromatography with 
respect to the preparation of enantiomerically pure compounds is reviewed in the context 
of the competitive approaches and depending on the application scale, with a special 
emphasis on the recent progresses achieved in this particular field of separation. 
5.5. MICROEMULSION ELECTROKINETIC CHROMATOGRAPHY [61] 
Compared to MEKC, the presence of a water-immiscible oil phase in the microemulsion 
droplets of microemulsion EKC (MEEKC) gives rise to some special properties, such as 
enhanced solubilization capacity and enlarged migration window, which could allow for 
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the improved separation of various hydrophobic and hydrophilic compounds, with 
reduced sample pretreatment steps, unique selectivities and/or higher efficiencies. 
Typically, stable and optically clear oil-in-water microemulsions containing a surfactant 
(SDS), oil (octane or heptane), and cosurfactant (1-butanol) in phosphate buffer are 
employed as separation media in conventional MEEKC. However, in recent years, the 
applicability of reverse MEEKC (water-in-oil microemulsions) has also been 
demonstrated, such as for the enhanced separation of highly hydrophobic substances. 
Also, during the past few years, the development and application of MEEKC for the 
separation of chiral molecules has been expanded, based on the use of enantioselective 
microemulsions that contained a chiral surfactant or chiral alcohol.  
On the other hand, the application of MEEKC for the characterization of the lipophilicity 
of chemical substances remains an active and important area of research, such as the use 
of multiplex MEEKC for the high-throughput determination of partition coefficients 
(log P values) of pharmaceutical compounds. Emphases are placed on the discussion of 
MEEKC in the separation of chiral molecules and highly hydrophobic substances, as well 
as in the determination of partition coefficients, followed by a survey of recent 
applications of MEEKC in the analysis of pharmaceuticals, cosmetics and health-care 
products, biological and environmental compounds, plant materials, and foods. 
5.6. LC–MS IN FORENSIC & CLINICAL TOXICOLOGY [62] 
Liquid chromatographic–mass spectrometric (LC–MS) procedures are available for the 
identification and/or quantification of drugs of abuse, therapeutic drugs, poisons and/or 
their metabolites in biosamples (whole blood, plasma, serum, urine, cerebrospinal fluid, 
vitreous humor, liver or hair) of humans or animals (cattle, dog, horse, mouse, pig or rat). 
This is relevant to clinical toxicology, forensic toxicology, doping control or drug 
metabolism and pharmacokinetics. 
5.7. LC–MS TO THE CHARACTERIZATION OF FOOD PROTEINS AND 
 DERIVED PEPTIDES [63] 
This review describes the development of mass spectrometry off-line and on-line coupled 
with liquid chromatography to the analysis of food proteins. It includes the significant 
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results recently obtained in the field of milk, egg and cereal proteins. This paper also 
outlines the research carried out in the area of food protein hydrolysates, which are 
important components in foodstuffs due to their functional properties. Liquid 
chromatography and mass spectrometry have been particularly used for the 
characterization of food peptides and especially in dairy products. 
 
5.8. AFFINITY CHROMATOGRAPHY IN PROTEOMICS [64] 
 
Affinity chromatography is a powerful protein separation method that is based on the 
specific interaction between immobilized ligands and target proteins. Peptides can also be 
separated effectively by affinity chromatography through the use of peptide-specific 
ligands. Both two-dimensional electrophoresis (2-DE) - and non-2-DE-based proteomic 
approaches benefit from the application of affinity chromatography. Before protein 
separation by 2-DE, affinity separation is used primarily for preconcentration and 
pretreatment of samples. Those applications entail the removal of one protein or a class 
of proteins that might interfere with 2-DE resolution, the concentration of low-abundance 
proteins to enable them to be visualized in the gel, and the classification of total protein 
into two or more groups for further separation by gel electrophoresis. Non-2-DE-based 
approaches have extensively employed affinity chromatography to reduce the complexity 
of protein and peptide mixtures. Prior to mass spectrometry (MS), preconcentration and 
capture of specific proteins or peptides to enhance sensitivity can be accomplished by 
using affinity adsorption.  Affinity purification of protein complexes followed by 
identification of proteins by MS serves as a powerful tool for generating a map of 
protein–protein interactions and cellular locations of complexes. Affinity 
chromatography of peptide mixtures, coupled with mass spectrometry, provides a tool for 
the study of protein posttranslational modification (PTM) sites and quantitative 
proteomics.  
 
Quantitation of proteomes is possible via the use of isotope-coded affinity tags and 
isolation of proteolytic peptides by affinity chromatography. An emerging area of 
proteomics technology development is miniaturization. Affinity chromatography is 
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becoming more widely used for exploring PTM and protein–protein interactions, 
especially with a view toward developing new general tag systems and strategies of 
chemical derivatization on peptides for affinity selection. More applications of affinity-
based purification can be expected, including increasing the resolution in 2-DE, 
improving the sensitivity of MS quantification, and incorporating purification as part of 
multidimensional liquid chromatography.  
 
5.9. CLINICAL APPLICATIONS OF GAS CHROMATOGRAPHY AND GAS 
 CHROMATOGRAPHY–MASS SPECTROMETRY OF STEROIDS [65] 
 
This review article underlines the importance of gas chromatography–mass spectrometry 
(GC–MS) for determination of steroids in man. The use of steroids labelled with stable 
isotopes as internal standard and subsequent analysis by GC–MS yields up to now the 
only reliable measurement of steroids in serum. Isotope dilution GC–MS is the reference 
method for evaluation of routine analysis of serum steroid hormones. GC–MS is an 
important tool for detection of steroid hormone doping and combined with a combustion 
furnace and an isotope ratio mass spectrometer the misuse of testosterone by athletes can 
be discovered. Finally the so called urinary steroid profile by GC and GC–MS is the 
method of choice for detection of steroid metabolites in health and disease. 
 
5.10. LC-MS/MS FOR THE ANALYSIS OF PHARMACEUTICAL RESIDUES 
 IN ENVIRONMENTAL SAMPLES [66] 
 
Pharmaceutical residues are environmental contaminants of recent concern and the 
requirements for analytical methods are mainly dictated by low concentrations found in 
aqueous and solid environmental samples. This can be determined by LC-MS/MS. 
Pharmaceuticals included are antibiotics, non-steroidal anti-inflammatory drugs, β-
blockers, lipid regulating agents and psychiatric drugs. This can deal by advanced aspects 
of current LC–MS/MS methodology. 
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6.0 INTRODUCTION TO ANALYTICAL METHOD VALIDATION  
 
6.1. ANALYTICAL METHOD VALIDATION  
 
Validation of an analytical procedure is the process by which it is established, by 
laboratory studies, that the performance characteristics of the procedure meet the 
requirements for its intended use [67]. All analytical methods that are intended to be used 
for analyzing any samples will need to be validated. Validation of analytical methods is 
an essential but time - consuming activity for most analytical development laboratories. It 
is therefore important to understand the requirements of method validation in more detail 
and the options that are available to allow for optimal utilization of analytical resources in 
a development laboratory [68].  
 
6.2. ANALYTICAL METHOD VALIDATION CHARACTERISTICS [69-74] 
 
 Typical analytical performance characteristics that should be considered in the validation 
of the types of procedures described in this chapter are listed below. Each validation 
characteristic is deﬁned to ensure consistency in usage of terminology and interpretation:  
 
• Accuracy   
• Precision   
o Repeatability   
o Intermediate precision     
• Speciﬁcity   
• Detection limit   
• Quantitation limit   
• Linearity   
• Range   
• Robustness     
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6.2.1.   ACCURACY 
 
 The International Convention on Harmonization (ICH) deﬁ nes the accuracy of an 
analytical procedure as the closeness of agreement between the values that are accepted 
either as conventional true values or an accepted reference value and the value found. For 
drug substance, accuracy may be deﬁned by the application of the analytical procedure to 
an analyte of known purity (e.g., a reference standard). For the drug product, accuracy 
will be determined by application of the analytical procedure to synthetic mixtures of the 
drug product components to which known amounts of analyte have been added within the 
range of the procedure. The ICH document also recommends assessing a minimum of 
nine determinations over a minimum of three concentration levels covering the speciﬁed 
range (e.g., three concentrations/three replicates).  
 Accuracy is usually reported as percent recovery by the assay (using the proposed 
analytical procedure) of known added amount of analyte in the sample or as the 
difference between the mean and the accepted true value together with the conﬁdence 
intervals. The range for the accuracy limit should be within the linear range. Typical 
accuracy of the recovery of the drug substance is expected to be about 99 –101%. Typical 
accuracy of the recovery of the drug product is expected to be about 98 – 102%. Values 
of accuracy of recovery data beyond this range need to be investigated as appropriate. 
6.2.2. METHOD PRECISION  
 The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple samples of the same 
homogeneous sample under prescribed conditions. Precision is usually investigated at 
three levels: repeatability, intermediate precision, and reproducibility. For simple 
formulation it is important that precision be determined using authentic homogeneous 
samples. A justiﬁ cation will be required if a homogeneous sample is not possible and 
artiﬁcially prepared samples or sample solutions are used.  
6.2.2.1. REPEATABILITY       
Repeatability is a measure of the precision under the same operating conditions over a 
short interval of time, that is, under normal operating conditions of the analytical method 
with the same equipment. It is sometimes referred to as intra - assay precision.  
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 The ICH recommends that repeatability be assessed using a minimum of nine 
determinations covering the speciﬁ ed range for the procedure (e.g., three 
concentrations/three replicates as in the accuracy experiment) or using a minimum of six 
determinations at 100% of the test concentration. Reporting of the standard deviation, 
relative standard deviation (coefficient of variation), and conﬁ dence interval is required. 
The assay values are independent analyses of samples that have been carried through the 
complete analytical procedure from sample preparation to ﬁnal test result.  
 
6.2.2.2. INTERMEDIATE PRECISION       
Intermediate precision is deﬁ ned as the variation within the same laboratory. The extent 
to which intermediate precision needs to be established depends on the circumstances 
under which the procedure is intended to be used. Typical parameters that are 
investigated include day - to - day variation, analyst variation, and equipment variation. 
Depending on the extent of the study, the use of experimental design is encouraged. 
Experimental design will minimize the number of experiments that need to be performed. 
It is important to note that ICH allows exemption from doing intermediate precision 
when reproducibility is proven. It is expected that the intermediate precision should show 
variability that is in the same range or less than repeatability variation. ICH recommends 
the reporting of standard deviation, relative standard deviation (coefficient of variation), 
and conﬁdence interval of the data.   
6.2.2.3. REPRODUCIBILITY       
Reproducibility measures the precision between laboratories. This parameter is 
considered in the standardization of an analytical procedure (e.g., inclusion of procedures 
in pharmacopeias and method transfer between different laboratories).  
 To validate this characteristic, similar studies need to be performed at different 
laboratories using the same homogeneous sample lot and the same experimental design. 
In the case of method transfer between two laboratories, different approaches may be 
taken to achieve the successful transfer of the procedure. The most common approach is 
the direct - method transfer from the originating laboratory to the receiving laboratory. 
The originating laboratory is deﬁ ned as the laboratory that has developed and validated 
the analytical method or a laboratory that has previously been certiﬁ ed to perform the 
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procedure and will participate in the method transfer studies. The receiving laboratory is 
deﬁned as the laboratory to which the analytical procedure will be transferred and that 
will participate in the method transfer studies. In the direct - method transfer, it is 
recommended that a protocol be initiated with details of the experiments to be performed 
and acceptance criteria (in terms of the difference between the means of the two 
laboratories) for passing the method transfer. Table 1 provides examples of a set of 
method transfer data between two laboratories.     
 
 Runs Average percent 
Originating Laboratory 12 100.7 
Receiving Laboratory 4 100.2 
 
TABLE 1 Result from Method Transfer between Two Laboratories 
 
6.2.4   SPECIFICITY 
  
 The ICH deﬁnes speciﬁ city as the ability to assess unequivocally an analyte in the 
presence of components that may be expected to be present. In many publications 
selectivity and speciﬁ city are often used interchangeably. However, there are debates 
over the use of speciﬁ city over selectivity and some authorities, for example, the 
International Union of Pure and Applied Chemistry (IUPAC), have preferred the term 
selectivity reserving  speciﬁ city  for those procedures that are completely selective. For 
pharmaceutical application, the above deﬁnition of ICH will be used.  
 For identity test, compounds of closely related structures which are likely to be present 
should be discriminated from each other. This could be conﬁ rmed by obtaining positive 
results (by comparison with a known reference material) from samples containing the 
analyte, coupled with negative results from samples which do not contain the analyte. 
Furthermore, the identiﬁ cation test may be applied to material structurally similar or 
closely related to the analyte to conﬁ rm that a positive response is not obtained. The 
choice of such potentially interfering materials should be based on sound scientiﬁ c 
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judgment with a consideration of the interferences that could occur. The speciﬁcity for an 
assay and impurity tests should be approached from two angles:  
6.2.4.1. IMPURITIES ARE AVAILABLE     
The speciﬁ city of an assay method is determined by comparing test results from an 
analysis of sample containing the impurities, degradation products, or placebo ingredients 
with those obtained from an analysis of samples without the impurities, degradation 
products, or placebo ingredients. For a stability - indicating assay method, degradation 
peaks need to be resolved from the drug substance. However, these impurities do not 
need to be resolved from each other.   
   For the impurity test, the determination should be established by spiking drug  
substance or drug product with the appropriate levels of impurities and demonstrating the 
separation of these impurities individually and/or from other components in the sample 
matrix. Representative chromatograms should be used.   
6.2.4.2.  IMPURITIES ARE NOT AVAILABLE     
Speciﬁcity may be demonstrated by comparing the test results of samples containing 
impurities or degradation products to a second well - characterized procedure or other 
validated analytical procedure (orthogonal method). This should include samples stored 
under relevant stress conditions (light, heat, humidity, acid/base hydrolysis and 
oxidation). For the assay method, the two results should be compared; for impurity tests, 
the impurity proﬁ les should be compared. Peak homogeneity tests should be performed 
using PDA or mass spectrometry to show that the analyte chromatographic peak is not 
attributable to more than one component.  
6.2.5.   DETECTION LIMIT  
 The detection limit (DL) is a characteristic for the limit test only. It is the lowest amount 
of analyte in a sample that can be detected but not necessarily quantitated under the stated 
experimental conditions. The detection is usually expressed as the concentration of the 
analyte in the sample.  
There are several approaches to establish the DL. Visual evaluation may be used for 
noninstrumental (e.g., solution color) and instrumental methods. In this case, the DL is 
determined by the analysis of a series of samples with known concentrations and 
establishing the minimum level at which the analyte can be reliably detected. 
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Presentation of relevant chromatograms or other relevant data is sufficient for 
justiﬁcation of the DL.  
 For instrumental procedures that exhibit background noise, it is common to compare 
measured signals from samples with known low concentrations of analyte with those of 
the blank samples. The minimum concentration at which the analyte can reliably be 
detected is established using an acceptable signal - to - noise ratio of 2:1 or 3:1. 
Presentation of relevant chromatograms is sufficient for justiﬁcation of the DL.  
 Another approach estimates the DL from the standard deviation of the response and the 
slope of the calibration curve. The standard deviation can be determined either from the 
standard deviation of multiple blank samples or from the standard deviation of they  
intercepts of the regression lines done in the range of the DL. This estimate will need to 
be subsequently validated by the independent analysis of a suitable number of samples 
near or at the DL: 
LOD = 3.3 σ/S 
Where σ is the standard deviation of the response and  S  is the slope of the calibration 
curve.   
 
6.2.6.   QUANTITATION LIMIT  
 
 The quantitation Limit (QL) is a characteristic of quantitative assays for low levels of 
compounds in sample matrices, such as impurities in bulk drug substances and 
degradation products in ﬁ nished pharmaceuticals. QL is deﬁ ned as the concentration of 
related substance in the sample that will give a signal - to - noise ratio of 10 : 1. The QL 
of a method is affected by both the detector sensitivity and the accuracy of sample 
preparation at the low concentration of the impurities. In practice, QL should be lower 
than the corresponding ICH report limit.  
 ICH recommends three approaches to the estimation of QL. The ﬁrst approach is to 
evaluate it by visual evaluation and may be used for noninstrumental methods and 
instrumental methods. QL is determined by the analysis of samples with known 
concentrations of analyte and by establishing the minimum level at which the analyte can 
be quantitated with acceptable accuracy and precision. The second approach determines 
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the signal - to - noise ratio by comparing measured signals from samples with known low 
concentrations of analyte with those of blank samples. QL is the minimum concentration 
at which the analyte can be reliably quantiﬁed at the signal to noise ratio of 10 : 1.  
 The third approach estimates QL by the equation 
LOQ = 10 σ/S 
The slope S may be estimated from the calibration curve of the analyte. The value of σ 
may be estimated by (1) calculating the standard deviation of the responses obtained from 
the measurement of the analytical background response of an appropriate number of 
blank samples or (2) calculating the residual standard deviation of the regression line 
from the calibration curve using samples containing the analyte in the range of the QL.  
 Whatever approach is applied, the QL should be subsequently validated by the analysis 
of a suitable number of samples prepared at the QL and determining the precision and 
accuracy at this level. 
 
6.2.7. LINEARITY 
  
 ICH deﬁnes linearity of an analytical procedure as the ability (within a given range) to 
obtain test results of variable data (e.g., absorbance and area under the curve) which are 
directly proportional to the concentration (amount of analyte) in the sample. The data 
variables that can be used for quantitation of the analyte are the peak areas, peak heights, 
or the ratio of peak areas (heights) of analyte to the internal standard peak. Quantitation 
of the analyte depends on it obeying Beer’s law for the spectroscopic method over a 
concentration range. Therefore, the working sample  
concentration and samples tested for accuracy should be in the linear range. There are 
two general approaches for determining the linearity of the method. The ﬁ rst approach is 
to weigh different amounts of standard directly to prepare linearity solutions at different 
concentrations. However, it is not suitable to prepare solution at very low concentration, 
as the weighing error will be relatively high. Another approach is to prepare a stock 
solution of high concentration. Linearity is then demonstrated directly by dilution of the 
standard stock solution. This is more popular and the recommended approach. Linearity 
is best evaluated by visual inspection of a plot of the signals as a function of analyte 
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concentration. Subsequently, the variable data are generally used to calculate a regression 
line by the least - squares method. At least ﬁ ve concentration levels should be used. 
Under normal circumstances, linearity is acceptable with a coefficient of determination 
(r2
 The slope of the regression line will provide an idea of the sensitivity of the regression, 
and hence the method that is being validated. They intercept will provide an estimate of 
the variability of the method. For example, the ratios percent of they  intercept with the 
variable data at nominal concentration are sometimes used to estimate the method 
variability.  
) of ≥0.997. The slope, residual sum of squares, and y intercept should also be reported 
as required by ICH.  
 For the determination of potency assay of a drug substance or a drug product, the usual 
range of linearity should be ± 20% of the target or nominal concentration. For the 
determination of content uniformity, it should be ± 30% of the target or nominal 
concentration. 
 
6.2.8.   RANGE  
 
 The range of an analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample for which it has been demonstrated that the 
analytical procedure has a suitable level of precision, accuracy, and linearity. The range is 
normally expressed in the same units as test results (e.g., percent, parts per million) 
obtained by the analytical procedure.  
 For the assay of drug substance or ﬁ nished drug product, it is normally recommended to 
have a range of 80 – 120% of the nominal concentration.  For content uniformity, a 
normal range would cover 70 – 130% of the nominal concentration, unless a wider and 
more appropriate range (e.g., metered - dose inhalers) is justiﬁed.  For dissolution testing, 
a normal range is ± 20% over the speciﬁ ed range. If the acceptance criterion for a 
controlled - release product covers a region from 20% after 1   h, and up to 90% after 24   
h, the validated range would be 0 – 110% of the label claim. In this case, the lowest 
appropriate quantiﬁable concentration of analyte will be used as the lowest limit as 0% is 
not appropriate.   
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6.2.9.   ROBUSTNESS  
 
 Robustness of an analytical procedure is a measure of the analytical method to remain 
unaffected by small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage.  
 The evaluation of robustness is normally considered during the development phase and 
depends on the type of procedure under study. Experimental design (e.g., fractional 
factorial design or Plackett – Burman design) is common and useful to investigate 
multiple parameters simultaneously. The result will help to identify critical parameters 
that will affect the performance of the method. Common method parameters that can 
affect the analytical procedure should be considered based on the analytical technique 
and properties of the samples:  
 
  1.    Sample preparation   
   a.  Extraction time   
   b.  Sample solvent (pH    ±    0.05 unit, percent organic    ±    2% absolute)   
   c. Membrane filters   
   d.  Sample and standard stability     
  2.    High - performance liquid chromatography (HPLC) conditions  
    a.  Mobile - phase composition (pH    ±    0.05 unit, percent organic   ±    2%  
        Absolute)   
  b.  Column used (equivalent columns, lots and/or suppliers, age)   
   c.  Temperature   
   d.  Flow rate     
  3.    Gas chromatography (GC) conditions  
    a.  Column used (lots and/or suppliers, age)   
    b.  Temperature   
   c.  Flow rate      
 
6.3.  PROCESS OF ANALYTICAL METHOD VALIDATION 
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The typical process that is followed in an analytical method validation is chronologically 
listed below: 
 
1.  Planning and deciding on the method validation experiments 
2.  Writing and approval of method validation protocol 
3.  Execution of the method validation protocol 
4.  Analysis of the method validation data 
5.  Reporting the analytical method validation 
6.  Finalizing the analytical method procedure 
The method validation experiments should be well planned and laid out to ensure 
efficient use of time and resources during execution of the method validation. The best 
way to ensure a well - planned validation study is to write a method validation protocol 
that will be reviewed and signed by the appropriate person (e.g., laboratory management 
and quality assurance). The validation parameters that will be evaluated will depend on 
the type of method to be validated. Analytical methods that are commonly validated can 
be classified into three main categories: identification, testing for impurities, and assay. 
Table 2 lists the ICH recommendations for each of these methods. Execution of the 
method validation protocol should be carefully planned to optimize the resources and 
time required to complete the full validation study. For example, in the validation of an 
assay method, linearity and accuracy may be validated at the same time as both 
experiments can use the same standard solutions. A normal validation protocol should 
contain the following contents at a minimum: 
(a) Objective of the protocol 
(b) Validation parameters that will be evaluated 
(c) Acceptance criteria for all the validation parameters evaluated 
(d) Details of the experiments to be performed 
(e) Draft analytical procedure 
The data from the method validation data should be analyzed as the data are obtained and 
processed to ensure a smooth flow of information. If an experimental error is detected, it 
should be resolved as soon as possible to reduce any impact it may have on later 
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experiments. Analysis of the data includes visual examination of the numerical values of 
the data and chromatograms followed by statistical treatment of the data if required. 
 
TABLE 2:  VALIDATION PARAMETERS 
Type of Analytical 
Procedure 
Characteristics 
Identification 
Testing for impurities Assay-Dissolution 
(measurement Only)-
Content/Potency Quantitation Limit 
Accuracy - + _ + 
Precision -    
Repeatability - + _ + 
Intermediate 
Precision  + _ 
a +a 
Specificity + b + +  + 
Detection Limit - - + c - 
Quantitation Limit - + - - 
Linearity - + - + 
Range - + _ + 
 
Note: −, characteristic not normally evaluated; +, characteristic normally evaluated. a In 
cases where reproducibility has been performed, intermediate precision is not needed. b 
Lack of specificity of one analytical procedure could be compensated by other supporting 
analytical procedure(s). c May be needed in some cases. 
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1.  INTRODUCTION 
 
Pain is an ill-defined, unpleasant sensation, usually evoked by an external or internal 
noxious stimulus [1]. Excessive pain may produces other effects like sinking 
sensation,apprehension, sweating, nausea, palpitation, rise or fall in BP or tachypnoea, 
analgesics relieve pain as a symptoms without affecting its cause [2,3]. Pain may be acute 
or chronic, renal colic pain and labour pain is most common and chronic pain generally 
not contolled by Non Steroidal Anti-inflammatory Drugs (NSAIDS) and more potent 
drug needed to controll pain. Drotaverine HCl is a benzylisoquinoline derivative,and is an 
analogue of papaverine(opium alkaloid) which is an antispasmodic drug acts by 
phosphodiesterase- IV inhibition  to increases the intracellular level of cyclic adenosine 
monophosphate (cAMP) which causes relaxation of smooth muscle that suppress the pain 
associated with spasm caused by smooth muscle contraction, specially in tubular organs 
like stomach, intestine, ureter, urinary bladder, cholecystalgia, chronic cholecystitis, neck 
of uterus spasm during delivery and also used as a cerebral and coronary vasodialator in 
subarachnoid haemorrhage, coronary artery bypass surgery and microsurgery [4-7]. 
Drotaverine hydrochloride (DRO) Chemically 1-[(3,4-[diethoxyphenyl) methylene]-6,7-
Diethoxy-1, 2,3,4-tetrahydroisoquinoline. Its molecular formula is (C24H31NO4.HCl) and 
its molecular weight is 433.97 g/mole. It is crystalline powder with pale yellow colour. 
Its solubility found in ethanol (96%), easily soluble in chloroform and moderately soluble 
in water.Its Melting point is 210 ºC and pH is 4.14. It causes smooth muscle relaxation by 
increasing intercellular levels of cyclic adenosine monophosphate (cAMP) secondary to 
inhibition platelet aggregation in a dose dependent manner Drotaverine is a selective 
inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been 
shown to possess dose-dependent analgesic effects in animal models. One small study 
has shown drotaverine to be eliminated mainly non-renally. A few small 2003 studies 
found drotaverine to be nearly 80% effective in treating renal colic. It has also been 
studied in accelerating labor by speeding up cervical dilation, but the results have been 
conflicting. Drotaverine has been shown to be effective in blocking managing pain during 
hysteroscopy and endometrial biopsy when administered together with mefenamic acid. 
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IBS patients presenting with predominant diarrhea are more likely to benefit 
from Buscopan. Drotaverin has also been tested in combination with rimantadine for 
antiviral activity against A and B type influenza. Drotaverin has an adverse effects 
frequency of 0.9%, side effects being relatively uncommon. Drotaverine in sold under 
brand name No-Spa (Chinoin Pharmaceutical and Chemical Works, Hungary, a member 
of the Sanofi-Aventis). The pharmacokinetics and bioavailability of drotaverine was 
studied in 10 healthy volunteers after administration of single 80 mg oral and intravenous 
doses of the HCl salt of the drug, in a crossover fashion. The pharmacokinetic 
parameters, such as elimination half-life, plasma clearance, renal clearance and apparent 
volume of distribution, were not influenced by the route of drug administration.  [8]. It is 
a highly potent spasmolytic agent.  
 
 
 
 
 
 
Figure 1: Chemical Structure of Drotaverine Hydrochloride 
 
2.  LITERATURE REVIEW 
 
The literature reviews regarding Drotaverine hydrochloride suggest that various 
analytical methods are reported for drug substance as well as in pharmaceutical 
formulation and also in various biological fluids. The literature reviews for analysis of 
Drotaverine hydrochloride are as under. 
Syal P K, Sahoo M. Inagale K D, Inagale S S, Choudhary V P, Kuchekar B S    have 
developed and validated method for simultaneous estimation of drotaverine and etoricoxib in 
tablet by RP-HPLC-PDA achieved on Waters Kromosil C18 column (250 mm × 4.6 mm, 
NH
O
O
O
O .HCl
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5.0 μ particle size) using methanol: THF: acetate buffer (51:09:40 vol./vol.) pH adjusted 
to 6.0 with acetic acid, flow rate was 0.9 mL/min and column was maintained at 55° at 
244nm   [9].  
 
Mezei J, Kuttel S, Szentmiklosi P, Marton S and Racz I have describes the HPLC method 
for drotaverine in plasma  using a microporous silica column, with a variable-wavelength 
UV detector set at 302 nm allowed the measurement of drotaverine at the 50-ng/mL level. 
. Basic plasma samples were adjusted to pH 1.5 and extracted with chloroform. HPLC [n-
heptane-dichloromelhane-diethylamine (50:25:2)] [10]. 
 
Lalla J K, Shah M U, Jain M B and Sharma A H have reported the method for the analysis 
of drotaverine in human plasma. An HPLC method is described for the determination of 
drotaverine in plasma; papaverine is used as the internal standard. The lower limit of 
quantitation is 50 ng ml−1
Abdellatef HE, Ayad MM, Soliman SM, Youssef NF have given the method for 
Spectrophotometric and spectrodensitometric determination of paracetamol and 
drotaverine HCl in combination using using ethyl acetate:methanol:ammonia 
(100:1:5 v/v/v) as a mobile phase. The spots of the two drugs were scanned at 249 and 
308 nm over concentration ranges of 60–1200 μg/ml and 20–400 μg/ml. [13] 
 with an inter-assay precision (RSD) of below 4%. The method 
has been validated and successfully used to assay clinical trial samples in healthy 
volunteers [11] 
 
Magda M, Ayad,Nadia F, Youssef, Hisham, Ezzat A, and Suzan M S have studied the 
analysis  method by Various spectometries with Thin Laye Chromatography for 
simultaneous analysis of drotaverine and nifuroxazide using UNICAM UV 300, thermo 
Spectronic, with vision 32 software. TLC-UV densitometric method was achieved on 
silica gel plates using ethyl acetate: methanol: ammonia 33% (10 : 1 : 0.1 v/v/v) as the 
mobile phase in the linear range of 0.2 - 4 µg/spot and 0.6 - 12 µg/spot, the detection was 
performed at 308 and 287 nm [12]. 
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Metwally F H has developed: Simultaneous determination of nifuroxazide and 
drotaverine hydrochloride in pharmaceutical preparations by bivariate and multivariate 
spectral analysis. [14] 
 Dahivelkar P P, Mahajan V K, Bari S B, Shirkhedkar A A, Fursule R A, Surana S 
J have given the method for Simultaneous derivative and multi component 
Spectrophotometric determination of Drotaverine hydrochloride and mefenamic acid in 
two-component tablet formulation. The methods employed are, first derivative 
spectophotometry, using zero crossing technique and multi component analysis. [15] 
 
K S Topagi, R M Jeswani, P K Sinha, M. C. Damle has published a paper on Detection 
and quantifycation of drotaverine hydrochloride and omeprazole, by High performance 
liquid chromatography achieved on HiQsil column using UV detector. The mobile phase 
consisting of n-heptane: dichloromethane : methanolic ammonia (5%) : methanol at a 
flow rate of 1.0 ml/min was used. [16].   
 
Ayad M M, Youssef N F, Abdellatif H E, Soliman S M has reported: A comparative 
study on various spectrometries with thin layer chromatography for simultaneous analysis 
of drotaverine and nifuroxazide in capsules. [17] 
 
Metwally F H, Abdelkawy M, Naguib I A has worked on determination of nifuroxazide 
and drotaverine hydrochloride in pharmaceutical preparations which was separated on a 
silica gel plate using chloroform–acetone–methanol–glacial acetic acid (6 : 3 : 0.9 : 0.1) 
as the mobile phase and ultraviolet (UV) detection at 365 nm over a concentration range 
of 0.2–1 μg/band for both drugs [18]. 
 
Ziyatdinova G K, Samigullin A I, Budnikov G K developed the method where 
Isoquinoline derivatives (papaverine and drotaverine) are oxidized at a graphite electrode 
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in a 0.1 M sulfuric acid solution to give voltammetric waves at 1.1 V for papaverine and 
at 1.05 and 1.28 V for drotaverine. Determination limits and linearity ranges of currents 
as functions of papaverine and drotaverine concentrations are estimated. Microgram 
amounts of papaverine and drotaverine are determined in model solutions (RSD = 1–4%). 
A procedure for the direct determination of papaverine and drotaverine in 
pharmaceuticals is proposed. [19]. 
P P Dahivelkar, S B Bari, S Bhoir  and A M Bhagwat have cited the method for 
estimation of drotaverine hydrochloride and mefenamic acid on High performance liquid 
chromatography using thermo BDS Hypersil C8 (25.0 cm×4.6 mm, 5 μm particle size) 
column in isocratic mode with a mixture of acetonitrile and ammonium acetate buffer (20 
mM, pH 3.5 ± 0.05 adjusted with 85% phosphoric acid) in a ratio of 55: 45 (v/v), as the 
mobile phase, at a flow rate of 1.0 mL min-1. Calibration plots were linear within the 
range of 32-960 ng mL-1 and 100-3000 ng mL-1 for drotaverine hydrochloride and 
mefenamic acid, respectively. The effluent was monitored by UV detection at 230 nm. 
[20]. 
Shaikh K A, Patil S D have reported the stability indicating rapid RP-HPLC method for 
the Drotaverine hydrochloride, domperidone and paracetamol in pharmaceutical dosage 
forms. .  Chromatography was carried out at 25°C on a 4.6 mm × 150 mm, 5 μ
Symmetry shield RP 18 column with the isocratic mobile phase of 0.02M aq. potassium 
dihydrogen phosphate buffer (pH 7.5) and acetonitrile (40:60, vol./vol.) at a flow rate of 
0.5 mL/min.[21] 
 
Ankam R, Mukkanti K, Durgaprasad S, Naidu P V L developed RP-HPLC method 
for the drotaverine hydrochloride and mefenemic acid. The retention times of drotaverine 
hydrochloride and mefenamic acid were found to be 3.05 and 9.52 min, resp.  The 
method was linear over the range of 16 to 47 ppm with R2 = 0.9999 for drotaverine 
hydrochloride and 100 to 300 ppm with R2 = 0.9999 for mefenamic acid.[22] 
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2.  AIM OF THE PRESENT WORK 
 
The above literature reveals that there are many methods for the quantification of 
Drotaverine hydrochloride as a drug substance as well as in pharmaceutical dosage form, 
few of the methods are also which deals the bioanalytical study but very few methods are 
available describing the forced degradation. Furthermore these methods are not 
impressionable to achieve the high throughput study which can be possible by optimizing 
the method. Hence, it can be maximum utilize for the analysis of formulation 
development and stability testing as well as at quality control laboratory for routine use. 
The aim and scope of the proposed work are as under. 
 
3.1. To develop rapid RP-HPLC method for quantification of the drug substance with 
highest selectivity, precision and accuracy. 
3.2. Forced Degradation Study to confirm the stability of the drug substance. 
3.3.  Perform analytical method validation for the proposed method as per ICH 
guideline [23]. 
 
3. EXPERIMENTAL 
4.1. MATERIALS, CHEMICALS AND REAGENTS 
Emcure pharmaceuticals Limited (Pune, India) has provided Drotaverine hydrochloride 
working standard. Drotaverine hydrochloride tablets containing 80 mg Drotaverine 
hydrochloride (Drotikind 80, Windlas Biotech Limited, Dehradun, India) and the inactive 
ingredients used in the drug matrix has obtained from the commercial market. HPLC 
grade methanol (Spectrochem) and formic acid (Merck) was used. Milli-Q water (HPLC 
grade) was used in mobile phase preparation. 
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4.2. INSTRUMENTATION 
Chromatography was performed under, ambient conditions, with  HPLC equipment 
(Waters Corporation, Milford, USA) consisted comprising quaternary 600 pump, a 
variable-wavelength  programmable  2489 UV-Visible detector and YMC C8 (150mm ×  
4.6mm id, 5 μm particle size) column was used. A Rheodyne injector with a 20µl loop 
was used for the injection of the sample. The HPLC system was equipped with Empower 
software for data processing. Sartorius microbalance and Equiptronics branded balance 
and heating oven was used for the weighing and heating purpose while Spinco ultrasonic 
bath used for degassing purpose. 100µL-1000µL micropipette (Eppendorf, Germany) 
was used for the mobile phase buffer preparation. 
4.3. METHOD DEVELOPMENT 
4.3.1. MOBILE PHASE SELECTION 
On the basis of literature survey, previous experience and several exploratory efforts, the 
chromatographic compatibility was achieved using Formic acid in water (0.2%v/v): 
Methanol (55:45) as an isocratic elution. This gives the best results as a mobile phase. 
4.3.2. COLUMN SELECTION 
Column selection is the most important part in the method development. Applying 
various column chemistry, the most suitable column was YMC C8 (150mm ×  4.6mm id, 
5 μm particle size). 
4.3.3. DETECTION WAVELENGTH SELECTION  
We screened the standard solution over 190 nm to 400 nm wavelength using the 
advantage of photo diode array detector. On the basis of peak absorption maxima of 
analyte and the degradation impurities, the 300 nm was decided as the detection 
wavelength. This gives the maximum chromatographic compatibility to the method. 
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4.3.4. MOBILE PHASE PREPARATION 
The mobile phase consist of Formic acid in water, 0.2%v/v: Methanol (55:45) was 
prepared by dissolving 2.0mL of Formic Acid was taken in 1000 ml of HPLC grade 
water which further mixed with Methanol (55:45) ratio and filtered through 0.45µn filter 
followed by degassing in ultra sonic bath for 20 min. 
4.3.5. STANDARD SOLUTION PREPARATION 
A Drotaverine Hydrochloride standard solution containing 100μg/ml was prepared in a 
100 ml volumetric flask by dissolving 10 mg Drotaverine Hydrochloride in 25 ml 
water- methanol (50:50, v/v) and then diluting to volume with water- methanol (50:50, 
v/v) to the mark. The sample has filtered through a 0.45 μn nylon syringe filter. 
4.3.6. SAMPLE SOLUTION PREPARATION 
Twenty commercially available 80.0mg label claimed tablets of Drotaverine 
hydrochloride have weighed, and the average weight of a tablet was determined. From 
these, 5 tablets were weighed and transferred into a 500 ml volumetric flask and added 50 
ml water- methanol (50:50, v/v)  followed by sonication of minimum 30 min with 
intermittent shaking. Then the solution has brought back to room temperature and diluted 
to volume with water- methanol (50:50, v/v). 1.25 ml of above solution was pipette out and 
transferred into 10 ml volumetric flask followed by diluted to volume with diluent. The 
concentration obtained is 100 μg/ml of analyte The sample has filtered through a 0.45 μn 
nylon syringe filter. The available concentration was 100 μg/ml of analyte. 
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 Figure2: Chromatograph of Working Standard 
Figure 3: Chromatograph of Commercial Sample of the Analyte 
Finally after several experiment in method development, the best chromatography results 
were achieved in following chromatographic condition. 
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4.4. METHOD VALIDATION 
 
Method for the determination of Drotaverine Hydrochloride in bulk drug as well as in 
pharmaceutical dosage form is further validated as per ICH Q2 (R1) guideline [27]. To 
prove this method, Stability Indicating, force degradation study was also being performed 
and also included. Validation of analytical method was performed using commercially 
available Drotaverine Hydrochloride (Drotikind 80) formulation as well as bulk drug 
substance equivalent to the formulation.  
 
4.4.1. SPECIFICITY  
 
The evaluation of the specificity of the method was determined against placebo and stress 
(forced degradation) application. The interference of the excipients of the claimed 
placebo present in the pharmaceutical dosage form was derived from placebo solution. 
Further the specificity of the method toward the drug was established by means of the 
interference of the degradation products against drug during the forced degradation study. 
 
Mobile Phase Buffer :  Formic acid in water (0.2%v/v) 
Organic                      :  Methanol  (HPLC grade) 
Composition                         : Mobile Phase Buffer: Organic (55:45) 
  Column   :  YMC C8 (150mm ×  4.6mm id, 5 μm particle size)  
Flow Rate   : 1.0 ml/min 
Detection   : 300 nm UV 
   Diluent    : Methanol: Water (HPLC grade) 
Injection Volume  : 20µl 
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: Blank preparation: 
Diluent was used as blank. 
Standard solution preparation, 
Stock solution: 25.00 mg of Drotaverine hydrochloride working standard was accurately 
weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one minute. 
Then, volume of the flask was made up with diluent. The concentration obtained was 
1000 μg/ml of Drotaverine hydrochloride. 5 ml of above standard stock solution was 
pipette out and transferred into 50 ml volumetric flask followed by diluted to volume 
with diluent. The concentration obtained is 100 μg/ml of analyte.  
 
: Test Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1896.00 mg) and transferred 
into 100 ml volumetric flask. 70 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-shaking. 
Then, the flask was cooled to room temperature and diluted to volume with diluent. 25 ml 
of this solution was filtered through 0.45 μn nylon syringe filter. The concentration 
obtained was about 8000 μg/ml of drug substance. 1.25 ml of above test stock solution 
was pipette out and transferred into 100 ml volumetric flask followed by diluted to 
volume with diluent. The concentration obtained is about 100 μg/ml of Drotaverine 
hydrochloride. 
: Average weight of the tablets: 
Randomly selected 20 tablets were weighed accurately (3792.00 mg) and the mean weight 
was calculated for the same. This mean weight (189.60 mg) was used as average weight 
throughout all experiments. 
: Placebo preparation: 
Stock solution: Placebo equivalent to 10 times of average placebo weight was weighed 
(1100.0 mg) and transferred into 100 ml volumetric flask.70 ml of diluent was added into 
the volumetric flask and sonicate for 30 minutes with normal hand-shaking. The 
volumetric flask was cooled to room temperature and diluted to volume with diluent. 25 
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ml of this solution was filtered through 0.45 μm nylon syringe filter. 1.25 ml of above 
placebo stock solution was pipette out and transferred into 100 ml volumetric flask 
followed by dilute up to volume with diluent. 
 
 
Figure 4: Chromatogram of Diluent in Specificity Experiment. 
 
Figure 5: Chromatogram of Placebo in Specificity Experiment. 
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Figure 6: Chromatogram Test preparation (commercial sample) 
 
 
Forced Degradation Study: 
The degradation samples were prepared by transferring intact tablets, samples were 
employed for acidic, alkaline and oxidant media and also for thermal and photolytic 
conditions. After the degradation treatments were completed, the stress content solutions 
were diluted with diluent to attain about 100µg/ml concentration. Specific conditions 
were described as follows. 
 
A) Acidic Degradation:  Acidic degradation study was performed by refluxing the 
drug content in 30 ml of 1 N HCl at about 100° C for 1 hour and after cooling to room 
temperature it was neutralized with 1 N NaOH solution. Further solution was diluted to 
achieve concentrations 100 µg/ml with diluent. 
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                     Figure 7: Chromatogram Test preparation (Acidic Degradation) 
 
B) Alkali Degradation: Alkaline degradation was performed by heating the drug 
content in 1 M NaOH at around 100˚ C for 1 hour and then the mixture was neutralized 
with 1 M HCl. It was further diluted with diluent to achieve 100 µg/ml concentrations. 
   Figure 8: Chromatogram of Alkali Degradation Study 
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C) Oxidative Degradation Study: Oxidative degradation study was performed by 
refluxing the drug content in 3% v/v H2O2 at 100°C for 1 hour then diluted to 100µg/ml 
with diluent. 
Figure 9: Chromatogram of Oxidative Degradation Study 
 
 
D) Thermal Degradation Study: Thermal degradation study was performing by 
keeping powdered drug content at around 80˚C for 72 hour . After this it was allowed to 
come at room temperature. 
 
This powdered drug was used for the stock solution preparation as per procedure on page 
56, then it was diluted to attain 100 µg/ml, the same was used in the forced degradation 
study by confirming against the freshly prepared standard solution. Aim of this 
experiment was to study the thermal liability of the drug as well as the formulated 
pharmaceutical dosage form.  
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Figure 10: Chromatogram of Thermal Degradation Study 
 
E) Photolytic Degradation Study: Photolytic degradation study was performed by 
exposing drug content in sun-light for 72 hour, further it diluted to 100 µg/ml using 
diluent. 
Figure 11: Chromatogram of Photolytic Degradation Stud 
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Observations: 
 
(1)  Any interference was not observed from blank or placebo to the peak of interest, 
in addition to this peak purity was also within the acceptance criteria proved by 
the photo diode detector. 
(2) From the above chromatogram it can be conclude that there is no interference of 
any degradation product to the peak of interest and impurity has been generated 
by each stress condition. 
 
Stress Condition Acidic Alkali Oxidative Thermal Photolytic 
% Degradation 17.21 27.24 16.84 6.82 13.16 
    
Table 1: % Degradation observed by applying the stress condition 
 
4.4.2. LINEARITY AND RANGE  
 
The linearity plot was prepared with 8 concentration levels (40, 60, 80, 100, 120, 140, 
160 and 180 μg/ml of Drotaverine hydrochloride). These concentration levels were 
respectively corresponding to 40, 60, 80, 100, 120, 140, 160 and 180% of standard 
solution concentration. The peak areas vs. concentration data were evaluated by linear 
regression analysis. 
Stock solution for Linearity study was prepared as per procedure on page 56 and further 
diluted to attain concentration of about 40, 60, 80, 100, 120, 140,160 and 180% of 
standard solution concentration. 
 
Linearity Standard Solution Preparation: 
From Standard Stock Solution of accurately 1000 µg/ml pipette out exact 0.4, 0.6, 0.8, 
1.0, 1.2, 1.4, 1.6 and 1.8 ml and dilute it up to 10 ml each with diluent to achieve 40-180 
µg/ml concentration range. 
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Linearity 
Level 
Concentration 
(µg/ml) 
Peak Area 
1 180 4485622 
2 160 4034192 
3 140 3525684 
4 120 2998577 
5 100 2499589 
6 80 1988284 
7 60 1516129 
8 40 972630 
 
Table 2: Linearity and Range - Concentration Vs Peak area response data 
 
 
X axis = Concentration (µg/ml) Y axis = Peak Area 
Chart 1: Regression Analysis chart of linearity Study 
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Correlation coefficient of the linearity study was found to R2 
4.4.3. LIMIT OF DETECTION AND LIMIT OF QUANTITATION STUDY 
= 0.9998 with linear 
regression equation y = 25174x - 16560, which proves the method is linear over the 
working range 40 – 180 µg/ml. 
LOD is the lowest amount of the drug content which can be detected by the proposed 
method while LOQ is the lowest amount which can be quantified by the method. The 
guideline suggest minimum signal to noise ratio (S/N) more than 3.3 for LOD and more 
than 10 for LOQ. On the basis of linearity data theoretically it can be also calculated by 
the given formula, 
LOD = 3.3 σ/S LOQ = 10 σ/S 
Where σ = Residual Standard Deviation of regression line and S = Slope of regression 
line. 
 
LOD Solution Preparation: 
Standard Stock Solution prepared as per procedure given on page 56. From the stock 
solution of 1000 µg/ml pipette out exact 1 ml to 100 ml volumetric flask followed by 
dilution up to the mark with diluent , assign this solution as Solution – A. 
Form the Solution – A, pipette out exact 0.15 ml to the 10 ml volumetric flask followed 
by dilution up to the mark with diluent to reach 0.15 µg/ml concentrations. 
 
LOQ Solution Preparation: 
Form the Solution – A, pipette out exact 0.6 ml to the 10 ml volumetric flask followed by 
dilution up to the mark with diluent to achieve 0.6 µg/ml concentrations. Six replicate 
injections were made to prove the precision of the LOQ level. 
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Injection Peak Area 
1 14439 
2 14162 
3 13500 
4 14374 
5 13499 
6 14339 
Mean 14052 
Std. Dev. 437.82 
% RSD 3.12 
 
Table 3: Limit of Quantification - Precision data 
 
Figure 12: Chromatogram of Limit of Detection 
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Figure 13: Chromatogram of Limit of Quantification 
LOQ of the analytical method can evaluated by establish linearity up to LOQ value. 
Hence linearity study is extended to LOQ value, 
 
 
X axis = Concentration (µg/ml) Y axis = Peak Area 
Chart 2: Regression Analysis chart of linearity Study included with LOQ level 
Limit of Quantification 
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All the results of LOD and LOQ data were within the acceptance criteria, hence it can be 
conclude that the LOD and LOQ of the method was 0.15 µg/ml and 0.6 µg/ml 
respectively which correspond to 0.6% and 0.15% of working concentration. 
 
4.4.4. PRECISION STUDY 
 
Precision study was established by evaluating method precision and intermediate 
precision study. Method precision of the analytical method was determined by analyzing 
six sets of sample solution preparation.  
Assay of all six replicate sample preparations was determined and mean % assay value, 
standard deviation and % relative standard deviation for the same was calculated. 
Intermediate precision of the analytical method was determined by performing same 
experiment as method precision on another day by another analyst using different make 
of raw materials under same experimental condition. Assay of all six replicate sample 
preparations was determined and mean % assay value, standard deviation and % relative 
standard deviation also calculated. Overall assay value of method precision and 
intermediate precision was compared and % difference and overall % relative standard 
deviation was calculated.  
 
:Solution Preparation for Precision Study: 
 
:Standard Solution Preparation: 
Standard Stock Solution prepared as per procedure on page 56 of 1000 µg/ml. pipette out 
exact 1.0 ml from this solution and dilute up to 10 ml to accomplish 100 µg/ml 
concentration.  
 
:Sample Solution Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1898.50 mg) and transferred 
into 100ml volumetric flask. 70 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-shaking.  
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Then, the flask was cooled to room temperature and diluted to volume with diluent. 25 ml 
of this solution was filtered through 0.45 μn nylon syringe filter. The concentration 
obtained was about 8000 μg/ml of drug substance. 1.25 ml of above test stock solution 
was pipette out and transferred into 100 ml volumetric flask followed by diluted to 
volume with diluent. The concentration obtained is about 100 μg/ml of Drotaverine 
hydrochloride. This solution is assign as Test Preparation Set – 01. 
The same procedure was used for preparing the six Test preparation Sets. Same approach 
was applied for the intermediate precision study on the second day with different analyst 
and different make of raw materials. 
 
 
Method Precision Data 
Samples Replicates Peak Area Mean Area % Assay 
Set 01 
Injection 01 2483591 
2475255 99.50 Injection 02 2471654 
Injection 03 2470520 
Set 02 
Injection 01 2484772 
2492891.3 101.03 Injection 02 2496635 
Injection 03 2497267 
Set 03 
Injection 01 2494730 
2493557.3 99.72 Injection 02 2493864 
Injection 03 2492078 
Set 04 
Injection 01 2506943 
2508589 98.97 Injection 02 2502602 
Injection 03 2516222 
Set 05 
Injection 01 2497254 
2487344.7 101.09 Injection 02 2485686 
Injection 03 2479094 
Set 06 
Injection 01 2511534 
2494333.3 101.05 Injection 02 2496617 
Injection 03 2474849 
  
Table 4: Method Precision Data 
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Intermediate Precision Data 
Samples Replicates Peak Area Mean Area % Assay 
Set 01 
Injection 01 2390183 
2439334 99.08 Injection 02 2477152 
Injection 03 2450667 
Set 02 
Injection 01 2480432 
2461131.67 100.32 Injection 02 2475165 
Injection 03 2427798 
Set 03 
Injection 01 2454846 
2474639 100.80 Injection 02 2481159 
Injection 03 2487912 
Set 04 
Injection 01 2490325 
2470574.33 100.11 Injection 02 2470837 
Injection 03 2450561 
Set 05 
Injection 01 2470283 
2462095 99.79 Injection 02 2480574 
Injection 03 2435428 
Set 06 
Injection 01 2483442 
2463636 99.70 Injection 02 2450497 
Injection 03 2456969 
 
  Table 5: Intermediate Precision Data 
% Assay calculation is as under: 
 
  
Where, 
AT = Average Area of Test Preparation. 
AS = Average Area of Standard Preparation. 
W1 = Weight of Working Standard (mg). 
W2 = Weight of Test Sample (mg). 
AW = Average Weight of Formulation (mg). 
LC = Label Claim Weight of Formulation (mg). 
P = Potency of Working Standard (%). 
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  Figure 14: Chromatograms of Sample Solution in Method Precision and Int. Precision 
Overall the data for the precision study suggest % Assay value for each Test Preparation 
is between 98 – 102% which is under the acceptance criteria while % RSD of all results 
are less than 2%. Hence from all the observation it can conclude that the proposed 
method is highly precise.  
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4.4.5.  ACCURACY STUDY    
This Experiment can be performed by the recovery test. Recovery of the method was 
evaluated at 3 different concentration levels (Generally corresponding to 50, 100 and 
150% of test solution concentration) by addition of known amounts of standard to 
placebo preparation. For each concentration level, 3 sets were prepared and injected in 
duplicate. 
 
Blank preparation: 
Diluent was used as blank. 
 
Standard preparation: 
Stock solution and standard solution has been prepared as per procedure on page 56. 
 
Sample preparations for accuracy levels are as under: 
 
Accuracy level 1 (50%)  
Test stock solution:  
400.0 mg of Drotaverine hydrochloride reference standard was accurately weighed and 
transferred into 200 ml volumetric flask. 550.0 mg placebo (equivalent of 05 average 
placebo weights) was weighed and transferred into the same 200 ml volumetric flask. 
Around 140 ml of diluent added into the volumetric flask. The volumetric flask was 
proceeding for sonication of 30 minutes with normal handshaking. Then, the flask was 
cooled to room temperature and diluted to volume with diluent. 10 ml of this solution was 
filtered through 0.45 μm nylon syringe filter. The concentration obtained was 2000 μg/ml 
of Drotaverine hydrochloride.  
2.5 ml of above test stock solution was pipette out and transferred into 100 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained is 50 μg/ml 
of Drotaverine hydrochloride. The same procedure was applied for preparing the three 
sets. 
 
Accuracy level 2 (100 %) 
Test stock solution:  
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800.0 mg of Drotaverine hydrochlorideworking standard was accurately weighed and 
transferred into 200 ml volumetric flask. 1100.0 mg placebo (equivalent of 10 average 
weights) was weighed and transferred into this 200 ml volumetric flask. 140 ml of diluent 
added into the volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal handshaking. 
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.45 μm nylon syringe filter. The concentration 
obtained was 4000 μg/ml of Drotaverine hydrochloride.  
2.5 ml of above test stock solution was pipette out and transferred into 100 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained was 100 
μg/ml of Drotaverine hydrochloride. The same procedure was applied for preparing the 
three sets. 
 
Accuracy level 3 (150 %) 
Test stock solution: 
 
1200.0 mg of Drotaverine hydrochloride Working standard was accurately weighed and 
transferred into 200 ml volumetric flask. 1650 mg placebo (equivalent of 10 average 
placebo weights) was weighed and transferred into this 200 ml volumetric flask. 140 ml 
of diluent added into the volumetric flask. The volumetric flask was proceeding for 
sonication of 30 minutes with normal handshaking. 
 
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.45 μm nylon syringe filter. The concentration 
obtained was 1500 μg/ml of Drotaverine hydrochloride.  2.5 ml of above test stock 
solution was pipette out and transferred into 100 ml volumetric flask followed by diluted 
to volume with diluent. The concentration obtained is 150.0 μg/ml of Drotaverine 
hydrochloride. The same procedure was applied for preparing the three sets. 
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Accuracy 
Replicates Area Mean Mean of each level 
Level-1 set 1 inj 01 1213632 
1216513 
1216267 
Level-1 set 1  inj 02 1219394 
Level-1 set 2  inj 01 1210291 
1217075 
Level-1 set 2 inj 02 1223858 
Level-1 set 3  inj 01 1216950 
1215214 
Level-1 set 3 inj 02 1213478 
Level-2 set 1 inj 01 2377778 
2427429 
2458153 
 
 
Level-2 set 1 inj 02 2477079 
Level-2 set 2 inj 01 2453804 
2460850 
Level-2 set 2 inj 02 2467895 
Level-2 set 3 inj 01 2484794 
2486182 
Level-2 set 3 inj 02 2487570 
Level-3 set 1 inj 01 3698871 
3658477 
3654836 
Level-3 set 1 inj 02 3618082 
Level-3 set 2 inj 01 3621359 
3643106 
Level-3 set 2 inj 02 3664853 
Level-3 set 3 inj 01 3671323 
3662924 
Level-3 set 3 inj 02 3654525 
 
  Table 6: Summery of Accuracy Data-01 
 
Calculation formulas for recovery study are as under: 
 
 
 
Where, Volume = Dilution given for preparing the solution. 
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From the above calculation the % Recovery was calculated which is given below. 
 
 
Accuracy (Recovery) Study 
Accuracy 
Level 
Set 
No 
Amount 
added 
(μg/ml ) 
Amount 
Found 
(μg/ml ) 
Recovery 
(%) 
Average 
recovery 
Std 
Dev. 
% 
RSD 
I (50%) 
1 50.13 50.09 99.92 
99.9 0.06 0.06 2 50.10 50.12 100.04 
3 50.21 50.18 99.94 
II (100%) 
1 98.21 98.64 100.44 
99.9 0.72 0.72 2 99.85 100.00 100.15 
3 100.98 101.03 99.07 
II (150%) 
1 149.76 148.66 99.27 
99.2 0.11 0.11 2 149.25 148.04 99.19 
3 150.27 148.84 99.05 
 
 
Table 7: Summary of Accuracy Data-02 
 
 
Figure 15: Chromatograms of Accuracy level -I (50 
%)
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Figure 16: Chromatograms of Accuracy level -II (100 %) 
 
 
    Figure 17: Chromatograms of Accuracy level -III (150 %) 
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From the all above data it has been proven that the % recovery is within the limit of 98 to 
102 % this is in the limit of acceptance criteria and % RSD value of % recovery of 
replicate set is below 2 % .Hence this suggest that proposed method is highly accurate. 
4.4.6. ROBUSTNESS STUDY 
 
Robustness of the method was evaluated by assaying test solutions under slight but 
deliberate changes in analytical conditions, such as change in flow rate, change in 
proportions of Buffer-Methanol (57:43 and 53:47,v/v), and change in column-lot. 
 
A) Flow Rate change: In this experiment the test samples were analyzed at the flow 
rate of 0.9 ml/min and 1.1 ml/min each and the results were observed in terms of assay 
value and chromatographic compatibility (System Suitability Test).Blank, Standards and 
Sample solutions were prepared as per the same procedure mentioned on page 56. A 
proto type chromatographic sequence of the robustness study is as under, 
 
 
Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
Flow Rate 0.9 
ml/min 
2 Standard  5 
3 Test 2 
4 Bracketing Standard 1 
5 Blank 1 
Flow Rate 1.1 
ml/min 
6 Standard  5 
7 Test 2 
8 Bracketing Standard 1 
  
 
Table 8: Experimental HPLC sequence for the robustness study -01 
The calculation formula for the determination of assay is, 
 
 
 
Chapter – 2                                      A Stability Indicating RP-HPLC method for Drotaverine hydrochloride 
Department of Chemistry, Saurashtra University, Rajkot-360005.                                                                               Page 77 
 
 
  
 
Where, AT = Average Area of Test Preparation. 
AS = Average Area of Standard Preparation. 
W1 = Weight of Working Standard (mg). 
 
W2 = Weight of Test Sample (mg). 
W2 
 Robustness 01 (Flow Rate: 0.9ml/min) 
= Weight of Test Sample (mg). 
AW = Average Weight of Formulation (mg). 
LC = Label Claim Weight of Formulation (mg). 
P = Potency of Working Standard (%). 
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Robustness (Flow Rate: 1.1ml/min) 
Figure 18: Chromatogram of Drotaverine hydrochloride at Flow Rate 0.9 and 1.1 ml/min. 
The assay value of test preparation was 101.24% and 99.15% at 0.9 and 1.1 ml/min 
respectively. The above chromatograms suggest that the flow rate affects on the retention 
time of drug but it did not have any impact on the response so the peak area were not 
change too much hence the assay value remain unaffected.  
B) Mobile Phase Proportion Change: In this experiment the test samples were 
analyzed at the mobile phase proportion of 57:43 and 53:47, v/v (Buffer: Methanol) each 
and the results were observed in terms of assay value and chromatographic compatibility 
(System Suitability Test). 
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 56.  A proto type chromatographic sequence of the robustness study is 
as under, 
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Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
57:43  
Buffer : Methanol 
2 Standard  5 
3 Test 2 
4 Bracketing Standard 1 
5 Blank 1 
53:47  
Buffer : Methanol 
6 Standard  5 
7 Test 2 
8 Bracketing Standard 1 
 
Table 9: Experimental HPLC sequence for the robustness study – 02 
The calculation formula for the determination of assay is, 
 
  
 
Where, AT = Average Area of Test Preparation. 
AS = Average Area of Standard Preparation 
W1 = Weight of Working Standard (mg). 
W2 = Weight of Test Sample (mg). 
W2 = Weight of Test Sample (mg). 
AW = Average Weight of Formulation (mg). 
LC = Label Claim Weight of Formulation (mg). 
P = Potency of Working Standard (%). 
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Robustness : Mobile Phase Ratio (53 : 47) 
 
Robustness : Mobile Phase Ratio (57 : 43) 
Figure 19: Chromatogram of Drotaverine hydrochloride at different mobile phase 
proportion. 
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The assay value of test preparation was 100.64% and 99.39% at 57:43 (Buffer: Methanol, 
v/v) and 53:47 (Buffer: Methanol, v/v) respectively. The above  data and chromatograms 
suggesting that the Mobile Phase proportion made a impact  on the retention time of drug 
but it did not have any significant change on the intensity so the peak area were not 
change too much hence the assay value remain unaffected  
 
C) Column Lot Change: In this experiment the test samples were analyzed using 
different column lot and the results were observed in terms of assay value and 
chromatographic compatibility (System Suitability Test). 
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 56. A proto type chromatographic sequence of the robustness study is 
as under. 
 
Experimental Sequence 
Sr.No. Sample Name No. of Injections Chromatographic condition 
1 Blank 1 
Different Column Lot 
2 Standard  5 
3 Test 2 
4 Bracketing Standard 1 
 
Table 10: Experimental HPLC sequence for the robustness study – 03 
 
The calculation formula for the Assay determination is as per given on the previous page 
79. The assay value is for the test preparation was 101.76%. 
The data and the chromatogram given below suggest that there is no considerable 
influence of the column lot change on the result of the analysis by this method or on 
chromatographic suitability of this method. Hence, it can be conclude from this 
experiment that the method is highly robust in terms of column lot change.  
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Figure 20: Chromatogram of Drotaverine hydrochlorideat different column lot. 
 
Summary of Robustness Study 
Robust 
Condition % Assay 
Retention time 
(min.) 
System Suitability 
Theoretical 
Plates Asymmetry 
Flow Change 0.9 
ml/min  
101.24 5.91 10824 1.26 
Flow Change 1.1 
ml/min  
99.15 4.57 10773 1.29 
MP Proportion 
Change 57:43 
100.64 6.89 10989 1.28 
MP Proportion 
Change 53:47 
99.39 4.35 11799 1.23 
Column Lot 
Change 
99.84 5.52 11320 1.26 
   
Table 11: Summary of robustness study  
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4.4.7. SOLUTION STABILITY 
Solution stability has the significant role in terms of the acceptability of the data 
generated during the method validation. Hence this study has to plan before starting the 
method validation and sometimes it is included in Pre Method Validation. On the basis 
of results achieved in PMV the solution stability can be planned and established in 
Method Validation. The Solution Stability can be established at two different time of 
period, 
(A) Long Term Stock Solution Stability (LTSSS). 
(B) Short Term Standard Solution Stability (STSSS) or Bench Top Solution Stability. 
LTSSS is established by comparing the response of the standard solution prepared from 
the kept stock solution at 2-4˚C for long time (in days) and fresh stock solution. While 
the STSSS is or bench top solution stability is established by comparing the response the 
standard solution kept on the bench for the short time (in hours) and freshly prepared 
standard solution. 
Preparation of Stock Solution for LTSSS: 25.00 mg of Drotaverine hydrochloride 
working standard was accurately weighed and transferred into 25 ml volumetric flask. 20 
ml of diluent was added into the volumetric flask and the standard substance was 
dissolved by sonication for one minute. Then, volume of the flask was making up with 
diluent. The concentration obtained is 1000 μg/ml of Drotaverine hydrochloride. This 
solution was prepared on the first day of the validation and kept at the 2-4˚C temp. in 
refrigerator without any disturbance until performance of the LTSSS experiment. 
After 10 day the stock solution was bring out of the refrigerator and keep it as such till it 
attains the room temp. 5 ml of this solution was pipette out in 50 ml volumetric flask and 
dilute it up to the mark to reach 100 of Drotaverine hydrochloride. This solution was 
assigned as LTSSS Standard solution. 
Preparation of Fresh Standard Solution: 25.00 mg of Drotaverine hydrochloride working 
standard was accurately weighed and transferred into 25 ml volumetric flask. 20 ml of 
diluent was added into the volumetric flask and the standard substance was dissolved by 
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sonication for one minute. Then, volume of the flask was making up with diluent. The 
concentration obtained is 1000 μg/ml of Drotaverine hydrochloride. Pipette out exactly 5 
ml of this solution in 50 ml volumetric flask and dilute it up to the mark accurately to 
confirm the 100 μg/ml of Drotaverine hydrochloride. This solution was assigned as Fresh 
Standard Solution. The proto-type experimental sequence is given below for LTSSS. 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 LTSSS-01( 10 day) 1 
4 Fresh Standard-01( 0 day) 1 
6 LTSSS-02 ( 10 day) 1 
7 Fresh Standard-02 ( 0 day) 1 
8 LTSSS-03 ( 10 day) 1 
9 Fresh Standard-03 ( 0 day) 1 
10 LTSSS-04 ( 10 day) 1 
11 Fresh Standard-04 ( 0 day) 1 
12 LTSSS-05 ( 10 day) 1 
13 Fresh Standard-05 ( 0 day) 1 
14 Bracketing Standard 1 
 
Table 12: Sequence for LTSSS. 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard         
Mean Area Ratio = 1.011 for this experiment. 
Preparation of Stock Solution for STSSS or Bench Top Solution Stability:  25.00 mg of 
Drotaverine hydrochloride working standard was accurately weighed and transferred into 
25 ml volumetric flask. 20 ml of diluent was added into the volumetric flask and the 
standard substance was dissolved by sonication for one minute. Then, volume of the flask 
was making up with diluent. The concentration obtained is 1000 μg/ml of Drotaverine 
hydrochloride. This solution was prepared before the 11 hour and kept on bench at 
ambient temperature without any disturbance until performance of the STSSS 
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experiment. After 11 hour on the bench. 5 ml of this solution was pipette out in 50 ml 
volumetric flask and dilute it up to the mark to reach 100 μg/ml of Drotaverine 
hydrochloride. This solution was assigned as STSSS Standard solution Preparation of 
Fresh Standard Solution: 25.00 mg of Drotaverine hydrochloride working standard was 
accurately weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was 
added into the volumetric flask and the standard substance was dissolved by sonication 
for one minute. Then, volume of the flask was making up with diluent. The concentration 
obtained is 1000 μg/ml of Drotaverine hydrochloride. Pipette out exactly 5 ml of this 
solution in 50 ml volumetric flask and dilute it up to the mark accurately to confirm the 
100 μg/ml of Drotaverine hydrochloride. This solution was assigned as Fresh Standard 
Solution. The proto-type experimental sequence is given below for STSSS. 
 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 STSSS-01( 11.0 hour) 1 
4 Fresh Standard-01( 0.0 hour) 1 
6 STSSS-02 ( 11.0 hour) 1 
7 Fresh Standard-02 ( 0.0 hour)  1 
8 STSSS-03 ( 11.0 hour) 1 
9 Fresh Standard-03 (0.0 hour) 1 
10 STSSS-04 ( 11.0 hour) 1 
11 Fresh Standard-04 (0.0 hour) 1 
12 STSSS-05 ( 11.0 hour) 1 
13 Fresh Standard-05 (0.0 hour) 1 
14 Bracketing Standard 1 
 
Table 13: Sequence for STSSS. 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
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Mean Area Ratio = 0.986 for this experiment. 
The Mean Area Ratio is within the acceptance criteria of 0.95 to 1.05, hence it can be 
concluded from this experiment that the Stock Solution is stable for the 10 days at 2 - 4˚ 
C in refrigerator, while Standard solution is remain unaffected on bench at ambient 
temperature and in normal light for 11 hour. In addition to this it confirms the reliability 
of the data generated during the method validation.  
4.4.8.  SYSTEM SUITABILITY STUDY 
A system suitability test for the chromatographic system was performed before each 
validation experiment. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. Only 
after the system suitability results were in acceptance criteria the experiments were 
precede further. 
 
The Theoretical plates should be more than 5000, Asymmetry should be less than 2.0 and 
% RSD should be less than 2.0. As the data suggest the system suitability was within the 
criteria in each validation experiment.  Hence the system was found suitable to perform 
the validation experiment which confirms the reliability of the data generated during the 
method validation. 
Summary of System Suitability Test 
Experiment Name Theoretical Plates Asymmetry % RSD 
Specificity 10832 1.28 0.67 
Linearity and Range 10989 1.22 0.87 
LOD and LOQ 10873 1.23 1.30 
Method Precision 11593 1.25 1.13 
Int. Precision 11138 1.29 0.76 
Accuracy 11292 1.23 0.42 
Robustness 10850 1.25 0.56 
Solution Stability 11389 1.26 1.40 
 
Table 14: Results of System Suitability Test after each Validation Experiment 
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4.  CONCLUSION 
The surveillance and outcome obtained from each validation experiment including 
specificity, linearity and range, LOD and LOQ, precision, accuracy, robustness, solution 
stability and system suitability lies well inside the acceptance criteria. Since, all the 
results are with-in the limit, the developed Analytical method is considered as validated 
and suitable for anticipated use.   
 
5. APPLICATION OF CURRENT WORK  AND  FURTHER 
AREA OF EXTENSION 
 
6.1. This method can be used for the quantification of Drotaverine hydrochloride in 
bulk drug as well as in pharmaceutical dosage form in routine or as a special test. 
6.2. As the stress condition analysis also did here it can be appropriately use for the 
stability study of Drotaverine hydrochloride. 
6.3. This method has also application over the chromatographic purity of Drotaverine 
hydrochloride. 
6.4. By optimizing certain chromatographic parameter it can be also used for the 
reaction monitoring of preparation of Drotaverine hydrochloride and its related 
compound. 
 
Further Area of Development, 
 
6.5. This method can be transferred to RP-UPLC which is highly useful for the high 
throughput analysis. 
6.6. It is highly specific over the degradation product hence it has scope for the 
isolation, characterization of impurity and their analysis. 
6.7. This method can be used for the analogue structure of the Drotaverine 
hydrochloride, additionally a general method can be develop and validate for the 
analogs of this molecule. 
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6.8. Further the method for the determination of Drotaverine hydrochloride and its 
intermediate during the preparation of the molecule can be developed and 
validate.   
6.9. This method may be applicable to other various formulations of papaverine types 
drugs also. 
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1.  INTRODUCTION 
Carvedilol is a non-selective beta-receptor blocking agent and a vasodilatation drug with 
antioxidant activity. [1] It has been confirmed that Carvedilol shows a far greater 
antioxidant activity than other commonly used beta-blockers.[2,3] Carvedilol is used in 
the treatment of mild to moderate hypertension and angina pectoris,[4,5] congestive heart 
failure (CHF)6 and is often used in combination with other drugs. Chemically it is named 
(±)-1-(carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy) ethyl) amino)-2-propanol. It blocks 
beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors. 
Pharmacology Indication For the treatment of mild or moderate (NYHA class II or III) 
heart failure of ischemic or cardiomyopathic origin. Pharmacodynamics Carvedilol is a 
nonselective beta-adrenergic blocking agent with alpha1-blocking activity and is 
indicated for the treatment of hypertension and mild or moderate (NYHA class II or III) 
heart failure of ischemic or cardiomyopathic origin. Carvedilol is a racemic mixture in 
which nonselective b-adrenoreceptor blocking activity is present in the S (-) enantiomer 
and a-adrenergic blocking activity is present in both R (+) and S(-) enantiomers at equal 
potency. Carvedilol has no intrinsic sympathomimetic activity. The effect of carvedilol's 
b-adrenoreceptor blocking activity has been demonstrated in animal and human studies 
showing that Carvedilol [7] reduces cardiac output in normal subjects; [8] reduces 
exercise-and/or isoproterenol-induced tachycardia and [9] reduces reflex orthostatic 
tachycardia.  
Mechanism of action Carvedilol is a racemic mixture in which nonselective beta-
adrenoreceptor blocking activity is present in the S (-) enantiomer and alpha-adrenergic 
blocking activity is present in both R (+) and S(-) enantiomers at equal potency. 
Carvedilol's beta-adrenergic receptor blocking ability decreases the heart rate, myocardial 
contractility, and myocardial oxygen demand. Carvedilol also decreases systemic 
vascular resistance via its alpha adrenergic receptor blocking properties. Carvedilol and 
its metabolite BM-910228 (a less potent beta blocker, but more potent antioxidant) have 
been shown to restore the inotropic responsiveness to Ca2+ in OH- free radical-treated 
myocardium. Carvedilol and its metabolites also prevent OH- radical-induced decrease in 
sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites  
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may be beneficial in chronic heart failure by preventing free radical damage. Absorption 
Carvedilol is rapidly and extensively absorbed following oral administration, with an 
absolute bioavailability of approximately 25% to 35% due to a significant degree of first-
pass metabolism. It is marketed various trade names 
including Coreg (GSK), Dilatrend (Roche), Eucardic (Roche), and Carloc (Cipla) as a 
generic drug (as of September 5, 2007 in the U.S.).,[10] and as a controlled-release 
formulation, marketed in the US as Coreg CR (GSK). 
 
 
 
 
 
 
 
 
 
Figure 1: Chemical Structure of Carvedilol 
 
 
 
Impurities in pharmaceuticals are the unwanted chemical that remain with the active 
pharmaceutical ingredients (APIs), or develop during formulation, or upon aging of the 
both API and formulated APIs to medicines. The presence of these unwanted chemicals, 
even in small amounts, many influence the efficacy and safety of the pharmaceutical 
products. Impurity profiling (i.e. the identity as well as the quantity in the 
pharmaceuticals), is now receiving important critical attention from regulatory 
authorities. The different pharmacopoeias, such as the British Pharmacopoeia (BP)and 
the United States Pharmacopoeia (USP) are slowly in-corporating limits to allowable 
levels of impurities present in the APIs or formulations. 
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The International Conference on Harmonization (ICH) has published guidelines on 
impurities in new drug substances [11], products [12] and residual solvents[13]. There is 
a good significant demand for the impurity reference standards along with the API 
reference standards for both regulatory authorities and pharmaceutical companies. 
Number recent articles [14-16] have described designed approach and guidance for 
isolating and identifying process-related impurities and degradation products using mass 
spectrometry, Nuclear Magnetic Resonance (NMR). High-performance liquid 
chromatography (HPLC), Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR-MS), and tandem mass spectrometry for pharmaceutical substances. 
 
1.1. SYNTHETIC METHOD  
 
There are many synthesis of Carvedilol in literature one important synthesis is given 
below [17]. 
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1.2. PROCESS RELATED IMPURITIES 
Preparation of Carvedilol by different routes yields many impurities; there are 
possibilities of generation of many process related impurities depending upon the process 
route, which is also mentioned in the European and United States pharmacopeia. 
 
 
 
 
Carvedilol R-Isomer 
(2R)-1-(9H-Carbazol-4-yloxy)-3- 
[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol 
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                                            Carvedilol S-Isomer 
(2S)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol 
 
 
 
Carvedilol USP Related Compound E 
2-(2-Methoxyphenoxy) ethylamine Hydrochloride ; Carvedilol Amine Impurity 
 
 
 
 
 
 
 
Carvedilol USP Related Compound A 
1-[[9-[2-hydroxy-3-[[2-(2-methoxyphenoxy)ethyl]amino]propyl]-9H-carbazol-4-yl]oxy]-3-[[2-(2-
methoxyphenoxy)ethyl]amino]propan-2-ol 
Figure 1: Chemical Structure of Possible process related impurities 
HN
O
HN
O
O
HO
H2N
O
O
.HCl
N
O
HN
O
O
HO
HN
OO
HO
 
Chapter – 3                  Development and Validation of Carvedilol and its Pharmacopeial three impurities by UPLC-PDA 
Page 97 
 
 
Reviewing the above reaction scheme there is possibility of generation of only three 
process related impurities namely, 1,1'-[[2-(2-methoxyphenoxy)ethyl]nitrilo]bis[3-(9H-
carbazol-4-yloxy)propan-2-ol], (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-
(9H-carbazol-4-yloxy)propan-2-ol and 4-(2,3-Epoxypropoxy) carbazole. These three 
molecules were considered in proposed work. 
 
 
 
 
 
USP Related Compound B  
1,1'-[[2-(2-methoxyphenoxy)ethyl]nitrilo]bis[3-(9H-carbazol-4-yloxy)propan-2-ol]   
  
 
 
 
 
USP Related Compound C 
(2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-carbazol-4-
yloxy)propan-2-ol 
 
 
USP Related Compound D 
4-(2,3-Epoxypropoxy)carbazole 
Figure 2: Chemical Structure of Possible process related impurities 
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2. LITERATURE REVIEW 
The literature reviews regarding Carvedilol revealed that various analytical methods are 
reported for drug substance as well as in pharmaceutical formulation and also in various 
biological fluids. The literature reviews for analysis of Carvedilol are as under. 
Soltani, Somaieh, Jouyban, Abolghasem have validated isocratic HPLC-UV method 
for the simultaneous determination of five drugs used in combined cardiovascular therapy 
in human plasma using  A MZ-anal. Column (15 mm × 4.6 mm, 5 μm) under an isocratic 
condition of acetonitrile/2-propanol/15 mM phosphate buffer (pH = 2) (32.5/2.5/65 
vol./vol./v) mobile phase. The max. Wavelength for the all detections was 225 nm.[18] 
Dey, Suddhasattya; Kumar, Dhiraj; Sreenivas, S. A.; Sandeep, D.; Choudhary, 
Avijt  have developed method for carvedilol by HPLC in bulk and dosage form using 
potassium dihydrogen phosphate,pH:2.0 adjusted with O-phosphoric acid and acetonitrile 
on 4.6 mm × 25 cm × 5 μ (C8), wave length 240 nm, flow rate 1 mL/min.[19] 
Verma, Navneet; Ghosh, A. K.; Chattopadhyay, P.have reported a work titled 
“Simultaneous spectrophotometric determination of carvedilol
 
 in its dosage form”. The 
method is based on the UV absorbance maxima of the above drug at 285 nm.  The drug 
obeyed Beer's law in the concn. range of 4-36 μg/mL with molar absorptivity of 12.6 × 
103 l/mol/cm in methanol.[20] 
LJ Patel, BN Suhagia, PB Shah, RR Shah has reported RP-HPLC and HPTLC for the 
estimation of carvedilol in bulk and pharmaceutical formulations using Lichrospher 100 
C-18, 5 µm column consisting of 200×4.6 mm i.d. in isocratic mode, with mobile phase 
containing 50 mM KH 2 PO 4 
 
buffer (pH 3.0±0.1): acetonitrile: methanol (60:50:10 v/v/v) 
was used. The flow rate was 1.0 ml/min and effluent was monitored at 242 nm.[21] 
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Pattana Sripalakit, Somsak Kaewnok  and Sakawrat Tubtonglang has developed a 
method for carvedilol assay in tablet dosage form using HPLC with fluorescence 
detection. Chromatographic separation was achieved on a Alltima® C18 (250 mm4.6 
mm) column using a mobile phase containing 0.01 M Na2HPO4 in water and acetonitrile 
(30:70 v/v) adjusted to pH 3.0 by orthophosphoric acid at a flow rate of 1.0 ml/min and 
employing fluorescence detection with 300nm excitation and 343-nm emission 
wavelengths.[23] 
 
R Gannu, V V Yamsani, Y M Rao has developed a RP-HPLC method for determination 
of Carvedilol in human serum. The mobile phase was made of acetonitrile, 15 mM 
orthophosphoric acid (37:63), and 0.25% v/v of triethylamine, with a flow rate of 
1 mL/min. Serum samples containing the carvedilol and internal standard, amitriptyline 
were eluted through a C8, Kromasil KR 100 5C8 column. Retention times of carvedilol 
was 6.10 min. [22] 
S. W. Myung and C. H. Jo has developed Gas chromatograph-mass spectrometric 
method for the determination of carvedilol and its metabolites in human urine. Urine 
samples were hydrolyzed with β-glucuronidase/arylsulfatase (from Helixpomatia) and the 
target compounds were extracted with liquid-liquid extraction. The extracts were 
completely derivatized with MSTFA and MBTFA and analyzed by GC-MS using an 
Ultra-2 column. The linearity of the assay ranges were 0.75-75 ng/ml for carvedilol 
and 
 
o-desmethyl carvedilol (o-DMC), and 3.0-75 ng/ml for 4-hydroxyphenyl carvedilol 
(4-HPC) and 5-hydroxyphenyl carvedilol (5-HPC).[24] 
J. Stojanović, V. Marinković, S. Vladimirov, D. Veličković and P. Sibinović has 
worked on Determination of Carvedilol and its Impurities in Pharmaceuticals. 
 
The best 
separation was achieved on a 100 mm × 4.6 mm, 5 µm particle size, Chromolit RP 8e 
column. Use of acetonitrile-water, 45:55 (v/v), adjusted to pH 2.5 with formic acid, as 
mobile phase at a flow rate of 0.5 mL min−1. [26]  
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3. AIM OF THE PRESENT WORK 
 
The above cited references suggest that there are no methods for the quantification of 
Carvedilol and its related known impurities by UPLC-PDA. Available methods deals 
with the bioanalytical study of Carvedilol and some methods deal with the metabolite of 
the same. Furthermore the present method has the advantage over the speed as well as the 
selectivity. It can be maximum utilize for the analysis and it could be also functional of 
quality control laboratory for routine use. The aim and scope of the proposed work are as 
under, 
 
3.1. To develop method for quantification of the drug substance with its process 
related impurities using the latest technology in liquid chromatography. 
3.2. To optimized the method at a maximum level to gain high throughput screening. 
3.3. Elaborate the technology suggesting the various applications.   
3.4. To perform analytical method validation for the proposed method as per ICH 
guideline [27]. 
4. EXPERIMENTAL 
4.1. MATERIALS, CHEMICALS AND REAGENTS. 
Matrix Laboratories Limited (Hyderabad) and Vijayasari Organics Limited (Hyderabad), 
provided Carvedilol working standard and its related impurities working standards. 
HPLC-grade Potassium dihydrogen phosphate was obtained from Finar Chemicals 
(Ahmedabad, India). HPLC grade orthophosphoric acid (88 %) was from Spectrochem 
(Mumbai, India). HPLC grade Acetonitrile was purchased from Spectrochem Pvt Ltd. 
HPLC grade water used was purified by Milli-Q Elix-3 water purification system. 
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4.2. INSTRUMENTATION  
The Waters AcquityTM UPLC chromatographic system used to perform development and 
validation. This system consist of a binary solvent manager (pump), photodiode array 
detector, sample manager(Auto sampler) and column oven connected to a multi-
instrument data acquisition and processing system Empower 2.1 version. Sartorius 
microbalance and Equiptronics branded balance was used for the weighing purpose while 
Spinco ultrasonic bath used for degassing purpose. 
4.3. METHOD DEVELOPMENT 
Analytical Method development is consist of following steps which can be shore up by 
the literature survey, previous experience and chemical nature of the reagents used in the 
development. 
4.3.1. MOBILE PHASE SELECTION 
On the basis of literature survey, several exploratory runs have been performed but 
initially proper selectivity and resolution between the drug substance and its impurities 
not achieved. After furnishing more importance to the literature it was concluded that 
Potassium dihydrogen phosphate has given the best results and 5 mM concentration was 
fulfilling the requirements. Above all 5 mM potassium dihydrogen phosphate used with 
acetonitrile as an organic component at gradient elution provides the desired outcome. 
4.3.2. COLUMN SELECTION 
Column selection is the most important part in the method development. In this case most 
suitable column chemistry was Phenyl. Among the column chemistry available with us 
the ACQUITY UPLC BEH Phenyl (100 x 2.1 mm id, 1.7μm particle size) gives the best 
consequences. 
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4.3.3. DETECTION WAVELENGTH SELECTION  
We have screened the standard solution over 190 nm to 400 nm using the advantage of 
photo diode array detector. On the basis of peak absorption maxima and peak purity 
index the 242 nm was decided as the detection wavelength which also gives the 
maximum chromatographic compatibility to the method. The absorption is shown in the 
figure 1 for Carvedilol and its related impurities at each wavelength. 
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Figure 3: UV absorption of Carvedilol and its related substance 
4.3.4. MOBILE PHASE  PREPARATION : 
The mobile phase consists of 5 mM Potassium dihydrogen phosphate salt (A): 
Acetonitrile (B). 5 mM Potassium di hydrogen ortho phosphate was prepared by 
dissolving 0.68 gm of Potassium di hydrogen ortho phosphate for HPLC in 1000 ml of 
HPLC grade water, the pH of the buffer solution was adjusted to 3.0 using 0.1% ortho 
phosphoric acid (HPLC grade) which further Sonicate for 20 minutes to remove of all 
dissolve gas and filtered through 0.45µn mobile phase filter. Gradient flow is mentioned 
in below table. 
 
 
Chapter – 3                  Development and Validation of Carvedilol and its Pharmacopeial three impurities by UPLC-PDA 
Page 103 
 
Gradient Flow:  
Time Flow in ml % A % B 
0.0 0.350 65.0 35.0 
0.350 0.350 15.0 85.0 
0.351 0.350 65.0 35.0 
5.00 0.350 65.0 35.0 
 
4.3.5. DILUENT PREPARATION 
Sample diluent was prepared by mixing Acetonitrile, Methanol and Milli-Q water in 
70:30:20 ratio, which was further sonicate to confirm uniformity and removal of all 
dissolve gas. 
 
4.3.6. STANDARD SOLUTION PREPARATION 
Carvedilol  and its related impurities working standard solution containing 100 μg/ml was 
prepared in a 25ml volumetric flask by dissolving 2.5 mg each in 10ml acetonitrile: 
methanol: water(70:30:20) and then diluting to volume with the same diluent. 
4.3.7. SAMPLE SOLUTION PREPARATION 
Carvedilol  and its related impurities sample (different batch) solution containing 100 
μg/ml was prepared in a 25 ml volumetric flask by dissolving 2.5 mg each in 10 ml 
acetonitrile: methanol: water(70:30:20) and then diluting to volume with the same 
diluent.  
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Figure 4: Chromatograms of Working Standard and Sample solution. 
In conclusion to Method development following chromatographic conditions suits the 
most and decided as a final method for validation experiments.  
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Mobile Phase A   : 5mM Potassium dihydrogen 
                                                 O- Phosphate salt, pH:3.0 
Mobile Phase B   : Acetonitrile (HPLC grade) 
Column    :  Phenyl (100 x 4.6 mm id, 5μ) 
Flow Rate   : 0.350 ml/min 
Detection               : 242 nm UV 
Diluent     : Acetonitrile: Methanol : Water (70:30:20) 
Injection Volume  : 03 µl 
 
 
Gradient elution at  :  
Time Flow in ml % A % B 
0.0 0.350 65.0 35.0 
0.350 0.350 15.0 85.0 
0.351 0.350 65.0 35.0 
5.00 0.350 65.0 35.0 
 
 
4.4. METHOD VALIDATION 
 
 
Method for the determination of Carvedilol and its related impurities in bulk drug is 
further validated as per ICH Q2 (R1) guideline [39]. Validation of analytical method was 
performed using Carvedilol working standard and sample batch drug substance. 
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4.4.1. SPECIFICITY  
 
The evaluation of the specificity of the method was determined against diluent 
application and each of the impurities to the drug substance. The interference of the 
diluent and each impurity was derived by injecting each individual impurities solution 
and individual drug substance. The retention time of each was taken in to consideration. 
Further the specificity of the method toward the drug was established by means of the 
interference of diluent at the retention time of the drug peak. 
Blank preparation: 
Diluent was used as blank solution. 
Impurity - B Solution preparation (100µg/ml): 
Weight exact 5.0 mg of 1,1'-[[2-(2-methoxyphenoxy)ethyl]nitrilo]bis[3-(9H-carbazol-4-
yloxy)propan-2-ol] in 50 ml volumetric flask dissolve it in diluent and followed by make 
up to the mark with diluent. Apply sonication to it in ultrasonic bath for 10 min and filter 
the solution with 0.22 µn membrane filter. 
 
Impurity - C Solution preparation (100µg/ml): 
Weight exact 5.0 mg of (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-
carbazol-4-yloxy)propan-2-ol in 50 ml volumetric flask dissolve it  and followed by make 
up to the mark with diluent. Apply sonication to it in ultrasonic bath for 10 min and filter 
the solution with 0.22 µn membrane filter. 
 
Impurity - D Solution preparation (100µg/ml): 
Weight exact 5.0 mg of 4-(2, 3-Epoxypropoxy)carbazole in 50 ml volumetric flask 
dissolve it and followed by make up to the mark with diluent. Apply sonication to it in 
ultrasonic bath for 10 min and filter the solution with 0.22 µn membrane filter. 
 
Drug substance solution preparation (100µg/ml): 
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Weight exact 5.0 mg of Carvedilol in 50 ml volumetric flask dissolve it in 50 ml of 
diluent followed by make up to the mark with diluent. Apply sonication to it in ultrasonic 
bath for 10 min and filter the solution with 0.22 µn membrane filter. 
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Impurity-C 
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Figure 5: Chromatograms of Diluent, each impurity and drug substance 
 
From the specificity experiment and subsequently achieved above chromatograms it has 
proven that any interference was not observed from blank or any related impurities to the 
peak of interest, in addition to this peak purity was also within the acceptance criteria 
confirmed by the photo diode detector. Hence it confirms that the proposed method is 
highly specific with respect to the diluent and related impurities. 
 
4.4.2. LINEARITY & RANGE  
 
The linearity curve was prepared with 8 concentration levels (20, 40, 60, 80, 100, 120, 
140, 160 and 180 μg/ml of Carvedilol and its related impurities). These concentration 
levels were respectively corresponding to 20, 40, 60, 80, 100, 120, 140,160, and 180 % of 
standard solution concentration. The peak areas vs. concentration data were evaluated by 
linear regression analysis. 
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Stock Solution Preparation:  
Weight accurately 25 mg of Carvedilol and Impurities B, C and D working standard, 
transfer it and dissolved into 25 ml volumetric flask and dilute it up to the mark with 
diluent. Apply sonication for minimum 30 min to confirm the uniform mixture. 
 
Linearity Standard Solution Preparation: 
From Standard Stock Solution of accurate 1000 µg/ml pipette out exactly 0.2, 0.4, 0.6, 
0.8, 1.0, 1.2, 1.4, 1.6 and 1.8 ml and dilute it up to 10 ml each with diluent to achieve 20-
180 µg/ml concentration of Carvedilol and its impurities. 
 
 
 
Linearity & Range 
Calibration 
Point 
Concentration 
(µg/ml) 
Peak Area 
Carvedilol IMP-D IMP-C IMP-B 
STD 1 180 6496523 9572840 5378813 6818979 
STD 2 160 5830726 8879388 4750104 6109489 
STD 3 140 5083480 7851795 4001946 5373118 
STD 4 120 4211038 6824547 3366980 4516445 
STD 5 100 3460870 5829983 2764197 3797215 
STD 6 80 2657352 4813635 2188274 3010944 
STD 7 60 1934507 3938126 1602315 2214382 
STD 8 40 1205837 2830288 965401 1484236 
STD 9 20 543642 1816896 288532 767124 
 
Table 1: Linearity and Range - Concentration Vs Peak area response data 
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Chart 1: Regression Analysis chart of linearity Study 
 
Where, X axis = Concentration (µg/ml), Y axis = Peak Area and Series 1(Y1) = 
Carvedilol, Series 2(Y2) = IMP-D (4-(2,3-Epoxypropoxy)carbazole), Series 3(Y3) = 
IMP-C((2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-carbazol-4-
yloxy)propan-2-ol),Series 4(Y4)=IMP-B(1,1'-[[2-(2-methoxyphenoxy)ethyl]nitrilo]bis[3-
(9H-carbazol-4-yloxy)propan-2-ol]). 
Above data and the chart suggest that correlation coefficient of the Carvedilol was R2 = 
0.9992 with linear regression equation Y1 = 37948x - 303266 and R2 = 0.9989, Y2 = 
49174x +900056 for IMP-D, R2 = 0.9991, Y3 = 31411x + 329260 for IMP-C, R2 = 
0.9997, Y4 = 38255x - 37520for IMP-B. 
Thus in conclusion the method counts to be highly linear for drug substance as well as for 
related impurities across the working concentration range. 
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4.4.3. LIMIT OF DETECTION AND LIMIT OF QUANTITATION 
 LOD is the lowest amount of the drug content which can be detected by the proposed 
method while LOQ is the lowest amount which can be quantified by the method. The 
guideline suggest minimum signal to noise ratio (S/N) should be more than 3.3 for LOD 
and more than 10 for LOQ. On the basis of linearity data theoretically it can be also 
calculated by the given formula, 
LOD = 3.3 σ/S LOQ = 10 σ/S 
Where σ = Residual Standard Deviation of regression line and S = Slope of regression 
line. 
 
LOD Solution Preparation: 
Individual solution preparation for Carvedilol (100µg/ml), IMP-D (100µg/ml), IMP-C 
(100µg/ml), and IMP-B (100µg/ml) procedure given on  page 106. From this 100µg/ml 
solution pipette out exact 1.0, 0.4, 0.5 and 1.0ml in to different 50ml volumetric flask 
then followed by dilution up to the mark with diluent to reach 2, 0.8, 1 and 2µg/ml 
concentrations of Carvedilol, IMP-D, IMP-C and IMP-B respectively. 
. 
LOQ Solution Preparation: 
Individual solutions preparation for Carvedilol (100µg/ml), IMP-D (100µg/ml), IMP-C 
(100µg/ml), and IMP-B (100µg/ml) procedure given on page 106. From this 100µg/ml 
solution pipette out exact 0.75, 2.5, 2.75 and 3.0ml in to different 25ml volumetric flask 
then followed by dilution up to the mark with diluent to reach 3, 10, 11 and 12µg/ml 
concentrations of Carvedilol, IMP-D, IMP-C and IMP-B respectively. 
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LOQ 
Replicates  CARVEDILOL  
IMP-D 
 
IMP-C 
 
IMP-B 
 
INJ 01 109540 1103296 207803 529732 
INJ 02 108615 1178538 210345 505834 
INJ 03 110932 1191275 198390 558959 
INJ 04 108348 1157349 209908 557884 
INJ 05 107858 1167048 209832 528342 
INJ 06 107256 1103296 209171 545794 
Mean 108758.17 1150133.67 207574.83 537757.50 
Std dev 1310.90 38013.43 4586.36 20451.58 
% RSD 1.21 3.31 2.21 3.80 
 
Table 2: Limit of Quantification – Summary of Replicate Injections 
 
 
      
Carvedilol LOD  
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IMP-B (LOD) 
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Figure 6: Chromatogram of Limit of Detection for Carvedilol, IMP-B, IMP-C and IMP-D 
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IMP-B LOQ  
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Figure 7: Chromatogram of Limit of Quantification for Carvedilol, IMP-B, IMP-C and        
IMP-D 
LOQ of the analytical method can evaluated by establish linearity up to LOQ value. For 
that linearity study is extended up to LOQ value, 
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Chart 2: Regression Analysis chart of linearity Study included with LOQ level 
Where, X axis = Concentration (µg/ml), Y axis = Peak Area and Series 1(Y1) = 
Carvedilol, Series 2(Y2) = IMP-D (4-(2,3-Epoxypropoxy)carbazole), Series 3(Y3) = 
IMP-C((2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-carbazol-4-
yloxy)propan-2-ol),Series 4(Y4)=IMP-B(1,1'-[[2-(2-methoxyphenoxy)ethyl]nitrilo]bis[3-
(9H-carbazol-4-yloxy)propan-2-ol]). 
All the results of LOD and LOQ data were within the acceptance criteria. The signal to 
noise ratio for the LOD was well within the acceptance criteria it means more than 3.3 
and for the LOQ it was more than 10.0. Furthermore the % RSD of the six replicate 
injection of LOQ preparation less than 4.0 and the data of linearity extension chart up to 
LOQ level also suggest that the Carvedilol, IMP-D, IMP-C and IMP-B can be quantified 
up to 3, 10, 11 and 12 µg/ml well precisely and accurately.  
 
4.4.4. PRECISION  
 
Precision study was established by evaluating method precision and intermediate 
precision study. Method precision of the analytical method was determined by analyzing 
six sets of sample solution preparation. Mean standard deviation and % relative standard 
deviation for the same was calculated. Intermediate precision of the analytical method 
was determined by performing same procedure as method precision on another day by 
another analyst using different make of raw materials under same experimental condition. 
Area of all six replicate sample preparations was determined and standard deviation and 
% relative standard deviation also calculated. 
 
Standard Solution Preparation: 
Standard Stock Solution prepared as per procedure on page 110 of 1000 µg/ml. pipette 
out exact 1.0 ml from this solution and dilute up to 10 ml to accomplish 100 µg/ml 
concentration.  
 
Sample Solution Preparation:  
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Weight accurately 2.5 mg of Carvedilol and Impurities  B, C and D sample, transfer it 
into 25 ml volumetric flask and dissolved then dilute it up to the mark with diluent. 
Apply sonication for minimum 30 min to confirm the uniform mixture. The concentration 
obtained is about 100 μg/ml of drug substance as well as each impurities. This solution is 
assign as Test Preparation Set – 01. The same procedure was used for preparing the six 
Test preparation Sets. Same approach was applied for the intermediate precision study on 
the second day with different analyst and different make of raw materials. 
 
 
METHOD PRECISION 
Replicates Peak Area 
CARVEDILOL IMP-D IMP-C IMP-B 
Set 01 3503344.0 5806233.5 2723768 3896904.5 
Set 02 3380693.0 5834339.0 2767958 3813524.0 
Set 03 3461716.0 5734205.5 2760661 3837854.5 
Set 04 3416462.5 5818465.0 2692237 3773125.5 
Set 05 3466157.5 5841855.5 2754337 3871995.5 
Set 06 3466827.0 5894174.0 2752763 3846874.0 
Mean 3449200.0 5821545.4 2741953.8 3840046.3 
Standard 
Deviation 
43477.5 52389.5 28631.6 43558.8 
% RSD 1.3 0.9 1.0 1.1 
 
Table 3: Method Precision Data  
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INTERMEDIATE PRECISION 
Replicates Peak Area 
CARVEDILOL IMP-D IMP-C IMP-B 
Set 01 3580920.5 5773120.5 2764410.0 3896904.5 
Set 02 3498637.5 5806745.5 2670590.5 3813524.0 
Set 03 3533288.5 5782684.0 2762105.0 3837854.5 
Set 04 3542020.0 5686789.5 2724336.0 3773125.5 
Set 05 3530866.5 5870532.0 2766381.5 3871995.5 
Set 06 3614231.0 5834863.0 2736536.0 3846874.0 
Mean 3549994.0 5792455.8 2737393.2 3811383.7 
Standard 
Deviation 
41058.1 62822.2 36918.1 47111.5 
% RSD 1.2 1.1 1.3 1.2 
 
Table 4: Intermediate Precision Data 
 
 
Method Precision 
 
Carvedilol-2.019 
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Figure 8: Chromatograms of Sample Solution for Method Precision and Int.Precision 
The data generated in method precision study and intermediate precision study suggest % 
RSD value of peak area for each set is less than 2.0 and overall % RSD value for all six 
set is less than 2.0 which suggest that method is highly precise for determination of all 
four components. 
4.4.5. ACCURACY     
This Experiment can be performed by the recovery test. Recovery of the method is 
evaluated at 3 different concentration levels (corresponding to 40, 100 and 160% of test 
solution concentration) by addition of known amounts of standard to Sample preparation. 
For each concentration level, 3 sets were prepared and injected in duplicate. 
 
Blank preparation: 
Diluent was used as blank solution. 
 
Standard preparation: 
Stock solution and standard solution has been prepared as per procedure on page 110. 
 
Sample preparations for accuracy levels are as under: 
Intermediate Precision 
 
Carvedilol -2.019 
          IMP-D -2.317 
      IMP-C-2.942 
3.161 -IMP-B 
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Accuracy level 1 (40%)  
Test stock solution:  
40.0 mg of Carvedilol and its related impurities working standard was accurately 
weighed and transferred into 200 ml volumetric flask. 40.0 mg Carvedilol and its related 
impurities sample (different batch) was weighed and transferred into the same 200 ml 
volumetric flask. Around 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal handshaking. 
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained was 400 μg/ml of Carvedilol and its related impurities. 5.0 ml of above test 
stock solution was pipette out and transferred into 50 ml volumetric flask followed by 
diluted to volume with diluent. The concentration obtained is 40 μg/ml Carvedilol and its 
related impurities. The same procedure was applied for preparing the three sets. 
 
Accuracy level 2 (100 %) 
Test stock solution:  
100.0 mg of Carvedilol and its related impurities working standard was accurately 
weighed and transferred into 200 ml volumetric flask. 100.0 mg of Carvedilol and its 
related impurities sample (different batch) was weighed and transferred into the same 200 
ml volumetric flask. 140 ml of diluent added into the volumetric flask. The volumetric 
flask was proceeding for sonication of 30 minutes with normal handshaking. Then, the 
flask was cooled to room temperature and diluted to volume with diluent. 10 ml of this 
solution was filtered through 0.22 μm nylon syringe filter. The concentration obtained 
was 1000 μg/ml of Carvedilol and its related impurities. 5.0 ml of above test stock 
solution was pipette out and transferred into 50 ml volumetric flask followed by diluted 
to volume with diluent. The concentration obtained is 100 μg/ml of Carvedilol and its 
related impurities. The same procedure was applied for preparing the three sets. 
Accuracy level 3 (160 %) 
Test stock solution:  
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160.0 mg of Carvedilol and its related impurities working standard was accurately 
weighed and transferred into 200 ml volumetric flask. 160.0 mg of Carvedilol and its 
related impurities sample (different batch) was weighed and transferred into the same 200 
ml volumetric flask. 140 ml of diluent added into the volumetric flask. The volumetric 
flask was proceeding for sonication of 30 minutes with normal handshaking. Then, the 
flask was cooled to room temperature and diluted to volume with diluent. 10 ml of this 
solution was filtered through 0.22 μm nylon syringe filter. The concentration obtained 
was 1600 μg/ml of Carvedilol and its related impurities. 5.0 ml of above test stock 
solution was pipette out and transferred into 50 ml volumetric flask followed by diluted 
to volume with diluent. The concentration obtained is 160 μg/ml of Carvedilol and its 
related impurities. The same procedure was applied for preparing the three sets 
 
Accuracy 
Replicates 
Carvedilol IMP-D IMP-C IMP-B 
Area % RSD Area 
% 
RSD Area 
% 
RSD Area 
% 
RSD 
160 % set 
01 
5845894 
0.46 
8868439 
0.13 
4857493 
0.80 
6145674 
0.39 160 % set 02 
5810943 8876743 4789434 6128430 
160 % set 
03 
5863458 8853592 4791458 6175899 
100 % set 
01 
3485728 
0.30 
5878323 
0.49 
2780935 
0.28 
3785468 
0.69 100 % set 02 
3465397 5897674 2777572 3737657 
100 % set 
03 
3478130 5840535 2792472 3779033 
040 % set 
01 
1203934 
0.62 
2878329 
0.45 
969338 
0.78 
1485504 
0.43 040 % set 02 
1215832 2897563 954746 1473829 
040 % set 
03 
1217863 2872954 965366 1484291 
 
Table 5: Summery of Accuracy Data-01 
Calculation formulas for recovery study are as under: 
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Where, Volume = Dilution given for preparing the solution. 
 
 
 
 
 
 
 
 
 
From the above calculation the % Recovery was calculated which is given below. 
 
Recovery for Carvedilol 
Accuracy 
Level 
Set 
No 
Amount 
Added 
(μg/ml ) 
Amount 
Found 
(μg/ml ) 
Recovery 
(%) 
Average 
Recovery 
Std. 
Dev. 
% 
RSD 
I (40%) 
1 40.11 40.09 99.95 
99.85 0.46 0.46 
2 40.22 39.96 99.35 
3 39.96 40.06 100.25 
II 
(100%) 
1 100.05 100.03 99.98 
100.08 0.23 0.23 
2 100.01 100.35 100.34 
3 100.09 100.01 99.92 
II 
(160%) 
1 160.12 160.05 99.96 
99.98 0.12 0.12 
2 160.05 160.23 100.11 
3 160.22 160.01 99.87 
 
Table 6: Summary of Accuracy Study – 2 
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 Figure 9: Chromatogram of Accuracy level -1 (160 %) 
 
 
  Figure 10: Chromatogram of Accuracy level -2 (100 %) 
 
 
   Carvedilol-2.001 
2.320 -IMP-D 
IMP-C- 2.918 
IMP-B-3.144 AU 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
Carvedilol -2.020 
2.322- IMP-D 
2.941- IMP-C  
3.161- IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
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Figure 11: Chromatogram of Accuracy level -3 (40 %) 
From the all above data and chromatograms it has been confirmed that the % recovery is 
within 98 to 102 % and this is in the limit of acceptance criteria. Additionally % RSD 
value of % recovery of replicate sets is below 2 % .consequently this suggests that 
proposed method is highly accurate. 
4.4.6. ROBUSTNESS  
 
Robustness of the method was evaluated by assaying test solutions under slight but 
deliberate changes in analytical conditions, such as change in flow rate(0.375 and 0.325 
ml/min, change in initial proportions of Buffer: Acetonitrile (60:40 to 15:85 and 70:30 to 
15:85,v/v), and change in column-lot. 
 
A) Flow Rate change: In this experiment the test samples were analyzed at the flow 
rate of 0.375 ml/min and 0.325 ml/min each and the results were observed in terms of 
Peak Response (Peak Area) and chromatographic compatibility (System Suitability Test). 
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 103.  A proto type chromatographic sequence of the robustness study 
is as under, 
Carvedilol-2.035 
2.318 -IMP-D 
2.964 -IMP-C 
IMP-B-3.177 AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 
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Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
Flow Rate 0.375 
ml/min 
2 Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 
Flow Rate 
0.325ml/min 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
  
Table 7: Experimental UPLC sequence for the robustness study -01 
 
 
Figure 12: Chromatogram of Robustness study at 0.375 ml/min flow rate 
 
 
Robustness 01 
 
Carvedilol-1.913 
2.210- IMP-D 
2.819 IMP-C 
3.040 -IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
 
Chapter – 3                  Development and Validation of Carvedilol and its Pharmacopeial three impurities by UPLC-PDA 
Page 128 
 
l
 
Figure 13: Chromatogram of Robustness study at flow Rate 0.325ml/min. 
 
The Peak Response and area value of test preparation wasn’t much influenced at 1.1 and 
1.3 ml/min. The above chromatograms suggest that the flow rate affects on the retention 
time of drug but it did not have any impact on the response, hence the peak area value 
remain unaffected. 
B) Mobile Phase Proportion Change: In this experiment the test samples were 
analyzed at the initial mobile phase proportion of 60:40 to 15:85 and 70:30 to 15:85, v/v 
(Buffer: Acetonitrile) each and the results were observed in terms of peak response, area 
value and chromatographic compatibility (System Suitability Test). Blank, Standards and 
Sample solutions were prepared as per the same procedure mentioned on page 103. 
 
 A proto type chromatographic sequence of the robustness study is as under, 
 
 
 
Robustness 02 
 
Carvedilol-2.134 
2.442 -IMP-D 
3.070- IMP-C 
3.286- IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
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Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
60:40 to 15:85  
Buffer : Acetonitrile 
2 Sys Suit Standard 5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 
70:30 to 15:85 
Buffer: Acetonitrile 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
 
Table 8: Experimental UPLC sequence for the robustness study – 02 
 
 
Figure 14: Chromatogram of Test Preparations at ratio 60:40 to 15:85,  
v/v of mobile phase. 
 
 
 
Robustness 03 
 
Carvedilol-1.886 
2.192- IMP-D 
2.830 -IMP-C 
3.061 -IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
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Figure 15: Chromatogram of Test Preparations at ratio 70:30 to 15:85 v/v of mobile 
phase. 
The Peak Response and area value of test preparation wasn’t much influenced at ratio 
60:40 to 15:85 and 70:30 to 15:85 of mobile phase but there is the minor change in 
retention time of each component. The above chromatograms suggest that the ratio 
affects on the retention time of drug but it did not have any impact on resolution and the 
response, hence the peak area value and chromatography remain unaffected. 
C) Column Lot Change: In this experiment the test samples were analyzed using 
different column lot and the results were observed in terms of area value (Peak Response) 
and chromatographic compatibility (System Suitability Test). Blank, Standards and 
Sample solutions were prepared as per the same procedure mentioned on page 103.  
 
Robustness 04 
 
Carvedilol -2.378 
2.672 -IMP-D 
3.273 -IMP-C 
3.469- IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
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Figure 16: Chromatogram of Test Preparations using different column lot 
 
The Peak Response and area value of test preparation wasn’t much changed with 
different column, in addition to this in this case the retention time was also remain. The 
above chromatograms suggest that diff. column does not affect on the retention time of 
drug and it did not have any impact on the response, hence the peak area value remain 
unaffected.  
A proto type chromatographic sequence of the robustness study is as under, 
 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
Chromatographic 
condition 
1 Blank 1 
Different Column 
Lot 
2  Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
 
Table 9: Experimental UPLC sequence for the robustness study – 03 
Carvedilol -1.870 
2.340- IMP-D 
2.740- IMP-C 
2.979 -IMP-B AU 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
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Summary of Robustness Study 
Robust 
Condition 
Peak  
Response 
Retention 
Time 
Variation 
(min.) 
System Suitability 
Theoretical 
Plates Asymmetry 
Flow Change 
0.325 ml/min Unaffected +0.1 21400 ±400 1.31 ± 0.24 
Flow Change 
0.375 ml/min Unaffected - 0.1 23700±600 1.22 ± 0.23 
MP Proportion 
Change 60:40 
to 15:85 
Unaffected - 0.2 20300 ± 300 1.24 ± 0.35 
MP Proportion 
Change 70:30 
to 15:85 
Unaffected + 0.3 20000 ±250 1.20 ± 0.20 
Column Lot 
Change Unaffected - 0.2 25000 ±150 1.15 ± 0.10 
                   Where, ± sign suggest statistics of all four analyte peaks. 
Table 10: Summary of robustness study  
The data and the chromatogram given above suggest that there is no considerable 
influence of the column lot change on the result of the analysis by this method or on 
chromatographic suitability of this method. Hence, it can be conclude from this 
experiment that the method is highly robust in terms of column lot change. Overall the all 
the experiment in robustness parameter succeeded in terms of acceptance criteria hence 
the proposed method is robust for above small changes in chromatographic condition. 
4.4.7. SOLUTION STABILITY 
Solution stability has the significant role in terms of the acceptability of the data 
generated during the method validation. Hence this study has to plan before starting the 
method validation and sometimes it is included in Pre Method Validation (PMV). On the 
basis of results achieved in PMV the solution stability can be planned and established in 
Method Validation. The Solution Stability can be established at two different time period, 
(A) Long Term Stock Solution Stability (LTSSS). 
(B) Short Term Standard Solution Stability (STSSS) or Bench Top Solution Stability. 
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LTSSS is established by comparing the response of the standard solution prepared from 
the kept stock solution at 2-4˚C for long time (in days) and fresh stock solution. While 
the STSSS is or bench top solution stability is established by comparing the response the 
standard solution kept on the bench for the short time (in hours) and freshly prepared 
standard solution. 
Preparation of Stock Solution for LTSSS: 
 25.00 mg of Carvedilol and its related impurities working standard were accurately 
weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was added into the 
volumetric flask and the standard substances were dissolved by sonication for ten minute. 
Then, volume of the flask was making up with diluent. The concentration obtained is 
1000 μg/ml of Carvedilol and its related impurities  
This solution was prepared on the first day of the validation and kept at the 2-4˚C 
temperature in refrigerator without any disturbance until performance of the LTSSS 
experiment. After 8 day the stock solution was bring out of the refrigerator and keep it as 
such till it attains the room temp. 5 ml of this solution was pipette out in 50 ml volumetric 
flask and dilute it up to the mark to reach 100 μg/ml of analyte This solution was 
assigned as LTSSS Standard solution. 
Preparation of Fresh Standard Solution:  
25.00 mg of Carvedilol and its related impurities working standard was accurately 
weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was added into the 
volumetric flask and the standard substances were dissolved by sonication for ten minute. 
Then, volume of the flask was making up with diluent. The concentration obtained is 
1000 μg/ml of all components. Pipette out exactly 5 ml of this solution in 50 ml 
volumetric flask and dilute it up to the mark accurately to confirm the 100 μg/ml of drug 
substance and impurities. This solution was assigned as Fresh Standard Solution. The 
proto-type experimental sequence is given below for LTSSS. 
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Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard 5 
3 LTSSS-01( 08 day) 1 
4 Fresh Standard-01( 0 day) 1 
6 LTSSS-02 (08 day) 1 
7 Fresh Standard-02 ( 0 day) 1 
8 LTSSS-03 (08 day) 1 
9 Fresh Standard-03 ( 0 day) 1 
10 LTSSS-04 (08day) 1 
11 Fresh Standard-04 ( 0 day) 1 
12 LTSSS-05 (08 day) 1 
13 Fresh Standard-05 ( 0 day) 1 
14 Bracketing Standard 1 
 
Table 11: Sequence for LTSSS. 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
 Mean Area Ratio = 1.057 for IMP-D, 0.988 for IMP-C 1.056 for IMP-B and 1.023 for 
Carvedilol.  
Preparation of Stock Solution for STSSS or Bench Top Solution Stability:  
25.00 mg of Carvedilol and its related impurities working standard were accurately 
weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was added into the 
volumetric flask and the standard substances were dissolved by sonication for ten minute. 
Then, volume of the flask was making up with diluent. The concentration obtained is 
1000 μg/ml of all components. This solution was prepared before the 09 hour and kept on 
bench at ambient temperature without any disturbance until performance of the STSSS 
experiment. After 09 hour on the bench. 5 ml of this solution was pipette out in 50 ml 
volumetric flask and dilute it up to the mark to reach 100 μg/ml drug substance and 
impurities.  This solution was assigned as STSSS Standard solution 
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Preparation of Fresh Standard Solution:  
25.00 mg of Carvedilol and its related impurities working standard were accurately 
weighed and transferred into 25 ml volumetric flask. 20 ml of diluent was added into the 
volumetric flask and the standard substances were dissolved by sonication for one 
minute. Then, volume of the flask was making up with diluent. The concentration 
obtained is 1000 μg/ml of all components. Pipette out exactly 5 ml of this solution in 50 
ml volumetric flask and dilute it up to the mark accurately to confirm the 100 μg/ml drug 
substance and impurities. This solution was assigned as Fresh Standard Solution 
 
The proto-type experimental sequence is given below for STSSS 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard 5 
3 STSSS-01( 9.0 hour) 1 
4 Fresh Standard-01( 0.0 hour) 1 
6 STSSS-02 ( 9.0 hour) 1 
7 Fresh Standard-02 ( 0.0 hour) 1 
8 STSSS-03 ( 9.0 hour) 1 
9 Fresh Standard-03 (0.0 hour) 1 
10 STSSS-04 ( 9.0 hour) 1 
11 Fresh Standard-04 (0.0 hour) 1 
12 STSSS-05 ( 9.0 hour) 1 
13 Fresh Standard-05 (0.0 hour) 1 
14 Bracketing Standard 1 
 
Table 12: Sequence for STSSS. 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
 
Chapter – 3                  Development and Validation of Carvedilol and its Pharmacopeial three impurities by UPLC-PDA 
Page 136 
 
Mean Area Ratio = 0.977for Pentanoic acid, 1.019 for 2- Ethyl Pentanoic acid 0.989 for 
2(1-methyl, ethyl) Pentanoic acid and 1.004 for Carvedilol. 
The Mean Area Ratio is within the acceptance criteria of 0.95 to 1.05, hence it can be 
concluded from this experiment that the Stock Solution is stable for the 8 days at 2 - 4˚ C 
in refrigerator, while Standard solution is remain unaffected on bench at ambient 
temperature and in normal light for 9 hour. In addition to this it confirms the reliability of 
the data generated during the method validation.  
4.4.8. SYSTEM SUITABILITY STUDY 
A system suitability test for the chromatographic system was performed before each 
validation experiment. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. Only 
after the system suitability results were in acceptance criteria the experiments were 
precede further. 
 
Summary of System Suitability Test 
Experiment Name Theoretical Plates Asymmetry % RSD 
Specificity  23500 ± 300 1.18 ± 0.1 1.25 
Linearity and Range  23700 ± 500 1.15± 0.1 0.35 
LOD and LOQ  24000± 1000 1.40 ± 0.2 1.81 
Method Precision  22800± 600 1.23 ± 0.1 1.26 
Intermediate Precision 24500 ± 250 1.24 ± 0.1 0.53 
Accuracy 23350 ± 100 1.05 ± 0.2 0.49 
Robustness 21400± 700 1.17 ± 0.1 0.67 
Solution Stability 23200 ± 400 1.21± 0.1 1.67 
 
Table 13: Results of System Suitability Test after each Validation Experiment 
 
Where, ± sign suggest statistics of all four component peaks. 
As per guideline the Theoretical plates should be more than 5000, Asymmetry should be 
less than 2.0 and % RSD should be less than 2.0. As the data suggest the system 
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suitability was within the criteria in each validation experiment. Hence the system was 
found suitable to perform the validation experiment which confirms the reliability of the 
data generated during the method validation. 
5. CONCLUSION 
The surveillance and results obtained from each validation experiment including 
specificity, linearity and range, LOD and LOQ, precision, accuracy, robustness, solution 
stability and system suitability lies well inside the acceptance criteria of ICH guideline. 
Since, all the results are with-in the limit, the developed Analytical method is considered 
as validated and suitable for probable use. 
6. APPLICATION OF CURRENT FINDINGS  
6.1. This method can be used for the quantification of Carvedilol in bulk drug as well 
as in pharmaceutical dosage form in routine or as a special test. 
6.2. This method can be used for the determination of process related impurities of 
Carvedilol more specifically for IMP-B, IMP-C and IMP-D. 
6.3. This method has also application over the chromatographic purity of Carvedilol. 
6.4. By optimizing certain chromatographic parameter it can be also used for the 
reaction monitoring of preparation of Carvedilol and its related compound. 
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1. INTRODUCTION 
The antihypertensives are a class of drugs that are used to treat hypertension (high blood 
pressure) [1]. Evidence suggests that reduction of the blood pressure by 5 mmHg can 
decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the 
likelihood of dementia, heart failure, and mortality from cardiovascular disease [2]. There 
are many classes of antihypertensives, which lower blood pressure by different means; 
among the most important and most widely used are the thiazide diuretics, the ACE 
inhibitors, the calcium channel blockers, the beta blockers, and the angiotensin II receptor 
antagonists or ARBs. Which type of medication to use initially for hypertension has been 
the subject of several large studies and resulting national guidelines. The fundamental 
goal of treatment should be the prevention of the important endpoints of hypertension, 
such as heart attack, stroke and heart failure. Patient age, associated clinical conditions 
and end-organ damage also play a part in determining dosage and type of medication 
administered [3]. The several classes of antihypertensives differ in side effect profiles, 
ability to prevent endpoints, and cost. The choice of more expensive agents, where 
cheaper ones would be equally effective, may have negative impacts on national 
healthcare budgets [4]. As of 2009, the best available evidence favors the thiazide 
diuretics as the first-line treatment of choice for high blood pressure when drugs are 
necessary [5].  
 
Diltiazem (DLZ) is a benzothiazepine calcium channel blocker with peripheral and 
coronary vasodilator properties. It lowers the blood pressure and has effect on cardiac 
conduction. It is administered orally in the treatment of angina pectoris and hypertension 
and may be given intravenously in the treatment of arterial fibrillation or flutter and 
paroxysmal supraventricular tachycardia [6].Diltiazem is a non-dihydropyridine (non-
DHP) member of the class of drugs known as calcium channel blockers, used in the 
treatment of hypertension, angina pectoris, and some types of arrhythmia. It is also an 
effective preventive medication for migraine. It is a class 3 anti-anginal drug, and a class 
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IV antiarrhythmic. It is a common adulterant of cocaine seized in the UK [7] and has 
been found to reduce cocaine cravings in rats, indicating that it may prolong the "high" 
(see below). It incites very minimal reflex sympathetic changes. It is based upon a1,4-
thiazepine vasodilatorring. Diltiazem is a potent , increasing blood flow and variably 
decreasing the heart rate via strong depression of A-V node conduction. Its 
pharmacological activity is somewhat similar to verapamil [8]. 
 
Olmesartan medoxomil (OST) is a prodrug and is hydrolyzed to the active olmesartan 
during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype 
angiotensin II receptor antagonist. A literature survey revealed that OST is not yet official 
in any pharmacopoeia. Olmesartan is indicated for the treatment of hypertension. It may 
be used alone or in combination with other antihypertensive agents [9]. The FDA has 
determined that the benefits of Benicar continue to outweigh its potential risks when used 
for the treatment of patients with high blood pressure according to the drug label [10].  In 
studies of angiotensin-converting enzyme (ACE) inhibitors such as Olmesartan, patients 
with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood 
urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan 
medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results 
may be expected [11]. 
 
The prodrug Candesartan cilexetil (CST) AstraZeneca is marketed by  and Takeda 
Pharmaceuticals. Candesartan cilexetil is an angiotensin II receptor antagonist used 
mainly for the treatment of hypertension. As all angiotensin II receptor antagonists, 
candesartan cilexetil is indicated for the treatment of hypertension. Results from the 
CHARM study in the early 2000s demonstrated the morbidity and mortality reduction 
benefits of candesartan therapy in congestive heart failure [12]. Thus, while ACE are still 
considered first-line therapy in heart failure, candesartan cilexetil can be used in 
combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone 
and additionally is an alternative in patients intolerant of ACE inhibitor therapy. In a 
four-year randomized controlled trial, candesartan cilexetil was compared to placebo to 
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see whether it could prevent or postpone the development of full-blown hypertension in 
people with so-called prehypertension. During the first two years of the trial, half of 
participants were given candesartan cilexetil, and the others received placebo; 
candesartan cilexetil reduced the risk of developing hypertension by nearly two-thirds 
during this period. In the last two years of the study, all participants were switched to 
placebo. By the end of the study, candesartan had significantly reduced the risk of 
hypertension, by more than 15%. Serious side effects were actually more common among 
participants receiving placebo than in those given candesartan cilexetil. [13]. 
 
Carvedilol (CRV) is a non-selective beta-receptor blocking agent and a vasodilatation 
drug with antioxidant activity [14].It has been confirmed that carvedilol shows a far 
greater antioxidant activity than other commonly used beta-blockers [15, 16]. Carvedilol 
is used in the treatment of mild to moderate hypertension and angina pectoris, [17,18] 
congestive heart failure (CHF) [19] and is often used in combination with other drugs. 
 
Quinapril hydrochloride (QNP) is a pro-drug which after administration to the human 
body is hydrolysed to the active metabolite-quinaprilate. Quinaprilate (quinapril diacid), 
by acting on the enzyme angiotensin convertase (ACE) inhibits the transformation of 
angiotensin I into angiotensin II. This inhibition brings about peripheral vasodilatation 
and reduction of aldosterone secretion with the consequent depletion of sodium and 
concomitant increase of potassium level [20-22].So, far conducted studies of quinapril 
hydrochloride we dealing only with the amorphous form of the drug [23-25]. 
 
Losartan potassium (LST) is an angiotensin II receptor antagonist drug used mainly to 
treat high blood pressure (hypertension). As with all angiotensin II type 1 receptor (AT1) 
antagonists, losartan is indicated for the treatment of hypertension. The LIFE study 
demonstrated losartan was significantly superior to atenolol in the primary prevention of 
adverse cardiovascular events (myocardial infarction or stroke), with a significant 
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reduction in cardiovascular morbidity and mortality for a comparable reduction in blood 
pressure. Losartan has been found to down regulate the expression of transforming 
growth factor beta (TGF-β) types I and II receptors in the kidney of diabetic rats, which 
may partially account for its nephroprotective effects.[26] Effects on TGF-β expression 
may also account for its potential efficacy in Marfan syndrome and Duchenne muscular 
dystrophy (DMD) – losartan has been shown to prevent aortic aneurysm and certain 
pulmonary complications in a mouse model of the disease[27].Losartan is an uricosuric. 
Because losartan can cause hyperkalemia, potassium supplements or salt substitutes 
containing potassium should not be used without consulting the prescribing physician 
. 
Valsartan (VST)  is an angiotensin II receptor antagonist (more commonly called an 
"ARB", or angiotensin receptor blocker), with particularly high affinity for the type I 
(AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood 
vessels and reduces blood pressure.[28] In the U.S., valsartan is indicated for treatment 
of high blood pressure, congestive heart failure (CHF), or post-myocardial 
infarction (MI) [29]. A study released by the Journal of Clinical Investigation in 2007 
found some efficacy in the use of valsartan in the treatment and prevention of 
Alzheimer's disease (in a mouse model) although such use is considered to be highly 
experimental [30]. 
 
Ranolazine (RNZ) is indicated for the treatment of chronic angina. Ranolazine may be 
used with beta-blockers, nitrates, calcium channel blockers, anti-platelet, therapy, lipid-
lowering therapy, ACE inhibitors, and angiotensin receptor blockers. It has been shown 
to decrease angina episodes in individuals with coronary artery disease on maximal doses 
of amlodipine [31]. In addition, it has been shown to both decrease angina episodes and 
increase exercise tolerance in individuals taking concomitant atenolol, amlodipine, or 
diltiazem [32]. 
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Figure 1: Chemical Structure of mentioned antihypertensive molecules 
 
2.  LITERATURE REVIEW 
The literature reviews concerning analytical method these eight antihypertensive drugs, 
there is no Ultra Performance Liquid Chromatographic method which describes the 
simultaneous chromatographic quantification these molecules. However various high 
performance liquid chromatographic analytical methods are reported for determination of 
those in bulk drug. Pharmaceutical dosage form and/or in biological matrix in single or in 
combination of two molecules, which provides the important reference and the initiative 
information about the molecule behavior under various chromatographic conditions. Few 
of them are mentioned below. 
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Shivram K, Shah A C, Newalkar B L, Kamath B V, have developed A Stability-
Indicating LC Method for diltiazem using octadecyl silane-bonded silica column at 
ambient temp. with UV detection at 240 nm.  The mobile phase consisting of MeCN-
MeOH-0.05M monobasic potassium phosphate (25:20:55) was pumped at 2 mL/min.  
The internal std. was cyproheptadine-HCl. [33].Some other methods are also available in 
literature for the determination of diltiazem single and also in biological matrix [34] [35]. 
Kaja R K, Surendranath K V, Satyanarayana P V V, worked on Validation and 
application of a stability-indicating HPLC method for olmesartan medoxomil using 
seperation was achieved using a C18-CN column (150 X 4.6) mm with 3.5 µm particles 
with simple mobile phase combination of buffer and acetonitrile in the ratio of 65:35 
(v/v).  Buffer consist of 20mM sodium dihydrogen ortho phosphate monohydrate, pH 
adjusted to 3.0 using phosphoric acid, delivered in isocratic mode at a flow rate of 1.0 mL 
min-1 and quantitation was carried out using UV detection at a wavelength of 210 
nm.[36]. Few other references are also available for analytical method of olmesartan 
medoxomil [37] [38]. 
Qutub S S, Razzaq S N, Ashfaq M,  Shuja Z A, and  Khan I U
 
Koteswari P, Ramakrishna S, Reddy V P, Janani V R, Sireesha K R, Narasu L M,  
have published a paper for a study on HPLC method with Phenomenex C18 of carvedilol 
in bulk and pharmaceutical dosage forms[41], and He Chun, Dong Haijun, Li 
Jianchun, developed a method for Carvedilol in human serum by LC/MS[42]. 
publish a paper for 
Simultaneous analysis  of Hydrochlorothiazide and Candesartan cilexetil in bulk and their 
pharmaceutical dosage forms by LC-UV.  Chromatographic separation was achieved on a 
Phenyl-2 column with a 25:75:0.2 mixture of 0.02 M potassium dihydrogen phosphate, 
methanol, and triethyl-amine, final pH 6.0 ± 0.1, as mobile phase. [39] while, SAKUR A A, 
FAEL H,    worked on Spectrofluorimetry method for the determination of Candesartan in 
tablets [40]. 
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Mao Shilong, Wu Yali, Zhang Rongrong, Miao Jikang, Ji Ying, Zhu Jianmin, have 
worked  on the HPLC  determination of related substances in  quinapril   hydrochloride  
tablets [43] and Parekh S A, Pudage A, Joshi S S, Vaidya V V, Gomes N A, Kamat S 
S published a paper for Simultaneous determination of hydrochlorothiazide,  quinapril  
and quinaprilat in human plasma by liquid chromatography-tandem  mass  spectrometry 
[44]. 
Many methods are available for the losartan potassium in combination or as a single drug 
in pharmaceutical dosage form like Kathiresan K, Gothandaraman S, Manickam M S, 
Kumar S M, Manavalan R,   have came out Method Development and Validation for 
estimation of losartan potassium in Tablet Dosage Forms[45] and Prasad S V S G B, 
Shivakumar S, Sudhir T, Mital R, Devala R G, worked on the development and 
validation of  LC/MS/MS method for the simultaneous estimation of Losartan   
potassium  and Irbesartan in rat plasma[46]. 
Rao K S, Jena N, Rao M E B,  worked on specific stability indicating high performance 
liquid chromatographic method for valsartan using Symmetry C18 (250 mm x 4.6 mm x 
5µ) column with the mobile phase consisting of 0.02 mM sodium dihydrogen ortho-
phosphate, pH adjusted to 2.5 using ortho-phosphoric acid (solvent A), and acetonitrile 
(solvent B) in the ratio of 58:42% v/ [47]. 
Cheng J, Liu Z, Qing X, Yang G,    published a paper for  determination of content of  
ranolazine  hydrochloride and related substances by High Performance Liquid 
Chromatography [48] and also found LC/MS/MS method for Ranolazine in human 
plasma [49]. 
3. AIM OF THE PRESENT WORK 
 
The above literature recommends that there are no methods for the determination of these 
eight most popular antihypertensive molecules by UPLC-PDA, All available methods are 
high performance liquid chromatographic methods and in single or in combination with 
one another molecule in dosage form but no methods deals with such high no. of 
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molecule in exclusive work. Furthermore the present method has the advantage over the 
speed which confirm by the short analysis time of just 13.0 minute and the selectivity, it 
can be maximum utilize for the analysis and it could be also functional of quality control 
laboratory for routine use. The aim and scope of the proposed work are as under,  
 
3.1. To develop method for quantification of the drug substance using the latest 
technology in liquid chromatography. 
3.2. To attain a method without precolumn or post column derivatization. 
3.3.  To optimized the method at a maximum level to gain High Throughput 
Screening. 
3.4.  Elaborate the technology suggesting the various applications.   
3.5.  To perform analytical method validation for the proposed method as per ICH 
guideline [50]. 
 
4.  EXPERIMENTAL 
4.1. MATERIALS, CHEMICALS AND REAGENTS. 
Matrix Laboratories Limited (Hyderabad, India), Symed Labs Limited (Hyderabad, 
India) and Hetero drugs Limited (Hyderabad, India), provided working standards and 
samples of all eight antihypertensive drugs. Formic Acid (HPLC) and HPLC grade 
Acetonitrile has purchased from Merck Ltd. and Spectrochem Pvt Ltd respectively. 
HPLC grade water used was purified by Milli-Q Elix-3 water purification system. 
4.2. INSTRUMENTATION  
The Waters AcquityTM UPLC chromatographic system used to perform development and 
validation. This system consists of a Binary Solvent Manager (pump), Photodiode Array 
Detector, Sample Manager (Auto sampler) and column oven connected to a multi-
instrument data acquisition and processing system Empower 2.1 version. Sartorius 
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microbalance and Equiptronics branded balance and heating oven was used for the 
weighing and heating purpose while Spinco ultrasonic bath used for degassing purpose. 
4.3.  METHOD DEVELOPMENT 
Analytical Method development is consist of following steps which can be shore up by 
the literature survey, previous experience and chemical nature of the reagents used in the 
development. 
4.3.1.  MOBILE PHASE SELECTION 
On the basis of literature survey, several exploratory runs have been performed but 
initially proper selectivity and resolution between the all drug substances were not 
achieved. After furnishing more importance to the literature, the Formic Acid in water, 
0.2% v/v, gave the maximum resolution with acetonitrile as an organic component, which 
was used in gradient programming with respect to time and composition of mobile phase. 
4.3.2. COLUMN SELECTION 
Column selection is the most important part in the method development. In this case most 
suitable column chemistry was BEH Silica C8. Among the column chemistry available 
with us the Acquity BEH C8
 
 (100 mm x 2.1 mm id, 1.7μ particle size) gives the best 
consequences. 
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4.3.3. DETECTION WAVELENGTH SELECTION  
We have screened the standard solution over 190 nm to 400 nm Using the advantage of 
photo diode array detector. On the basis of peak absorption maxima and peak purity 
index the 211 nm was decided as the detection wavelength which also gives the 
maximum chromatographic compatibility to the method. The absorption is shown in the 
figure 1 of all mentioned eight molecules at each wavelength.  
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Figure 2: UV absorption of all eight molecules in overlaid format 
4.3.4.  BUFFER SOLUTION PREPARATION 
Formic Acid in Water, 0.2% v/v was prepared by pipette out 2.0ml in 1000 ml of 
volumetric flask and make up to the mark with HPLC grade water which further Sonicate 
for 20 minutes to remove of all dissolve gas and filtered through 0.45µn filter.  
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4.3.5. DILUENT PREPARATION 
Sample diluent was prepared by mixing Acetonitrile and Milli-Q water in 50:50 ratio, 
which was further sonicate to confirm uniformity and removal of all dissolve gas. 
4.3.6. STANDARD SOLUTION PREPARATION 
Standard solution of 100 μg/ml concentration was prepared by dissolving 10.0 mg of 
each working standard in a 25 ml of acetonitrile: water (50:50) diluent then diluting it up 
to mark with the same diluent in the 100 ml volumetric flask. 
4.3.7. SAMPLE SOLUTION PREPARATION 
Sample solution of 100 μg/ml concentration was prepared by dissolving 10.0 mg of each 
Sample (Different batch) in a 25 ml of acetonitrile: water (50:50) diluent then diluting it 
up to mark with the same diluent in the 100 ml volumetric flask. 
 
Figure 3: Chromatograms of Working Standard 
 
 
 
 
 
     Ranolazine   -4.791 
              Diltiazem -5.351 
              Carvedilol -5.644 
                                                                          
   6.490- Quinapril 
                                   6.901- Olmesartan Medoxomil 
    7.294- Losartan Potassium 
      Valsartan-10.297 
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      Working Standard              Candesartan cilexetil --11.789  
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Figure 4: Chromatograms of Sample Solution. 
In conclusion to Method development following chromatographic conditions suits the 
most and decided as a final method for validation experiments. 
 
 
Mobile Phase A  : Formic Acid in Water, 0.2% v/v 
Mobile Phase B  : Acetonitrile (HPLC grade) 
Column   :  Acquity BEH C8 (100  x 2.1 mm id, 1.7μ particle size) 
Flow Rate  : 0.350 ml/min 
Gradient elution   : As per Table 1 
Detection   : 211 nm UV 
Diluent    : Acetonitrile: Water (1:1) 
Injection Volume : 03 µl 
Sample 
Ranolazine-4.790 
Diltiazem-5.349 
Carvedilol-5.642 
6.489-Quinapril 
6.902-Olmesartan medoxomil 
7.294-Losartan Potassium 
Valsartan-10.298 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Minutes 
0.00 2.00 4.00 6.00 8.00 10.00 12.00 
              Candesartan cilexetil-11.790 
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Table 1: Gradient Programming of proposed method 
 
 
4.4. METHOD VALIDATION 
 
Method for the simultaneous determination of eight most pertinent antihypertensive 
molecules bulk drug is further validated as per ICH Q2 (R1) guideline [50]. Validation of 
analytical method was performed using working standards and samples of different batch 
of drug substances. 
 
4.4.1. SPECIFICITY  
 
 
The evaluation of the specificity of the method was determined against diluent 
application and each of the Molecules to another drug substance, which were taken in to 
the consideration. The interference of the diluent and each molecule was derived by 
injecting each individual drug substance solution and diluent. The retention time of each 
is taken in to consideration. Further the specificity of the method toward the drug was 
established by means of the interference of diluent at the retention time of the drug peak. 
 
Time Flow Rate % of Buffer % of Organic Curve 
0.0 0.350 95.0 5.0 Initial 
5.0 0.350 65.0 35.0 6 
8.5 0.350 65.0 35.0 6 
12.0 0.350 5.0 95.0 6 
12.1 0.350 95.0 5.0 6 
13.0 0.350 95.0 5.0 6 
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Blank preparation: 
 
Diluent was used as blank solution. 
Solution preparation: 
Weight exact 10.0 mg of each drug substance in separate 100 ml volumetric flasks and 
dissolve them in 25 ml of diluent followed by make up to the mark with diluent. Apply 
sonication to them in ultrasonic bath for 10 min and filter the solution with 0.22 µn 
membrane filter. 
 
 
 
Figure 5: Chromatogram of Diluent (Blank) of Specificity Experiment 
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Figure 6: Chromatogram of Losartan Potassium of Specificity Experiment 
 
 Figure 7: Chromatogram of Valsartan of Specificity Experiment 
Losartan Potassium 
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Figure 8: Chromatogram of Quinapril of Specificity Experiment 
 
 
Figure 9: Chromatogram of Diltiazem of Specificity Experiment 
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Figure 10: Chromatogram of Carvedilol of Specificity Experiment 
 
Figure 11: Chromatogram of Olmesartan Medoxomil of Specificity Experiment 
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Figure 12: Chromatogram of Ranolazine of Specificity Experiment 
 
 
Figure 13: Chromatogram of Candesartan cilexetil of Specificity Experiment 
From the specificity experiment and subsequently achieved above chromatograms it has 
proven that any interference was not observed from blank or individual drug substance to 
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the peak of other (Drug Substance), in addition to this peak purity was also within the 
acceptance criteria confirmed by the photo diode detector. The chromatogram (3D View) 
of standard solution is shown in Figure 15. Hence it confirms that the proposed method is 
highly specific with respect to the diluent and each drug molecule to the other. 
 
 
 
Figure 14: Chromatogram of 3D – view of Standard preparation 
 
4.4.2. LINEARITY & RANGE  
 
The linearity curve was prepared with 8 concentration levels (40, 60, 80, 100, 120, 140, 
160 and 180μg/ml of each of drug molecule). These concentration levels were 
respectively corresponding to 40, 60, 80, 100, 120, 140, 160 and 180 % of standard 
solution concentration. The peak areas vs. concentration data were evaluated by linear 
regression analysis. 
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Stock Solution Preparation:   
Weight accurately 50 mg of each of drug molecule (working standard), transfer it into 
100 ml volumetric flask and dilute it up to the mark with diluent. Apply sonication for 
minimum 30 min to confirm the uniform mixture, which contains the 500 µg/ml of each 
analyte. 
 
Linearity Standard Solution Preparation: 
From Standard Stock Solution of accurate 500 µg/ml pipette out exactly 0.8, 1.2, 1.6, 2.0, 
2.4, 2.8, 3.2 and 3.6 ml and dilute it up to 10 ml each with diluent to achieve 40-180 
µg/ml concentration of analytes. 
 
Where, RNZ = Ranolazine, DLZ = Diltiazem, CRV = Carvedilol, QNP = Quinapril, OST 
= Olmesartan medoxomil, LST = Losartan Potassium, VST = Valsartan, CST = 
Candesartan cilexetil 
 
Linearity Range 
Conc. 
(µg/ml) 
Peak Area 
RNZ DLZ CRV QNP OST LST VST CST 
180 5315459 8974874 12777784 4223262 7243376 7212589 7862733 7029749 
160 4689801 7634224 11255461 3675260 6256764 6124043 6882477 6263475 
140 4063452 6760538 9769405 3053592 5485165 5417533 6073389 5321407 
120 3242729 5549919 8208520 2559953 4535470 4707315 5052603 4325460 
100 2816787 4725126 7016017 1860611 3742139 3719984 4253257 3792065 
80 2102257 3708467 5652459 1312219 2910610 2872356 3386076 3006111 
60 1427157 2663925 4168477 745132 2020099 1996660 2392332 2106313 
40 867135 1654540 2770633 260029 1237105 1201656 1440006 1251243 
 
Table 2: Linearity and Range - Concentration Vs Peak area response data 
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Linearity & Range 
Analyte  R² Y = mX + c 
Ranolazine (RNZ) 0.9982 y = 32001x - 454469 
Diltiazem (DLZ) 0.9981 y = 51235x - 426901 
Carvedilol (CRV)  0.9992 y = 70850x - 91176 
Quinapril (QNP) 0.9989 y = 28760x - 952339 
Olmesartan 
medoxomil (OST) 0.9994 y = 42705x - 518698 
Losartan Potassium 
(LST) 0.9984 y = 42462x - 514313 
Valsartan (VST) 0.9994 y = 45399x - 326082 
Candesartan cilexetil 
(CST) 0.9974 y = 40902x - 362195 
 
Table 3: Linearity and Range – Regression analysis data 
Where R2 
Standard Stock Solution for each drug prepared as per procedure given on page 161. 
From the stock solution of 500 µg/ml pipette out exact 0.55, 0.40, 0.25, 0.30, 0.25, 0.35, 
= Co-relation co efficient and Y = mX + c is regression analysis equation  
All above data suggests that the value of correlation coefficient and regression analysis 
equation are well within the criteria Thus in conclusion the method counts to be highly 
linear across the definite range for all eight drug substance. 
4.4.3. LIMIT OF DETECTION AND LIMIT OF QUANTITATION 
LOD is the lowest amount of the drug content which can be detected by the proposed 
method while LOQ is the lowest amount which can be quantified by the method. The 
guideline suggest minimum signal to noise ratio (S/N) should be more than 3.3 for LOD 
and more than 10 for LOQ. On the basis of linearity data theoretically it can be also 
calculated by the given formula, 
LOD = 3.3 σ/S LOQ = 10 σ/S 
Where σ = Residual Standard Deviation of regression line and S = Slope of regression 
line. 
LOD Solution Preparation: 
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0.25 and 0.30 ml in to different 25.0 ml volumetric flask then followed by dilution up to 
the mark with diluent to reach 11, 8, 5, 6, 5, 7, 5, and 6µg/ml concentrations of Quinapril, 
Olmesartan medoxomil, Candesartan cilexetil, Losartan potassium, Diltiazem, 
Ranolazine, Carvedilol and Valsartan respectively. 
LOQ Solution Preparation: 
Standard Stock Solution for each drug prepared as per procedure given on page 161. 
From the stock solution of 500 µg/ml pipette out exact 1.75, 0.90, 0.70, 0.65, 0.55, 1.0, 
0.45 and 0.75 ml in to different 25.0 ml volumetric flask then followed by dilution up to 
the mark with diluent to reach 35, 18, 14, 13, 11, 20, 9 and 15µg/ml concentrations of 
Quinapril, Olmesartan medoxomil, Candesartan cilexetil, Losartan potassium, Diltiazem, 
Ranolazine, Carvedilol and Valsartan respectively. Six replicate injections were made to 
prove the precision of the LOQ level 
LOQ 
Replicates 
Peak Area 
RNZ DLZ CRV QNP OST LST VST CST RNZ 
INJ 01 293252 426829 597235 39179 301250 363632 653700 387638 293252 
INJ 02 298658 427923 596382 39389 305683 362316 657589 383477 298658 
INJ 03 295663 423362 595738 38738 307832 368247 653734 386786 295663 
INJ 04 298532 424369 592785 39386 301817 365784 653978 385271 298532 
INJ 05 298926 423725 599498 39528 309864 363782 656546 382422 298926 
INJ 06 294328 426383 598345 39436 305548 366149 653244 383494 294328 
Mean 296559.8 425431.8 596663.8 39276 305332.3 364985 654798.5 384848 296559.8 
Std Dev 2474.58 1864.93 2330.97 287.34 3345.95 2146.41 1803.90 2064.82 2474.58 
% RSD 0.83 0.44 0.39 0.73 1.10 0.59 0.28 0.54 0.83 
Table 4: Limit of Quantification – Summary of Replicate Injections 
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 LOQ 
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 LOQ Diltiazem-5.443 
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Figure 15: Chromatogram of Limit of Quantification 
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Figure 16: Chromatogram of Limit of Detection 
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Signal to Noise ratio for LOQ and LOD is more than 10.0 and 3.3 respectively which are 
well within the acceptance criteria for each analyte. All the results of LOD and LOQ data 
were within the acceptance criteria, hence it can be conclude that the LOD of the method 
was 11, 8, 5, 6, 5, 7, 5, and 6µg/ml concentrations of Quinapril, Olmesartan medoxomil, 
Candesartan cilexetil, Losartan potassium, Diltiazem, Ranolazine, Carvedilol and 
Valsartan respectively and the LOQ of the method was 35, 18, 14, 13, 11, 20, 9 and 
15µg/ml concentrations of Quinapril, Olmesartan medoxomil, Candesartan cilexetil, 
Losartan potassium, Diltiazem, Ranolazine, Carvedilol and Valsartan respectively.  
Furthermore the % RSD of the six replicate injection of LOQ preparation less than 5.0.  
 
4.4.4. PRECISION  
 
Precision study was established by evaluating method precision and intermediate 
precision study. Method precision of the analytical method was determined by analyzing 
six sets of sample solution preparation. The mean, standard deviation and % relative 
standard deviation for peak area of all sets was calculated. Intermediate precision of the 
analytical method was determined by performing method precision on another day by 
another analyst using different make of raw materials under same experimental condition. 
The mean, standard deviation and % relative standard deviation for peak area of all sets 
was calculated. 
 
Standard Solution Preparation: 
Standard Stock Solution of 500 µg/ml prepared as per procedure on page 161. Pipette out 
exact 2.0 ml from this solution and dilute it up to 10 ml to accomplish 100 µg/ml 
concentrations.  
Sample Solution Preparation: 
Weight accurately 50.0 mg of each analyte sample and transfer it into 100 ml volumetric 
flask and dilute it up to the mark with diluent. Apply sonication for minimum 30 min to 
confirm the uniform mixture. 
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10.0 ml of above test stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained is about 100 
μg/ml of each drug substance. This solution is assign as Test Preparation Set – 01. 
The same procedure was used for preparing the six Test preparation Sets. Same approach 
was applied for the intermediate precision study on the second day with different analyst 
and different make of raw materials. 
 
Method Precision 
Replicat
-es 
Peak Area 
RNZ DLZ CRV QNP OST LST VST CST 
Set01 
1934535 3626763 5521167 1128532 2987651 2844636 3412712 3083237 
1922926 3625830 5508975 1116921 2982129 2837752 3406455 3079881 
Set02 
1883331 3559907 5415507 1087101 2921640 2778029 3341297 3017239 
1884849 3561235 5414111 1090438 2920971 2810072 3342144 3016232 
Set03 
1894480 3576115 5441996 1086133 2931298 2818573 3354197 3029774 
1900502 3582392 5440264 1097094 2934525 2824038 3359629 3032678 
Set04 
1883975 3552091 5405551 1085198 2910145 2800142 3332885 3008188 
1889030 3557617 5412129 1087497 2912919 2803617 3337547 3012353 
Set05 
1932775 3565552 5413985 1094093 2913592 2807722 3344740 3016910 
1892876 3564416 5414076 1095164 2913992 2807475 3343645 3017387 
Set06 
1881918 3549392 5397172 1098477 2897468 2792924 3327344 3002689 
1875761 3539902 5382016 1093950 2887733 2783933 3316702 2993826 
Mean 
1898079.
8 
3571767.7 5430579.1 1096716.5 2926171.9 2809076.1 3351608.1 3025866.2 
Std. 
Dev. 
20513.27 27841.75 42707.81 13150.18 30294.14 19938.22 29348.73 28040.42 
%RSD 1.08 0.78 0.79 1.20 1.04 0.71 0.88 0.93 
 
Table 5: Method Precision Data  
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Where, RNZ = Ranolazine, DLZ = Diltiazem, CRV = Carvedilol, QNP = Quinapril, OST 
= Olmesartan medoxomil, LST = Losartan Potassium, VST = Valsartan, CST = 
Candesartan cilexetil 
 
Intermediate Precision 
Replica
-tes 
Peak Area 
RNZ DLZ CRV QNP OST LST VST CST 
Set01 
1923827 3548900 5387437 1082870 2871050 2799516 3303952 2965011 
1928753 3556047 5400249 1060408 2875698 2804459 3308992 2971297 
Set02 
1954770 3600227 5423466 1098459 2920148 2846170 3356295 3010655 
1962004 3609199 5433462 1097173 2926461 2851998 3366384 3018656 
Set03 
1932968 3560079 5411972 1061266 2880079 2805826 3311803 2971422 
1934803 3557421 5417060 1067729 2880535 2804770 3310941 2970447 
Set04 
1941011 3565685 5421645 1064409 2883138 2809447 3317142 2976193 
1944767 3573272 5433034 1094318 2888687 2815338 3322353 2982016 
Set05 
1954589 3587445 5456745 1088475 2902751 2828833 3338643 2998422 
1955711 3585876 5459867 1059468 2903547 2829233 3338579 2999183 
Set06 
1963438 3597240 5473437 1060939 2911305 2836794 3348838 3007795 
1965866 3598401 5476127 1041203 2910315 2837609 3349979 3007283 
Mean 1946875.6 3578316.0 5432875.1 1073059.8 2896142.8 2822499.4 3331158.4 2989865.0 
Std. 
Dev. 14464.30 20563.10 28357.28 18491.44 18583.17 18131.42 21190.62 19007.87 
%RSD 0.74 0.57 0.52 1.72 0.64 0.64 0.64 0.64 
 
Table 6: Intermediate Precision Data  
The data generated in method precision study and intermediate precision study suggest % 
RSD value of peak area for each set is less than 2.0 and overall % RSD value for all six 
set is less than 2.0 which suggest that method is highly precise for determination of all 
eight components. The Chromatograms of Method Precision and Intermediate Precision 
of test preparation is given as under, 
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Figure 17: Chromatogram of Test Preparation in Method Precision study 
 
            Figure 18: Chromatogram of Test Preparation in Intermediate precision study 
 
4.4.5. ACCURACY STUDY    
Method Precision 
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      Candesartan cilexetil-11.782 
 
Chapter – 4                                            Analysis of eight antihypertensive drugs using small particle column by UPLC- PDA 
Department of Chemistry, Saurashtra University, Rajkot-360005                                                                  Page 176 
 
This Experiment can be performed by the recovery test. Recovery of the method is 
evaluated at 3 different concentration levels (corresponding to 50, 100 and 150% of test 
solution concentration) by addition of known amounts of Standard to Sample preparation. 
For each concentration level, 3 sets were prepared and injected to evaluate the study. 
 
Blank preparation: 
Diluent was used as blank solution. 
 
Standard preparation: 
Stock solution and standard solution has been prepared as per procedure on page 161. 
 
Sample preparations for accuracy levels are as under: 
 
Accuracy level 1 (50%)  
Test stock solution:  
50.0 mg of each analyte (working standard) was accurately weighed and transferred into 
200.0 ml volumetric flask. 50.0 mg each analyte (different batch) was weighed and 
transferred into the same 200 ml volumetric flask. Around 140 ml of diluent added into 
the volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes 
with normal handshaking.  Then, the flask was cooled to room temperature and diluted to 
volume with diluent. 10 ml of this solution was filtered through 0.22 μm nylon syringe 
filter. The concentration obtained is 500 μg/ml. 5.0 ml of above test stock solution was 
pipette out and transferred into 50 ml volumetric flask followed by diluted to volume 
with diluent. The concentration obtained is 50 μg/ml of each analyte; the same procedure 
was applied for preparing the three sets. 
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Accuracy level 2 (100 %) 
Test stock solution:  
 
100.0 mg of analytes (working standards) was accurately weighed and transferred into 
200 ml volumetric flask. 100.0 mg of analytes (sample; different batch) was weighed and 
transferred into the same 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes with 
normal handshaking. 
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained is 1000 μg/ml of drug substances. 5.0 ml of above test stock solution was pipette 
out and transferred into 50 ml volumetric flask followed by diluted to volume with 
diluent. The concentration obtained is 100μg/ml. The same procedure was applied for 
preparing the three sets. 
 
Accuracy level 3 (150 %) 
Test stock solution:  
150.0 mg of analytes (working standards) was accurately weighed and transferred into 
200 ml volumetric flask. 150.0 mg of analytes (sample; different batch) was weighed and 
transferred into the same 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes with 
normal handshaking.  
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained is 1500 μg/ml of drug substances. 5.0 ml of above test stock solution was pipette 
out and transferred into 50 ml volumetric flask followed by diluted to volume with 
diluent. The concentration obtained is 150μg/ml. The same procedure was applied for 
preparing the three sets. 
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Accuracy 
Replicates 
Peak Area 
RNZ DLZ CRV QNP OST LST VST CST 
level 01 
50 % 
Set 01 
907114 1843074 3059521 248138 1395023 1344052 1600921 1398113 
908544 1842936 3058587 249266 1396106 1344868 1601059 1395739 
level 01 
50 % 
Set 02 
907184 1841336 3056794 247461 1393757 1342325 1598314 1393507 
905642 1836858 3048610 245731 1389490 1338128 1592286 1388218 
level 01 
50 % 
Set 03 
905221 1838087 3053956 243963 1390354 1338700 1595763 1390154 
907148 1840598 3053401 248768 1393120 1342144 1598437 1393985 
level 02 
100% 
Set 01 
2222702 3993936 6085847 1272613 3220936 3118503 3640847 3231320 
2217797 3985493 6073806 1269621 3212863 3110473 3631336 3224542 
level 02 
100% 
Set 02 
2210816 3973686 6057432 1262406 3204045 3101574 3622820 3218885 
2202179 3962796 6042238 1256421 3193473 3090463 3609210 3205555 
level 02 
100% 
Set 03 
2224946 3999657 6094480 1275391 3225672 3129010 3646208 3239225 
2227794 4004111 6099529 1276877 3229927 3131621 3651263 3242766 
level 03 
150% 
Set 01 
3603052 6327940 9302574 2481357 5187185 5057187 5772145 5165142 
3606685 6334085 9314887 2484435 5191205 5062081 5773628 5171064 
level 03 
150% 
Set 02 
3731322 6540381 9605623 2604756 5405497 5245204 5966582 5349520 
3720106 6527634 9581887 2589954 5379539 5219505 5936666 5320058 
level 03 
150% 
Set 03 
3632421 6378877 9378938 2510863 5254371 5090520 5811489 5205911 
3629261 6372323 9369111 2505804 5247354 5083533 5804750 5192967 
 
Table 7: Accuracy Data – 01 
 
Calculation formulas for recovery study are as under: 
 
 
 
Where, Volume = Dilution given for preparing the solution. 
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From the above calculation the % Recovery was calculated which is given below 
 
% Recovery 
Replicates RNZ DLZ CRV QNP OST LST VST CST 
level 01 
50% Set 
01 
99.90 100.33 100.29 100.53 100.93 99.40 100.55 100.26 
level 01 
50% Set 
02 
99.53 100.40 99.78 99.68 100.64 99.82 100.09 101.34 
level 01 
50% Set 
03 
100.02 100.29 99.97 99.59 100.65 99.58 100.21 101.43 
level 02 
100% Set 
01 
99.68 99.88 100.28 100.88 100.17 99.18 100.87 99.14 
level 02 
100% Set 
02 
99.23 99.80 100.35 100.09 100.33 99.70 100.07 99.41 
level 02 
100% Set 
03 
99.77 99.93 99.51 100.58 100.54 99.33 100.42 100.47 
level 03 
150% Set 
01 
99.40 99.61 99.66 99.87 99.49 101.01 99.82 100.43 
level 03 
150% Set 
02 
100.75 100.84 100.67 101.08 101.02 100.54 100.53 100.45 
level 03 
150% Set 
03 
100.04 99.65 99.23 101.28 99.85 100.44 99.16 100.72 
Table 8: Accuracy Data – 02 
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   Figure 19: Chromatogram of Accuracy Level – 1 (50 %) 
 
 
Figure 20: Chromatogram of Accuracy Level – 2 (100%) 
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Figure 21: Chromatogram of Accuracy Level – 3 (150 %) 
From the all above data and chromatograms it has been confirmed that the % recovery 
was within 98 to 102 % and this is in the limit of acceptance criteria. Additionally % 
RSD value of % recovery of replicate sets is below 2 % .consequently this suggests that 
proposed method is highly accurate for all analyte. 
 
4.4.6. ROBUSTNESS  
 
Robustness of the method was evaluated by assaying test solutions under slight but 
deliberate changes in analytical conditions, such as change in flow rate, change in pH of 
Buffer and change in column-lot. 
 
A) Flow Rate change: In this experiment the test samples were analyzed at the flow 
rate of 0.375 ml/min and 0.325 ml/min each and the results were observed in terms of 
Peak Response (Peak Area) and chromatographic compatibility (System Suitability Test). 
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 152.  
Accuracy level-III (150%) 
Ranolazine-4.754 
Diltiazem-5.309 
Carvedilol-5.602 
6.437-Quinapril 
6.870-Olmesartan medoxomil 
7.269-Losartan Potassium 
Valsartan-10.287 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
1.80 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
            Candesartan cilexetil -11.782 
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A proto type chromatographic sequence of the robustness study is as under, 
 
Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
Flow Rate 0.375 
ml/min 
2 Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 
Flow Rate 0.325 
ml/min 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
  
 
Table 9: Experimental UPLC sequence for the robustness study -01 
 
 
 
Figure 22: Chromatogram of Test preparation at 0.375 ml/min 
 
Robustness 01 
Ranolazine-4.665 
Diltiazem-5.233 
Carvedilol-5.525 
6.363-Quinapril 
6.754-Olmesartan medoxomil 
7.111-Losartan Potassium 
Valsartan-10.166 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
            Candesartan cilexetil-11.685 
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Figure 23: Chromatogram of Test preparation at 0.325 ml/min 
 
The Peak Response and area value of test preparation wasn’t much influenced at 0.375 
and 0.325 ml/min. The above chromatograms suggest that the flow rate affects on the 
retention time of analyte but it did not have any impact on the response, hence the peak 
area value remain unaffected. 
 
B) Using buffer with different pH: In this experiment the test samples were analyzed 
at the mobile phase which consist of buffer Formic Acid in Water,0.225% v/v and Formic 
Acid in Water,0.175% v/v. Blank, Standards and Sample solutions were prepared as per 
the same procedure mentioned on page 152. 
 
A proto type chromatographic sequence of the robustness study is as under, 
 
 
 
Robustness 02 
 
Ranolazine-4.905 
Diltiazem-5.470 
Carvedilol-5.765 
6.669-Quinapril 
7.155-Olmesartan medoximil 
7.571-Losartan Potassium  
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
Valsartan-10.463 
        Candesartan cilexetil -11.921 
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Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 Formic Acid in water, 
0.225% v/v. 
 
 
2 Sys Suit Standard 5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 Formic Acid in water, 
0.175% v/v. 
 
 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
 
 
Table 10: Experimental UPLC sequence for the Robustness study – 02 
 
 
Figure 24: Chromatogram of Test preparation using Formic Acid in water, 0.225% v/v. 
 
Robustness 03 
 
Ranolazine -4.767 
Diltiazem-5.320 
Carvedilol -5.612 
6.489- Quinapril 
6.983- Olmesartan medoxomil 
7.341- Losartan potassium 
Valsartan -10.312 
Candesartan cilexetil -11.801 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
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Figure 25: Chromatogram of Test preparation using Formic Acid in water, 0.175% v/v. 
 
The Peak Response and area value of test preparation wasn’t much influenced at Formic 
Acid in water, 0.225% and 0.175% of buffer in mobile phase. The above chromatograms 
suggest that it did not have any impact on the response, hence the peak area value remain 
unaffected. 
C) Column Lot Change: In this experiment the test samples were analyzed using 
different column lot and the results were observed in terms of area value and 
chromatographic compatibility (System Suitability Test).  
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 152. 
A proto type chromatographic sequence of the robustness study is as under, 
 
 
 
 
 
 
Robustness 04 
 
 
 
 
 Ranolazine -4.763 
Diltiazem -5.304 
Carvedilol -5.595 
6.486- Quinapril 
7.031- Olmesartan medoxomil 
7.359- Losartan Potassium 
Valsartan-10.314 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
1.60 
1.80 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
Candesartan cilexetil -11.804 
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Experimental Sequence 
Sr.No. Sample Name No. of Injections 
Chromatographic 
condition 
1 Blank 1 
Different Column 
Lot 
2  Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
 
Table 11: Experimental UPLC sequence for the Robustness study – 03 
  Figure 26: Chromatogram of Test preparation at different column lot 
 
 
The Peak Response and area value of test preparation wasn’t much changed with 
different column, in addition to this in this case the retention time was also remain. The 
above chromatograms suggest that diff. column does not affect on the retention time of 
drug and it did not have any impact on the response, hence the peak area value remain 
unaffected. 
 
Ranolazine -4.807 
Diltiazem 5.361 
Carvedilol -5.643 
6.510- Quinapril 
6.928- Olmesartan medoxomil 
7.274- Losartan potassium 
Valsartan -10.280 
AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
Minutes 
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 
 Candesartan cilexetil -11.780 
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Summary of Robustness Study 
Robust 
Condition 
Peak  
Response 
Retention Time 
Variation 
(min.) 
System Suitability 
Theoretical Plates Asymmetry 
Flow Change 
0.375 ml/min Unaffected -  0.2 39000 ±900 1.15 ± 0.20 
Flow Change 
0.325 ml/min Unaffected + 0.2 35500 ±800 1.20 ± 0.35 
Formic Acid in 
water, 0.225% 
v/v 
Unaffected + 0.1 38850 ± 700 1.25 ± 0.28 
Formic Acid in 
water, 0.175% 
v/v 
Unaffected -0.1 39600 ±400 1.22 ± 0.20 
Column Lot 
Change Unaffected 0.02 40000 ±400 1.11 ± 0.20 
 
Table 12: Summary of Robustness study  
Where, ± sign suggest statistics of all eight analyte peaks.  
The data and the chromatogram given above suggest that there was no considerable 
influence of the column lot change on the result of the analysis by this method or on 
chromatographic suitability of this method. Hence, it can be conclude from this 
experiment that the method is highly robust in terms of column lot change. Overall the all 
the experiment in robustness parameter succeeded in terms of acceptance criteria hence 
the proposed method is robust for above small changes in chromatographic condition. 
4.4.7. SOLUTION STABILITY 
Solution stability has the significant role in terms of the acceptability of the data 
generated during the method validation. Hence this study has to plan before starting the 
method validation and sometimes it is included in Pre Method Validation (PMV). On the 
basis of results achieved in PMV the solution stability can be planned and established in 
Method Validation. The Solution Stability can be established at two different time of 
period. 
(A) Long Term Stock Solution Stability (LTSSS). 
(B) Short Term Standard Solution Stability (STSSS) or Bench Top Solution Stability. 
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LTSSS is established by comparing the response of the standard solution prepared from 
the kept stock solution at 2-4˚C for long time (in days) and fresh stock solution. While 
the STSSS is or bench top solution stability is established by comparing the response the 
standard solution kept on the bench for the short time (in hours) and freshly prepared 
standard solution. 
Preparation of Stock Solution for LTSSS:  
25.00 mg of each analyte (working standard) were accurately weighed and transferred 
into 25 ml volumetric flask. 20 ml of diluent was added into the volumetric flask and the 
standard substances were dissolved by sonication for ten minute. Then, volume of the 
flask was made up with diluent. The concentration obtained was 1000 μg/ml of all eight 
analytes. This solution was prepared on the first day of the validation and kept at the 2-
4˚C temperature in refrigerator without any disturbance until performance of the LTSSS 
experiment. After 4 day the stock solution was bring out of the refrigerator and keep it as 
such till it attains the room temp. 5 ml of this solution was pipette out in 50 ml volumetric 
flask and dilute it up to the mark to reach 100 μg/ml of all analyte. This solution was 
assigned as LTSSS Standard solution. 
Preparation of Fresh Standard Solution:  
25.00 mg of all analyte (working standard) was accurately weighed and transferred into 
25 ml volumetric flask. 20 ml of diluent was added into the volumetric flask and the 
standard substances were dissolved by sonication for ten minute. Then, volume of the 
flask was making up with diluent. The concentration obtained was 1000 μg/ml of all 
components. Pipette out exactly 5 ml of this solution in 50 ml volumetric flask and dilute 
it up to the mark accurately to confirm the 100 μg/ml of all drug substance. This solution 
was assigned as Fresh Standard Solution. 
The proto-type experimental sequence is given below for LTSSS. 
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Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 LTSSS-01( 4 day) 1 
4 Fresh Standard-01( 0 day) 1 
6 LTSSS-02 (4 day) 1 
7 Fresh Standard-02 ( 0 day) 1 
8 LTSSS-03 ( 4 day) 1 
9 Fresh Standard-03 ( 0 day) 1 
10 LTSSS-04 ( 4 day) 1 
11 Fresh Standard-04 ( 0 day) 1 
12 LTSSS-05 ( 4 day) 1 
13 Fresh Standard-05 ( 0 day) 1 
14 Bracketing Standard 1 
 
Table 13: Sequence for LTSSS. 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
Mean Area Ratio for all eight components are within 0.93 to 1.06. This is well within the 
acceptance criteria. 
Preparation of Stock Solution for STSSS or Bench Top Solution Stability 
25.00 mg of all analytes (working standard) were accurately weighed and transferred into 
25 ml volumetric flask. 20 ml of diluent was added into the volumetric flask and the 
standard substances were dissolved by sonication for ten minute. Then, volume of the 
flask was made up with diluent. The concentration obtained was 1000 μg/ml of all 
components. This solution was prepared before the 09 hour and kept on bench at ambient 
temperature without any disturbance until performance of the STSSS experiment. After 
09 hour on the bench. 5 ml of this solution was pipette out in 50 ml volumetric flask and 
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dilute it up to the mark to reach 200 μg/ml drug substances. This solution was assigned as 
STSSS Standard solution 
Preparation of Fresh Standard Solution:  
25.00 mg of all analyte (working standard) were accurately weighed and transferred into 
25 ml volumetric flask. 20 ml of diluent was added into the volumetric flask and the 
standard substances were dissolved by sonication for one minute. Then, volume of the 
flask was made up with diluent. The concentration obtained was 1000 μg/ml analyte. 
Pipette out exactly 5 ml of this solution in 50 ml volumetric flask and dilute it up to the 
mark accurately to confirm the 100 μg/ml of all drug substance. This solution was 
assigned as Fresh Standard Solution. The proto-type experimental sequence is given 
below for STSSS. 
Experimental Sequence 
Sr.No. Sample Name 
No. of 
Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 STSSS-01( 9.0 hour) 1 
4 Fresh Standard-01( 0.0 hour) 1 
6 STSSS-02 ( 9.0 hour) 1 
7 Fresh Standard-02 ( 0.0 hour)  1 
8 STSSS-03 ( 9.0 hour) 1 
9 Fresh Standard-03 (0.0 hour) 1 
10 STSSS-04 ( 9.0 hour) 1 
11 Fresh Standard-04 (0.0 hour) 1 
12 STSSS-05 ( 9.0 hour) 1 
13 Fresh Standard-05 (0.0 hour) 1 
14 Bracketing Standard 1 
 
Table 14: Sequence for STSSS. 
 
The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
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Mean Area Ratio for all eight components are within 0.94 to 1.08. This is well within the 
acceptance criteria. The Mean Area Ratio is within the acceptance criteria of 0.90 to 1.10, 
hence it can be concluded from this experiment that the Stock Solution is stable for the 4 
days at 2 - 4˚ C in refrigerator, while Standard solution is remain unaffected on bench at 
ambient temperature and in normal light for 9 hour. In addition to this it confirms the 
reliability of the data generated during the method validation.  
 
4.4.8. SYSTEM SUITABILITY  
A system suitability test for the chromatographic system was performed before each 
validation experiment. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. Only 
after the system suitability results were in acceptance criteria the experiments were 
precede further. 
 
Summary of System Suitability Test 
Experiment Name Theoretical Plates Asymmetry % RSD 
Specificity  39000± 800 1.10 ± 0.1 1.30 
Linearity and Range  38000± 500 1.05± 0.1 1.40 
LOD and LOQ    39500 ± 200 1.10 ± 0.2 1.37 
Method Precision  40000 ± 600 1.10 ± 0.1 0.90 
Intermediate Precision 40000 ± 300 1.10 ± 0.2 1.21 
Accuracy 39500 ± 700 1.05 ± 0.1 0.88 
Robustness 35500 ± 700 1.18 ± 0.27 1.63 
Solution Stability 37,000 ± 100 1.15 ± 0.2 0.80 
 
Table 15: Results of System Suitability Test after each Validation Experiment 
Where, ± sign suggest statistics of all eight component peaks. 
 As per guideline the Theoretical plates should be more than 5000, Asymmetry should be 
less than 2.0 and % RSD should be less than 2.0. As the data suggest the system 
suitability was within the criteria in each validation experiment. Hence the system was 
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found suitable to perform the validation experiment which confirms the reliability of the 
data generated during the method validation. 
 
5. CONCLUSION 
The observation and results obtained from each validation experiment including 
specificity, linearity and range, LOD and LOQ, precision, accuracy, robustness, solution 
stability and system suitability lies well inside the acceptance criteria of ICH guideline. 
Since, all the results are with-in the limit, the developed analytical method is considered 
as validated and suitable for probable use. 
 
6. APPLICATION OF CURRENT WORK  
 
6.1. This method can be used for the simultaneously quantification of all eight most 
pertinent antihypertensives in bulk drug as well as in pharmaceutical dosage form 
in routine or as a special test. 
6.2. This method can be used for the determination of all eight analyte individually or 
in combination dosage form. 
6.3. This method has also application over the chromatographic purity of all analytes. 
6.4. By optimizing certain chromatographic parameter it can be also used for the 
reaction monitoring of preparation for all molecules. 
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CHAPTER-5 
 
 ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC 
ANALYSIS OF ACYCLOVIR, ZIDOVUDINE, TENOFOVIR 
DISOPROXYL FUMARATE AND ADEFORVIR DIPIVOXIL: 
A SIMPLE, RAPID AND SENSITIVE QUANTIFICATION 
METHOD 
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1. INTRODUCTION 
Antiviral drugs are a class of medication used specifically for treating viral infections. 
Like antibiotics for bacteria, specific antivirals are used for specific viruses. Unlike most 
antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit their 
development. Antiviral drugs are one class of antimicrobials, a larger group which also 
includes antibiotic, antifungal and antiparasitic drugs. They are relatively harmless to the 
host, and therefore can be used to treat infections. They should be distinguished 
from viricides, which are not medication but destroy virus particles. Most of the antivirals 
now available are designed to help deal with HIV, herpes viruses (best known for 
causing cold sores and genital herpes, but actually causing a wide range of diseases), 
the hepatitis B and C viruses, which can cause liver cancer, and influenza 
A and B 
The emergence of antivirals is the product of a greatly expanded knowledge of the 
genetic and molecular function of organisms, allowing biomedical researchers to 
understand the structure and function of viruses, major advances in the techniques for 
finding new drugs, and the intense pressure placed on the medical profession to deal with 
the human immunodeficiency virus (
viruses. Researchers are working to extend the range of antivirals to other 
families of pathogens. Designing safe and effective antiviral drugs is difficult, because 
viruses use the host's cells to replicate. This makes it difficult to find targets for the drug 
that would interfere with the virus without also harming the host organism's cells. 
HIV), the cause of the deadly acquired 
immunodeficiency syndrome (AIDS) pandemic. 
Almost all anti-microbials, including anti-virals, are subject to drug resistance as 
the pathogens mutate over time, becoming less susceptible to the treatment. For instance, 
a recent study published in Nature Biotechnology emphasized the urgent need for 
augmentation of oseltamivir (Tamiflu) stockpiles with additional antiviral drugs 
including zanamivir (Relenza) based on an evaluation of the performance of these drugs 
in the scenario that the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the 
tamiflu-resistance (His274Tyr) mutation which is currently widespread in seasonal H1N1 
strains [1].  
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Adefovir dipivoxil (ADF) is a diester prodrug of the active moiety adefovir; it is an 
acyclic nucleotide analogue of adenosine monophosphate [2]. It is a novel antiviral drug, 
which is highly efficient in the treatment of human hepatitis B virus (HBV) and HIV. It 
was reported that adefovir dipivoxil dose at 10 mg, once daily taken orally in the 
treatment of chronic hepatitis in adults with evidence of active viral replication and either 
evidence of persistent elevations in serum aminotransferases or histological active 
disease. Adefovir is phosphorylated to the active metabolite, adefovir diphosphate, by 
cellular kinases, adefovir diphosphate inhibits HBV DNA polymerases [3] (reverse 
transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and 
by causing DNA chain termination after its incorporation into viral DNA. Adefovir 
dipivoxil is absorbed rapidly & extensively after oral administration, and approximate 
oral bioavailability of adefovir from adefovir dipivoxil is 59% [4]. In vitro binding of 
adefovir to human plasma or human serum proteins is 4% over the adefovir concentration 
range of 0.1 to 25 mg/mL. Metabolism involves the rapid conversion of adefovir 
dipivoxil to adefovir, 45% of the dose. Adefovir is renally excreted by a combination of 
glomerular filteration & active tubular secretion [5]. Since, adefovir dipivoxil is widely 
used in the antiviral therapy, it is important to develop and validate analytical methods 
for its determination in pharmaceutical dosage form. 
 
Acyclovir (ACY) is an acyclic guanosine derivative which exhibits a selective inhibition 
of herpes viruses replication with potent clinical antiviral activity against the herpes 
simplex and varicella-zoster viruses [6, 7]. Bioavailability issues have been of increasing 
concern to drug regulatory authorities once assessing the safety and efficacy of drug 
products. Local drug regulatory authorities have, therefore, issued guidelines to ensure 
adequate bioavailability studies in new drug applications for synonym drugs. 
 
Tenofovir disoproxil fumarate (TNF) [8, 9] is a fumaric acid, salt of bis-
isopropoxycarbonyloxy methyl ester derivative of tenofovir. Chemically it is 9-[(R)-2-
[[bis [[isopropoxycarbonyl) oxy] methyl] phosphinyl] methoxy] proply] adenine 
fumarate. TDF is the first nucleotide analog approved for HIV-1 treatment. Tenofovir is a 
nucleotide reverse transcriptase inhibitor [10] used in combination with other 
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antiretrovirals for the treatment of HIV infections [11]. TDF remains in cells for longer 
periods of time than many other antiretroviral drugs, thereby allowing for once-daily 
dosing. 
Zidovudine (ZDV) is the first drug approved for the treatment of AIDS patients [12], is 
still one of the most potent active agents against HIV, and is used as a primary option in 
AIDS treatment in combination with other HIV inhibitors. Nevertheless, utility of AZT is 
limited by its toxic effect on bone marrow [13], hepatic abnormalities [14], limited brain 
uptake [15], short half-life time in plasma [16], high susceptibility to catabolism [17], 
general myopathy [18], lipoatrophy [19] and the rapid progress of resistance by HIV-1 
[20]. For these reasons, numerous chemical strategies have been developed by medicinal 
scientists to design analogues or prodrugs of Zidovudine to increase its therapeutic 
efficacy [21] 
 
        
 
 
  
 Acyclovir    Adefovir dipivoxil 
     
 
 
 
 
 
        
Tenofovir disoproxil fumarate    Zidovudine 
Figure 1: Chemical Structure of Antiviral Drugs 
HN
N N
N
O
H2N
O
OH
HN
N N
N
O
H2N
O
O
P
O O
O
O
O
O
O
HN
N N
N
O
H2N
O
O
P
O O
O
O
O
O
O
.
O
OH
O
HO
N
NH
O
O
O
OHNNN
 
Chapter – 5                           UPLC analysis of Acyclovir, Zidovudine, Tenofovir disoproxyl fumarate and Adefovir dipivoxil 
Department of Chemistry, Saurashtra University, Rajkot-360005.                                                                   Page 201 
 
 
2. LITERATURE REVIEW 
 
The literature reviews concerning analytical method of these four antiviral drugs reveals 
that, there is no Ultra Performance Liquid Chromatographic method which describes the 
simultaneous chromatographic quantification of these molecules. However various high 
performance liquid chromatographic analytical methods are reported for determination of 
those in bulk drug. Pharmaceutical dosage form and/or in biological matrix in single or in 
combination of two molecules, which provides the important reference and the initiative 
information about the molecule behavior under various chromatographic conditions. Few 
of them are mentioning below. 
Hasan S, Chander  P, Ali J,  Baboota S, Ali M have developed and validated ultra 
performance liquid chromatographic method for determination of acyclovir. 
Chromatographic separation was performed using Acquity HSS T-3 (100 x 2.1 mm, 1.8 
µm) column maintained at a temp. of 50 ˚C with a gradient elution consisting of 1.0% tri-
Et amine in water and acetonitrile at a flow rate of 0.4 mL/min and detected at 254 
nm.[22] 
 
Wang Chao, Wang Changbin, Yuan Yu has worked on determination of adefovir 
dipivoxil tablets by HPLC and UV. The HPLC  method was performed on a C18 column 
(150 mm x 4.6 mm, 5 µm), with a wavelength at 261 nm and acetonitrile-0.02 mol/L-1 
dipotassium hydrogen phosphate soln. (adjust pH value to 5.0 through phosphoric acid) 
as the mobile phase, and flow rate was 1.0 mL/min.[23] 
 
Jiang Ye, Xu Zhiru, Zhang Xiaoqing have worked on adefovir dipivoxil and its 
degradation products by reversed phase high performance liquid chromatography. The 
separation between adefovir dipivoxil and its degradation products was performed on a 
CN-3 column and the quantitation was achieved with UV detection at 260 nm.  A mixture 
of acetonitrile and 25 mmol/L phosphate buffer (to adjust the pH to 4.0 with phosphoric 
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acid) (33:67, v/v) was used as the mobile phase for isocratic elution with a flow rate of 
1.0 mL/min [24]. 
 
Gomes Noel A, Vaidya Vikas V, Pudage Ashutosh, Joshi Santosh S, Parekh Sagar A 
has worked on simultaneous determination of  tenofovir  and emtricitabine in human 
plasma and its application to a bioequivalence study using LC-MS/MS. The method 
involves solid phase extraction from plasma, simple isocratic chromatographic conditions 
and mass spectrometric detection using an API 5000 instrument that enables detection at 
nano gram levels.  Lamivudine was used as the internal std.  The proposed method has 
been validated with a linear range of 10-600 ng/mL for Tenofovir and 25-2500 ng/mL for 
Emticitabine [25]. 
 
Jayadev S, Manikanta K, Sundar B. Syama, Rao V. Jayathirtha has published the 
method titled “Simultaneous estimation of lamivudine and  tenofovir  disoproxil fumarate 
by RP- HPLC  in the pharmaceutical dosage form.” Chromatog. was carried on Agilent 
eclipse XDB-C18 (5µm, 4.6 mm x 150 mm) column with mobile phase based comprising 
of methanol and potassium di-hydrogen orthophosphate (0.02 M) in the ratio 60:40 
vol./vol. adjusted to pH 3.0 with formic acid.  The flow rate was adjusted to 0.9 mL/min 
with UV detection at 260 nm. [26] 
 
Tarinas, A, Tapanes, R D, Ferrer G, Perez J  has worked on high-performance liquid 
chromatography  methods  for determination of  zidovudine , stavudine, lamivudine and 
indinavir in human plasma. Chromatographic seperation was performed on a C-18 
analytical columns and the retention time ranged from 6.8 to 8.0 min for stavudine, 7.5 to 
9.0 min for lamivudine, 11.2 to 11.9 min for zidovudine and indinavir.  Four methods 
were validated for specificity, inter-and intra-assay precision and accuracy, abs. recovery 
and stability.  Results: linear ranged from 10-1600 ng/mL for stavudine, 50-3200 ng/mL 
for lamivudine, 0.05-5.0 µg/mL for zidovudine and 0.1-10.0 µg/mL for indinavir [27]. 
 
Zhang Lijun, Yao Yamin, Sun Jianjun, Jia Xiaofang, Peng Xia, Lu Hongzhou Was 
developed the method for nevirapine, lamivudine, stavudine,  zidovudine  and efavirenz 
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in human plasma by HPLC-MS/MS. the analytes were chromatographed on a Eclipse 
XDB-C18 (150 mm x 4.6 mm, 5 µm) column.  An isocratic mobile phase consisting of 
0.3% formic acid in water-0.3% formic acid in water-0.30% formic acid in methanol 
(20:80) was used to sep. these five drugs.  The calibration curves of each drug showed a 
good linearity in a range of concn. between 25-3,200 µg/mL-1 for lamivudine, 
zidovudine, 50-6400 µg/mL-1 for Efavirenz, Nevirapine, and 50-3200 µg/mL-1 for 
stavudine [28]. 
 
 
3. AIM OF THE PRESENT WORK 
 
On the basis of literature survey, it can be concluded that there are no Ultra Performance 
Liquid Chromatographic methods for the simultaneous quantification of these antiviral 
drugs, since the methods are available that deals with the bioanalytical study of analytes 
and some methods deals for intracellular assay. Furthermore the present method may 
have the advantage over the speed as well as the selectivity and it can be maximum 
utilize for the analysis and it could be also functional of quality control laboratory for 
routine use. The aim and scope of the proposed work are as under. 
 
3.1.   To develop analytical method for quantification of the drug substance 
 simultaneously using the latest technology in liquid chromatography. 
3.2.   To optimized the method at a maximum level to gain high throughput screening. 
3.3.   Elaborate the technology suggesting the various applications.   
3.4.  To perform analytical method validation for the proposed method as per ICH         
 guideline [29]. 
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4. EXPERIMENTAL 
4.1. MATERIALS, CHEMICALS AND REAGENTS 
Emcure Pharmaceuticals Limited (Pune, India) and Hetero drugs Limited (Hyderabad, 
India) provided the Tenofovir disoproxil fumarate, adefovir dipivoxil, acyclovir and 
zidovudine working standard and samples. HPLC-grade Potassium dihydrogen phosphate 
was obtained from Finar Chemicals (Ahmedabad, India). HPLC grade orthophosphoric 
acid (88 %) and HPLC grade Acetonitrile were purchased from Spectrochem Pvt Ltd. 
HPLC grade water used was purified by Milli-Q Elix-3 water purification system.  
4.2. INSTRUMENTATION  
The Waters AcquityTM
4.3. METHOD DEVELOPMENT 
 UPLC chromatographic system was used to perform development 
and validation. This system consist of a binary solvent manager (pump), photodiode array 
detector, sample manager(Auto sampler) and column oven connected to a multi-
instrument data acquisition and processing system Empower 2.1 version. Sartorius 
microbalance and Equiptronics branded balance was used for the weighing while Spinco 
ultrasonic bath used for degassing purpose. 
Analytical Method development is consist of following steps which can be shown up by 
the literature survey, previous experience and chemical nature of the reagents used in the 
development. 
4.3.1. MOBILE PHASE SELECTION  
On the basis of literature survey, several exploratory runs have been performed but 
initially proper selectivity and resolution between the drug molecules was not achieved. 
After furnishing more importance to the literature it was concluded that the 
chromatography of these molecules are highly dependent on the pH of the mobile phase, 
best chromatography compatibility, resolution and selectivity between the four molecule 
are achieved using 5 mM Potassium di hydrogen ortho phosphate (pH=3.0). Above all 5 
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mM Potassium di hydrogen ortho phosphate (pH=3.0) and acetonitrile (HPLC grade) as 
an organic component was used in gradient programming with respect to time and 
composition of mobile phase. 
4.3.2. COLUMN SELECTION 
Column selection is the most important part in the method development. In this case most 
suitable column chemistry was BEH silica bonded with C8.Among the column chemistry 
available with us the Acquity BEH C8 (100 x 2.1 mm, 1.7μn) gives the best 
consequences. 
4.3.3. DETECTION WAVELENGTH SELECTION  
We have screened the standard solution over 190 nm to 400 nm using the advantage of 
photo diode array detector. On the basis of peak absorption maxima and peak purity 
index the 215 nm was decided as the detection wavelength which also gives the 
maximum chromatographic compatibility to the method. The absorption is shown in the 
figure 2 for all four Antiviral drugs at each wavelength.  
  
  
  
  
259.1
267.1
253.6
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0.00
0.20
0.40
0.60
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nm
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Figure 2: UV absorption of Antiviral drugs 
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4.3.4. BUFFER SOLUTION PREPARATION 
5 mM Potassium di hydrogen ortho phosphate was prepared by dissolving 0.68 gm of 
Potassium di hydrogen ortho phosphate for HPLC in 1000 ml of HPLC grade water, the 
pH of the buffer solution was adjusted to 3.0 using 0.1% ortho phosphoric acid (HPLC 
grade) which further Sonicate for 20 minutes to remove of all dissolve gas and filtered 
through 0.45µn mobile phase filter.  
4.3.5. DILUENT PREPARATION 
Sample diluent was prepared by mixing acetonitrile and Milli-Q water in 50:50 ratio, 
which was further sonicate to confirm uniformity and removal of all dissolve gas. 
4.3.6. STANDARD SOLUTION PREPARATION 
Antiviral drugs (working standard) solution containing 100 μg/ml was prepared in a 100 
ml volumetric flask by dissolving exact 10.0 mg each in 25 ml of diluent and then it was 
made up to volume with the same diluent. 
4.3.6. SAMPLE SOLUTION PREPARATION 
Antiviral drugs (Samples, Different Batch) solution containing 100 μg/ml was prepared 
in a 100 ml volumetric flask by dissolving exact 10.0 mg each in 25 ml of diluent and 
then it was made up to volume with the same diluent. 
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Figure 3: Chromatograms of Working Standard solution. 
 
 
 
Figure 4: Chromatograms of Sample solution. 
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In conclusion to Method development following chromatographic clauses suits the most 
and decided as a final method for validation experiments. 
 
 
Mobile Phase A  : 5 mM Pott. Di hydrogen ortho phosphate (pH=3.0) 
Mobile Phase B  : Acetonitrile (HPLC grade) 
Column   :  Acquity BEH C8 (100 x 2.1 mm , 1.7μn)  
Flow Rate  : 0.450 ml/min 
       Gradient elution               : As per Table 01 
Detection   : 260 nm UV 
Diluent               : HPLC grade Water: Acetonitrile (50:50) 
Injection Volume : 05 µl 
 
 
 
 
 
 
 
 
 
 
Table 1: Gradient Programming of proposed method 
 
 
 
 
Time Flow Rate % of Buffer % of Organic Curve 
0.0 0.450 90 10 Initial 
2.0 0.450 50 50 6 
2.1 0.450 90 10 6 
3.0 0.450 90 10 6 
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4.4. METHOD VALIDATION 
 
Method for the determination of Antiviral drugs in bulk drug is further validated as per 
ICH Q2 (R1) guideline [29]. Validation of analytical method was performed using 
Antiviral drugs working standard and sample batch drug substance. 
 
4.4.1. SPECIFICITY  
 
The evaluation of the specificity of the method was determined against diluent 
application and each of the drug substance. The interference of the diluent and each 
molecule was derived by injecting diluent solution and individual drug substance. The 
retention time of each was taken in to consideration. Further the specificity of the method 
toward the drug was established by means of the interference of diluent at the retention 
time of the drug peak. 
 
Blank preparation: 
Diluent was used as blank solution. 
 
Tenofovir Disoproxyl Fumarate (TNF) solution preparation: 
Weight exact 10.0 mg of Tenofovir Disoproxyl Fumarate in 100 ml volumetric flask 
dissolve it in 50 ml of diluent followed by make up to the mark with diluent. Apply 
sonication to it in ultrasonic bath for 10 min and filter the solution with 0.20 µn 
membrane filter. 
 
Zidovudine (ZDV) solution preparation: 
Weight exact 10.0 mg of Zidovudine (Working Standard) in 100 ml volumetric flask 
dissolve it in 50 ml of diluent followed by make up to the mark with diluent. Apply 
sonication to it in ultrasonic bath for 10 min and filter the solution with 20 µn membrane 
filter. 
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Acyclovir (ACY) solution preparation: 
Weight exact 10.0 mg of Acyclovir (Working Standard) in 100 ml volumetric flask 
dissolve it in 50 ml of diluent followed by make up to the mark with diluent. Apply 
sonication to it in ultrasonic bath for 10 min and filter the solution with 20 µn membrane 
filter. 
 
 
Adefovir dipivoxil (ADF) solution preparation: 
Weight exact 10.0 mg of Adefovir dipivoxil in 100 ml volumetric flask dissolve it in 50 
ml of diluent followed by make up to the mark with diluent. Apply sonication to it in 
ultrasonic bath for 10 min and filter the solution with 20 µn membrane filter. 
 
 
 
 
   
Figure 5: Chromatogram of Diluent in Specificity Experiment. 
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    Figure 6: Chromatogram of Tenofovir disoproxil fumarate in Specificity Experiment. 
 
 
Figure 7: Chromatogram of Zidovudine in Specificity Experiment. 
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Figure 8: Chromatogram of Acyclovir in Specificity Experiment. 
 
 
 
Figure 9: Chromatogram of Adefovir dipivoxil in Specificity Experiment. 
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Figure 10: Chromatogram of 3D – view of Standard preparation 
From the specificity experiment and subsequently achieved above chromatograms it was 
proven that any interference was not observed from blank or individual drug substance to 
the peak of other (Drug Substance), in addition to this peak purity was also within the 
acceptance criteria confirmed by the photo diode detector. The chromatogram (3D View) 
of standard solution is shown in Figure 10. Hence it confirms that the proposed method is 
highly specific with respect to the diluent and each drug molecule to the other. 
 
4.4.2. LINEARITY & RANGE  
 
The linearity curve was prepared with 8 concentration levels (20, 40, 60, 80, 100, 120, 
140, 160 and 180 μg/ml of each of drug molecule). These concentration levels were 
respectively corresponding to 20, 40, 60, 80, 100, 120, 140, 160, and 180 % of standard 
solution concentration. The peak areas vs. concentration data were evaluated by linear 
regression analysis. 
 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
AU 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
Minutes 
300.00 
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Stock Solution Preparation:  
Weight accurately 25 mg of Acyclovir (ACY), Zidovudine (ZDV), Tenofovir disoproxil 
fumarate (TNF) and Adefovir dipivoxil (ADF) working standard, transfer it and dissolved 
into 25 ml volumetric flask and dilute it up to the mark with diluent. Apply sonication for 
minimum 30 min to confirm the uniform mixture. 
Linearity Standard Solution Preparation: 
From Standard Stock Solution of accurate 1000 µg/ml pipette out exactly 0.2, 0.4, 0.6, 
0.8, 1.0, 1.2, 1.4, 1.6 and 1.8 ml and dilute it up to 10 ml each with diluent to achieve 20-
180 µg/ml concentration of Carvedilol and its impurities. 
 
Linearity & Range 
Calibration 
Point 
Concentration 
(µg/ml) 
Peak Area 
ACY ZDV TNF ADF 
STD 1 180 2442827 1780630 1141047 1307588 
STD 2 160 2183032 1588992 1017836 1166683 
STD 3 140 1915425 1392368 890267 1020959 
STD 4 120 1655699 1202562 768683 881554 
STD 5 100 1364380 989337 630883 724334 
STD 6 80 1089242 787972 501086 574365 
STD 7 60 809483 603829 382093 399432 
STD 8 40 522356 373227 234491 271824 
STD 9 20 237351 165933 101330 116899 
 
Table 2: Linearity and Range - Concentration Vs Peak area response data 
 
Where, ACY = Acyclovir, ZDV = Zidovudine, TNF = Tenofovir disoproxil, ADF = 
Adefovir dipivoxil. 
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Chart 1: Regression Analysis chart of linearity Study 
 
Where, X axis = Concentration (µg/ml), Y axis = Peak Area and Series 1(Y1) = 
Acyclovir Series 2(Y2) = Zidovudine, Series 3(Y3) = Tenofovir disoproxil fumare, Series 
4(Y4) = Adefovir dipivoxil 
Above data and the chart suggest that correlation coefficient of all four analyte R2 
 
= 
0.9997, 0.9996, 0.9996 and 0.9994 with linear regression equation Y1 = 13819.x – 
24101, Y2 = 10081.x – 20940, Y3 = 6494.x - 19658 and Y4 = 7498x – 31616 for 
Acyclovir, Zidovudine, Tenofovir disoproxil fumarate and Adefovir dipivoxil 
respectively. Thus in conclusion the method counts to be highly linear for all four drug 
substance in terms of concentration and response. 
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4.4.3. LIMIT OF DETECTION AND LIMIT OF QUANTITATION  
 
LOD is the lowest amount of the drug content which can be detected by the proposed 
method while LOQ is the lowest amount which can be quantified by the method. The 
guideline suggest minimum signal to noise ratio (S/N) should be more than 3.3 for LOD 
and more than 10 for LOQ. On the basis of linearity data theoretically it can be also 
calculated by the given formula, 
LOD = 3.3 σ/S LOQ = 10 σ/S 
Where σ = Residual Standard Deviation of regression line and S = Slope of regression 
line. 
 
LOD Solution Preparation: 
Standard Stock Solution prepared as per procedure given on page 214. From the stock 
solution of 500 µg/ml pipette out exact 1 ml to 100 ml volumetric flask followed by 
dilution up to the mark with diluent, assign this solution as Solution – A. 
Form the Solution - A pipette out exact 1.0 ml to the 50 ml volumetric flask followed by 
dilution up to the mark with diluent to reach 0.1 µg/ml concentrations of each. 
LOQ Solution Preparation: 
Form the Solution - A pipette out exact 10.0 ml to the 50.0 ml volumetric flask followed 
by dilution up to the mark with diluent to achieve 1.0 µg/ml concentrations. Six replicate 
injections were made to prove the precision of the LOQ level. 
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LOQ 
Replicates  
Peak Area 
ACY ZDV TNF ADF 
INJ 01 131101 98952 53210 65930 
INJ 02 134738 97783 57920 63902 
INJ 03 135832 100150 55829 69032 
INJ 04 137583 99362 56903 66814 
INJ 05 140157 104325 57101 65412 
INJ 06 133847 100378 57287 67832 
Mean 135543.0 100158.3 56375.0 66487.0 
Std dev 3123.78 2242.37 1693.52 1818.85 
% RSD 2.30 2.24 3.00 2.74 
 
Table 3: Limit of Quantification – Summary of Replicate Injections 
 
LOQ  1.801-  Tenofovir disoproxil 
 fumarate 
AU 
0.000 
0.005 
0.010 
0.015 
0.020 
0.025 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 
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LOQ  
0.936- Zidovudine 
 
AU 
0.000 
0.010 
0.020 
0.030 
0.040 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
LOQ  
0.325- Acyclovir 
 
AU 
0.000 
0.010 
0.020 
0.030 
0.040 
0.050 
0.060 
0.070 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 11: Chromatogram of Limit of Quantification 
 
 
 
 
  
LOQ  Adefovir-dipivoxil-2.003 
AU 
0.000 
0.005 
0.010 
0.015 
0.020 
0.025 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
LOD  1.801- Tenofovir disoproxil fumarate  
AU 
-0.001 
0.000 
0.001 
0.002 
0.003 
0.004 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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LOD  
0.936- Zidovudine 
AU 
0.000 
0.002 
0.004 
0.006 
0.008 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
LOD  
0.325- Acyclovir 
AU 
0.000 
0.002 
0.004 
0.006 
0.008 
0.010 
0.012 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 12: Chromatogram of Limit of Detection 
LOQ of the analytical method can evaluated by establish linearity up to LOQ value. For 
that linearity study is extended up to LOQ value, 
 
Chart 2: Regression Analysis chart of linearity Study included with LOQ level 
LOD  Adefovir dipivoxil -2.003 
AU 
-0.001 
0.000 
0.001 
0.002 
0.003 
0.004 
0.005 
0.006 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Where, X axis = Concentration (µg/ml), Y axis = Peak Area and Series 1 (Y1) = 
Acyclovir Series 2 (Y2) = Tenofovir dipivoxil fumarate, Series 3 (Y3) = Zidovudine, 
Series 4 (Y4) = Adefovir dipivoxil. 
All the results of LOD and LOQ data were within the acceptance criteria, hence it can be 
conclude that the LOD of the method was 1 µg/mL for all four mentioned antiviral drugs 
and LOQ of the method was 10, 10, 9 and 9µg/mL for Acyclovir, Zidovudine, Tenofovir 
disoproxyl fumarate and adefovir dipivoxil respectively and The signal to noise ratio for 
the LOD was well within the acceptance criteria it means more than 3.3 and for the LOQ 
it was more than 10.0. Furthermore the % RSD of the six replicate injection of LOQ 
preparation less than 5.0 and the data of linearity extension chart up to LOQ level also 
suggest that all the analytes can be quantified precisely and accurately.  
 
4.4.4. PRECISION  
 
Precision study was established by evaluating method precision and intermediate 
precision study. Method precision of the analytical method was determined by analyzing 
six sets of sample solution preparation. Mean Standard deviation and % relative standard 
deviation for the same was calculated. Intermediate precision of the analytical method 
was determined by performing method precision on another day by another analyst using 
different make of raw materials under same experimental condition. Assay of all six 
replicate sample preparations was determined and mean, standard deviation and % 
relative standard deviation also calculated. 
 
Standard Solution Preparation: 
 
Standard Stock Solution prepared as per procedure on page 214 of 1000 µg/ml. Pipette 
out exact 1.0 ml from this solution and dilute up to 10 ml to accomplish 100 µg/ml 
concentration.  
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Sample Solution Preparation: 
Weight accurately 50 mg Acyclovir, Zidovudine, Tenofovir disoproxil fumarate and 
adefovir dipivoxil transfer each into 50 ml volumetric flask and dilute it up to the mark 
with diluent. Apply sonication for minimum 30 min to confirm the uniform mixture. 
 
1.0 ml of above test stock solution was pipette out and transferred into 10 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained was about 
100 μg/ml of each analyte. This solution is assign as Test Preparation Set – 01. 
The same procedure was used for preparing the six Test preparation Sets. Same approach 
was applied for the intermediate precision study on the second day with different analyst 
and different make of raw materials. 
 
Method Precision 
Replicates 
Peak Area 
ACY ZDV TDF ADF 
Set 01 1246092 901017 575625 655610 
Set 02 1259711 910625 583371 659834 
Set 03 1241106 897131 572983 650023 
Set 04 1250448 909303 585112 656446 
Set 05 1259044 910346 581471 660019 
Set 06 1259660 910682 582170 660381 
Mean 1252677 906517 580122 657052 
Std Dev. 8012.28 5915.89 4746.78 3987.06 
% RSD 0.64 0.65 0.82 0.61 
 
 
Table 4: Method Precision Data  
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Intermediate Precision 
Replicates 
Peak Area 
ACY ZDV TDF ADF 
Set 01 1253097 906874 578085 655672 
Set 02 1236032 906540 579629 669606 
Set 03 1245600 901093 574075 651942 
Set 04 1230509 929138 585276 655554 
Set 05 1259144 910508 582061 660415 
Set 06 1258110 915780 585133 664549 
Mean 1247082 911655 580710 659623 
Std Dev. 11851.19 9844.456 4343.251 6568.328 
% RSD 0.95 1.08 0.75 1.00 
 
Table 5: Intermediate Precision Data 
Figure 13: Chromatogram of Test Preparation in Method Precision study 
 
Method Precision 
0.324- Acyclovir 
0.922- Zidovudine 
Tenofovir disoproxil 
fumarate  -1.777 
1.982- Adefovir dipivoxil 
 
AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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         Figure 14: Chromatogram of Test Preparation in Intermediate Precision study 
The data for the method precision study and intermediate precision study suggest %RSD 
value of peak area for each set is less than 2.0 and overall %RSD value for all six set is 
less than 2.0 which suggest that method is precise. 
 
4.4.5. ACCURACY   
This Experiment can be performed by the recovery test. Recovery of the method is 
evaluated at 3 different concentration levels (corresponding to 50, 100 and 150% of test 
solution concentration) by addition of known amounts of standard to Sample preparation. 
For each concentration level, 3 sets were prepared and injected in duplicate. 
 
Blank preparation: 
Diluent was used as blank solution. 
 
Standard preparation: 
Stock solution and standard solution has been prepared as per procedure on page 214. 
Sample preparations for accuracy levels are as under: 
Intermediate Precision 
0.324- Acyclovir 
Zidovudine-0.920 
Tenofovir disoproxil 
fumarate -1.774 
1.979- Adefovir dipivoxil AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 
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Accuracy level 1 (50%)  
Test stock solution:  
25.0 mg of each analyte (working standard) was accurately weighed and transferred into 
200 ml volumetric flask. 25.0 mg each analyte (sample, different batch) was weighed and 
transferred into the same 200 ml volumetric flask. Around 140 ml of diluent added into 
the volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes 
with normal handshaking.  
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained was 250 μg/ml of each drug substance. 5.0 ml of above test stock solution was 
pipette out and transferred into 25 ml volumetric flask followed by diluted to volume 
with diluent. The concentration obtained is 50 μg/ml of each molecule. The same 
procedure was applied for preparing the three sets. 
 
Accuracy level 2 (100 %) 
Test stock solution:  
50.0 mg of each analyte (working standard) was accurately weighed and transferred into 
200 ml volumetric flask.50.0 mg each analyte (sample, different batch) was weighed and 
transferred into the same 200 ml volumetric flask. Around 140 ml of diluent added into 
the volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes 
with normal handshaking.  
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained was 500 μg/ml of each drug substance. 5.0 ml of above test stock solution was 
pipette out and transferred into 25 ml volumetric flask followed by diluted to volume 
with diluent. The concentration obtained is 100 μg/ml of each molecule. The same 
procedure was applied for preparing the three sets. 
 
 
Accuracy level 3 (150 %) 
Test stock solution:  
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75.0 mg of each analyte (working standard) was accurately weighed and transferred into 
200 ml volumetric flask.75.0 mg each analyte (sample, different batch) was weighed and 
transferred into the same 200 ml volumetric flask. Around 140 ml of diluent added into 
the volumetric flask. The volumetric flask was proceeding for sonication of 30 minutes 
with normal handshaking.  
Then, the flask was cooled to room temperature and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.22 μm nylon syringe filter. The concentration 
obtained was 750 μg/ml of each drug substance. 5.0 ml of above test stock solution was 
pipette out and transferred into 25 ml volumetric flask followed by diluted to volume 
with diluent. The concentration obtained is 150 μg/ml of each molecule. The same 
procedure was applied for preparing the three sets. 
 
Calculation formulas for recovery study are as under: 
 
 
 
 
Where, Volume = Dilution given for preparing the solution. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter – 5                           UPLC analysis of Acyclovir, Zidovudine, Tenofovir disoproxyl fumarate and Adefovir dipivoxil 
Department of Chemistry, Saurashtra University, Rajkot-360005.                                                                   Page 228 
 
Table 6: Accuracy Data- 01 
% Recovery 
Replicates ACY ZDV TDF ADF 
Level 01 50 % Set 01 100.34 101.40 101.28 100.20 
Level 01 50 % Set 02 99.29 99.64 100.34 99.00 
Level 01 50 % Set 03 100.31 99.50 100.59 99.26 
Level 02 50 % Set 01 100.84 99.80 101.13 101.44 
Level 02 50 % Set 02 100.94 99.98 100.48 100.13 
Level 02 50 % Set 03 99.81 99.28 100.65 100.74 
Level 03 50 % Set 01 100.87 99.55 100.38 99.92 
Level 03 50 % Set 02 101.28 99.06 99.48 99.64 
Level 03 50 % Set 03 101.15 100.73 100.81 100.52 
 
Table 7: Accuracy Data- 02 
Accuracy 
Replicates 
ACY ZDV TDF ADF 
Area % RSD Area % RSD Area % RSD Area % RSD 
Level 01 50 % 
Set 01 
634163 
1.09 
456304 
0.63 
287272 
1.31 
330186 
0.72 Level 01 50 % Set 02 
621224 450689 279973 325520 
Level 01 50 % 
Set 03 
631697 452765 284869 328543 
Level 02 100 % 
Set 01 
1354485 
0.81 
964226 
0.81 
628601 
0.54 
711501 
1.41 Level 02 100 % Set 02 
1362695 952659 623805 693129 
Level 02 100 % 
Set 03 
1341063 949658 622155 696082 
Level 03 150 % 
Set 01 
1876025 
0.76 
1374840 
1.14 
879561 
1.02 
1007967 
0.83 Level 03 150 % 
Set 02 
1889720 1382606 882919 1013116 
Level 03 150 % 
Set 03 
1904826 1405238 896641 1024421 
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 Figure 15: Chromatogram of Accuracy level -1 (50 %) 
 
 
 
 
Figure 16: Chromatogram of Accuracy level -2 (100 %) 
Accuracy Level 01 50% 
 0.325- Acyclovir 
 
Zidovudine -0.909 
Tenofovir disoproxil 
fumarate - 1.755 
1.956- Adefovir dipivoxil AU 
0.00 
0.05 
0.10 
0.15 
0.20 
0.25 
0.30 
0.35 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
Accuracy Level 02 100% 
 0.324- Acyclovir 
0.908- Zidovudine 
Tenofovir disoproxil 
fumarate  -1.753 
1.953- Adefovir dipivoxil 
AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 17: Chromatogram of Accuracy level -3 (150 %) 
 
From the all above data and chromatograms it has been confirmed that the % recovery is 
within 98 to 102 % and this is in the limit of acceptance criteria. Additionally % RSD 
value of % recovery of replicate sets is below 2 % .consequently this suggests that 
proposed method is highly accurate. 
 
4.4.6. ROBUSTNESS  
 
Robustness of the method was evaluated by assaying test solutions under slight but 
deliberate changes in analytical conditions, such as change in flow rate, change in pH of 
Buffer solution and change in column-lot. 
 
A) Flow Rate change: In this experiment the test samples were analyzed at the flow 
rate of 0.435 ml/min and 0.465 ml/min each and the results were observed in terms of 
Peak Response (Peak Area) and chromatographic compatibility (System Suitability Test). 
Accuracy Level 03 150% 
 0.325- Acyclovir 
 
0.909- Zidovudine 
Tenofovir disoproxil 
fumarate  -1.750 
1.950- Adefovir dipivoxil AU 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 206. A proto type chromatographic sequence of the robustness study 
is as under, 
 
Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
Flow Rate 0.435 
ml/min 
2 Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 
Flow Rate 0.465 
ml/min 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
  
Table 8: Experimental UPLC sequence for the robustness study -01 
 
 
 
Figure 17: Chromatogram of Robustness study at 0.435 ml/min flow rate 
Robustness01 
0.363- Acyclovir 
Zidovudine -1.009 
Tenofovir disoproxil 
fumarate  -1.862 
2.073- Adefovir dipivoxil AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 18: Chromatogram of Robustness study at 0.465 ml/min flow rate 
The Peak Response and area value of test preparation wasn’t much influenced at 0.435 
and 0.465 ml/min. The above chromatograms suggest that the flow rate affects on the 
retention time of drug but it did not have any impact on the response, hence the peak area 
value remain unaffected. 
B) Using buffer with different pH: In this experiment the test samples were analyzed 
at the mobile phase which consist of buffer 5 mM Potassium di hydrogen ortho phosphate 
(pH = 3.1) and 5 mM Potassium  di hydrogen ortho phosphate (pH = 2.9). The results 
were observed in terms of Peak Response (Peak Area) and chromatographic compatibility 
(System Suitability Test).  
Blank, Standards and Sample solutions were prepared as per the same procedure 
mentioned on page 206.  
 
A proto type chromatographic sequence of the robustness study is as under, 
 
 
Robustness02 
 0.324- Acyclovir 
Zidovudine -0.906 
Tenofovir disoproxil 
fumarate  -1.752 
1.953- Adefovir dipivoxil 
 
AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Experimental Sequence 
Sr. 
No. Sample Name 
No. of 
Injections 
Chromatographic 
condition 
1 Blank 1 
Using Buffer of  pH = 3.1 
2 Sys Suit Standard 5 
3 Test Preparation 2 
4 Bracketing Standard 1 
5 Blank 1 
Using Buffer of  pH = 2.9 
6 Sys Suit Standard 5 
7 Test Preparation 2 
8 Bracketing Standard 1 
 
 
Table 9: Experimental UPLC sequence for the Robustness study – 02 
 
 
 
Figure19: Chromatogram of Test preparation using buffer of pH = 3.1  
 
 
Robustness03 
 0.325- Acyclovir 
Zidovudine -0.916 
Tenofovir 
disoproxil 
fumarate -1.771 
1.974- Adefovir dipivoxil 
AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 20: Chromatogram of Test preparation using buffer of pH = 2.9  
The Peak Response and area value of test preparation wasn’t much influenced at pH = 3.1 
and pH = 2.9 of buffer in mobile phase but the selectivity of each component is slightly 
transform. The above chromatograms suggest that the pH affects on the chromatographic 
selectivity of drug but it did not have any impact on the response, hence the peak area 
value remain unaffected. 
C) Column Lot Change: In this experiment the test samples were analyzed using 
different column lot and the results were observed in terms of area value (Peak Response) 
and chromatographic compatibility (System Suitability Test). Blank, Standards and 
Sample solutions were prepared as per the same procedure mentioned on page 206. A 
proto type chromatographic sequence of the robustness study is as under, 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
Chromatographic 
condition 
1 Blank 1 
Different Column 
Lot 
2  Sys Suit Standard  5 
3 Test Preparation 2 
4 Bracketing Standard 1 
 
Table 9: Experimental UPLC sequence for the robustness study – 03 
Robustness04 
 0.326- Acyclovir 
Zidovudine -0.938 
Tenofovir 
disoproxil 
fumarate  -1.804 
2.008- Adefovir dipivoxil AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Figure 21: Chromatogram of Test preparation at different column lot 
The Peak Response and area value of test preparation wasn’t much changed with 
different column, in addition to this in this case the retention time was also remain same. 
The data and the chromatogram given above suggest that there is no considerable 
influence of the column lot change on the result of the analysis by this method or on 
chromatographic suitability of this method. Hence, it can be conclude from this 
experiment that the method is highly robust in terms of column lot change. 
Summary of Robustness Study 
Robust 
Condition Peak  Response 
Retention Time 
Variation (min.) 
System Suitability 
Theoretical 
Plates Asymmetry 
Flow Change 
0.465 ml/min Unaffected -  0.03 20000 ±400 1.40 ± 0.2 
Flow Change 
0.435 ml/min Unaffected + 0.09 17000 ±400 1.50 ± 0.15 
At pH 3.1 of 
buffer soln. Unaffected - 0.06 19500 ± 500 1.35 ± 0.10 
At pH 2.9 of 
buffer soln. Unaffected + 0.03 18000 ±300 1.30 ± 0.4 
Column Lot 
Change Unaffected 0.03 18000 ±200 1.35 ± 0.1 
Table 10: Summary of robustness study  
0.324- Acyclovir 
Zidovudine-0.906 
Tenofovir disoproxil 
fumarate -1.751 1.952- Adefovir dipivoxil 
AU 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0.70 
Minutes 
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 
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Where, ± sign suggest statistics of all four analyte peaks.  
Overall the all the experiment in robustness parameter succeeded in terms of acceptance 
criteria hence the proposed method is robust for above small changes in chromatographic 
condition. 
 
4.4.7. SOLUTION STABILITY 
Solution stability has the significant role in terms of the acceptability of the data 
generated during the method validation. Hence this study has to plan before starting the 
method validation and sometimes it is included in Pre Method Validation (PMV). On the 
basis of results achieved in PMV the solution stability can be planned and established in 
Method Validation. The Solution Stability can be established at two different time of 
period, 
(A) Long Term Stock Solution Stability (LTSSS). 
(B) Short Term Standard Solution Stability (STSSS) or Bench Top Solution Stability. 
LTSSS is established by comparing the response of the standard solution prepared from 
the kept stock solution at 2-4˚C for long time (in days) and fresh stock solution. While 
the STSSS is or bench top solution stability is established by comparing the response the 
standard solution kept on the bench for the short time (in hours) and freshly prepared 
standard solution. 
Preparation of Stock Solution for LTSSS:  
50.00 mg of each four antiviral drugs (working standard) were accurately weighed and 
transferred into 100 ml volumetric flask. 50 ml of diluent was added into the volumetric 
flask and the standard substances were dissolved by sonication for ten minute. Then, 
volume of the flask was making up with diluent. The concentration obtained was 500 
μg/ml. This solution was prepared on the first day of the validation and kept at the 2-4˚C 
temperature in refrigerator without any disturbance until performance of the LTSSS 
experiment. After 6 day the stock solution was bring out of the refrigerator and keep it as 
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such till it attains the room temp. 10 ml of this solution was pipette out in 50 ml 
volumetric flask and dilute it up to the mark to reach 100 μg/ml of analytes. This solution 
was assigned as LTSSS Standard solution. 
 
Preparation of Fresh Standard Solution:  
50.00 mg of each four antiviral drugs working standard was accurately weighed and 
transferred into 100 ml volumetric flask. 50 ml of diluent was added into the volumetric 
flask and the standard substances were dissolved by sonication for ten minute. Then, 
volume of the flask was making up with diluent. The concentration obtained was 500 
μg/ml of all components. Pipette out exactly 10 ml of this solution in 50 ml volumetric 
flask and dilute it up to the mark accurately to confirm the 100 μg/ml of analytes. This 
solution was assigned as Fresh Standard Solution. 
 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 LTSSS-01( 06 day) 1 
4 Fresh Standard-01( 0 day) 1 
6 LTSSS-02 ( 06 day) 1 
7 Fresh Standard-02 ( 0 day) 1 
8 LTSSS-03 ( 06 day) 1 
9 Fresh Standard-03 ( 0 day) 1 
10 LTSSS-04 ( 06 day) 1 
11 Fresh Standard-04 ( 0 day) 1 
12 LTSSS-05 ( 06 day) 1 
13 Fresh Standard-05 ( 0 day) 1 
14 Bracketing Standard 1 
 
Table 11: Sequence for LTSSS. 
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The Mean peak area ratio of five LTSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of LTSSS Standard/ Mean Area of Fresh Standard 
Mean Area Ratio = 1.01 for Acyclovir, 0.98 for Zidovudine, 0.96 for Tenofovir 
disoproxyl fumarate and 1.04 for Adefovir dipivoxil.  
Preparation of Stock Solution for STSSS:  
50.00 mg of each four antiviral drugs (working standard) were accurately weighed and 
transferred into 100 ml volumetric flask. 50 ml of diluent was added into the volumetric 
flask and the standard substances were dissolved by sonication for ten minute. Then, 
volume of the flask was making up with diluent. The concentration obtained was 500 
μg/ml. This solution was prepared before the 07 hour and kept on bench at ambient 
temperature without any disturbance until performance of the STSSS experiment. After 
07 hour on the bench. 10 ml of this solution was pipette out in 50 ml volumetric flask and 
dilute it up to the mark to reach 100 μg/ml drug substances. This solution was assigned as 
STSSS Standard solution 
Preparation of Fresh Standard Solution:  
50.00 mg of each four antiviral drugs working standard was accurately weighed and 
transferred into 100 ml volumetric flask. 50 ml of diluent was added into the volumetric 
flask and the standard substances were dissolved by sonication for ten minute. Then, 
volume of the flask was making up with diluent. The concentration obtained was 500 
μg/ml of all components. Pipette out exactly 10 ml of this solution in 50 ml volumetric 
flask and dilute it up to the mark accurately to confirm the 100 μg/ml of drug substance. 
This solution was assigned as Fresh Standard Solution.  
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The proto-type experimental sequence is given below for STSSS. 
Experimental Sequence 
Sr.No. Sample Name No. of Injections 
1 Blank 1 
2 System Suitability Standard  5 
3 STSSS-01( 7.0 hour) 1 
4 Fresh Standard-01( 0.0 hour) 1 
6 STSSS-02 ( 7.0 hour) 1 
7 Fresh Standard-02 ( 0.0 hour)  1 
8 STSSS-03 ( 7.0 hour) 1 
9 Fresh Standard-03 (0.0 hour) 1 
10 STSSS-04 ( 7.0 hour) 1 
11 Fresh Standard-04 (0.0 hour) 1 
12 STSSS-05 ( 7.0 hour) 1 
13 Fresh Standard-05 (0.0 hour) 1 
14 Bracketing Standard 1 
 
Table 12: Sequence for STSSS.  
The Mean peak area ratio of five STSSS standard injections and Fresh Standard solution 
was calculated. 
Mean Area Ratio = Mean Area of STSSS Standard/ Mean Area of Fresh Standard 
Mean Area Ratio = 1.03 for Acyclovir, 0.95 Zidovudine, 1.03 for Tenofovir disoproxyl 
fumarate and 0.98 for Adefovir dipivoxil.  
The Mean Area Ratio is within the acceptance criteria of 0.95 to 1.05, hence it can be 
concluded from this experiment that the Stock Solution is stable for the 06 days at 2 - 4˚ 
C in refrigerator, while standard solution was remain unaffected on bench at ambient 
temperature and in normal light for 7 hour. In addition to this it confirms the reliability of 
the data generated during the method validation.  
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4.4.8. SYSTEM SUITABILITY  
A system suitability test for the chromatographic system was performed before each 
validation experiment. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. Only 
after the system suitability results were in acceptance criteria the experiments were 
proceed further. 
 
Summary of System Suitability Test 
Experiment Name Theoretical Plates Asymmetry % RSD 
Specificity 20000 ± 400 1.40 ± 0.2 0.55 
Linearity and Range 20000± 500 1.35± 0.3 0.70 
LOD and LOQ 19000 ± 300 1.50 ± 0.2 1.22 
Method Precision 20500 ± 500 1.40 ± 0.1 0.40 
Intermediate Precision 20000 ± 100 1.45 ± 0.1 0.75 
Accuracy 19500 ± 400 1.35 ± 0.2 0.90 
Robustness 19400 ± 600 1.40 ± 0.2 1.87 
Solution Stability 20000 ± 300 1.35 ± 0.1 1.46 
 
Table 13: Results of System Suitability Test after each Validation Experiment 
Where, ± sign suggest statistics of all four component peaks. 
As per guideline the Theoretical plates should be more than 5000, Asymmetry should be 
less than 2.0 and % RSD should be less than 2.0. As the data suggest the system 
suitability was within the criteria in each validation experiment.  Hence the system was 
found suitable to perform the validation experiment which confirms the reliability of the 
data generated during the method validation. 
 
5. CONCLUSION 
The surveillance and results obtained from each validation experiment including 
specificity, linearity and range, LOD and LOQ, precision, accuracy, robustness, solution 
stability and system suitability lies well inside the acceptance criteria of ICH guideline. 
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Since, all the results are with-in the limit, the developed Analytical method is considered 
as validated and suitable for probable use. 
 
6. APPLICATION OF CURRENT FINDINGS  
 
6.1. This method can be used for the simultaneously quantification of Acyclovir, 
Zidovudine, Tenofovir disoproxyl fumarate and adefovir dipivoxil in bulk drug in 
routine or as a special test. 
6.2. This method has also application over the chromatographic purity of all four 
analyte. 
6.3. By optimizing certain chromatographic parameter it can be also used for the 
reaction monitoring of preparation of all four compounds. 
6.4. This method can be used for the determination of all analyte individually or in 
combination pharmaceutical dosage form. 
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SUMMARY 
 
The work represented in the thesis entitled “INSTRUMENTAL AND ANALYTICAL 
STUDY OF ACTIVE PHARMACEUTICAL INGREDIENTS AND BIO ACTIVE 
MOLECULES” is divided into five chapters which can be summarized as under. 
Chapter – 1 includes the historical review as well as introduction to various types of 
chromatography and its application. Further the basic principal, function and operational 
overview of the High Performance Liquid Chromatography (HPLC) and Ultra 
Performance Liquid Chromatography has discussed. Addition to this the Analytical 
Method Validation, its requirement and all the experimental parameter of it covered in 
this segment of thesis. 
Chapter – 2 deals with the stability indicating Reversed Phase High Performance 
Liquid Chromatographic method for determination of Drotaverine Hydrochloride in 
pharmaceutical dosage form which has the significance over total analysis time of just 10 
minutes and validation of the method is also included here as per ICH guideline. 
Chapter – 3   comprises of an UPLC-PDA method for determination Carvedilol and its 
Pharmacopeial three impurities. It is faster method with total analysis time of just 5 
minutes. It illustrates the method for carvedilol and its process related three impurities of 
Carvedilol namely; USP Related Compound B, USP Related Compound C and USP 
Related Compound D. In addition to this, it also confirms that the same is applicable for 
determination of active content in pharmaceutical dosage form. 
Chapter – 4 conferring for the method for simultaneous analysis of eight 
antihypertensive molecules, this covers Ranolazine, Diltiazem, Carvedilol, Quinapril, 
Olmesartan medoxomil, Losartan Potassium, Valsartan, Candesartan cilexetil. This 
effort demonstrates the high throughput screening of eight analytes in just 13 minutes run 
time. This clearly signifies the advantage of latest technology in liquid chromatography. 
Further this work also includes the analysis of these molecules simultaneously as well as 
individually in bulk drug and in pharmaceutical dosage form. 
Chapter – 5 covers the method development and validation for quantitative analysis of 
Acyclovir, Zidovudine, Tenofovir disoproxyl fumarate and adefovir dipivoxil which 
currently in Indian and abroad market. It includes the simultaneous quantification by 
Ultra Performance Liquid Chromatography with total analysis time of just 3 minutes. 
However, it successfully developed and validated. This attempt was exemplifies the high 
throughput screening of these analytes in bulk drug and the current findings are 
functional in pharmaceutical dosage form as well. 
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